



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|---|
| (51) International Patent Classification ⁶ : C12N 15/12, 15/62, C07K 14/705, 16/28, C12N 15/70 | A2 | (11) International Publication Number: WO 98/50547 (43) International Publication Date: 12 November 1998 (12.11.98) |
|---|-----------|---|

(21) International Application Number: PCT/US98/08979

(22) International Filing Date: 7 May 1998 (07.05.98)

(30) Priority Data:

| | | |
|------------|----------------------------|----|
| 60/044,293 | 7 May 1997 (07.05.97) | US |
| 60/072,212 | 22 January 1998 (22.01.98) | US |
| 60/076,947 | 5 March 1998 (05.03.98) | US |

(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).

(72) Inventors: HARDIMAN, Gerard, T.; 4 Howe Street, Watertown, MA 02172 (US). ROCK, Fernando, L.; 721 Shell Boulevard #203, Foster City, CA 94404 (US). BAZAN, J., Fernando; 775 University Drive, Menlo Park, CA 94025 (US). KASTELEIN, Robert, A.; 463 Summit Drive, Redwood City, CA 94062 (US).

(74) Agents: McLAUGHLIN, Jaye, P. et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).

(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).


Published

Without international search report and to be republished upon receipt of that report.

(54) Title: HUMAN TOLL-LIKE RECEPTOR PROTEINS, RELATED REAGENTS AND METHODS

(57) Abstract

Nucleic acids encoding nine human receptors, designated DNAX Toll-like receptors 2-10 (DTLR2-10), homologous to the Drosophila Toll receptor and the human IL-1 receptor, purified DTLR proteins and fragments thereof, mono-/polyclonal antibodies against these receptors, and methods for diagnostic and therapeutic use.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NI | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | | | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

HUMAN RECEPTOR PROTEINS; RELATED REAGENTS AND METHODS

This filing claims priority from U.S. Patent
5 Applications USSN 60/044,293, filed May 7, 1997; USSN
60/072,212, filed January 22, 1998; and USSN 60/076,947,
filed March 5, 1998, each of which is incorporated herein
by reference.

10 FIELD OF THE INVENTION

The present invention relates to compositions and
methods for affecting mammalian physiology, including
morphogenesis or immune system function. In particular,
it provides nucleic acids, proteins, and antibodies which
15 regulate development and/or the immune system.
Diagnostic and therapeutic uses of these materials are
also disclosed.

BACKGROUND OF THE INVENTION

20 Recombinant DNA technology refers generally to
techniques of integrating genetic information from a
donor source into vectors for subsequent processing, such
as through introduction into a host, whereby the
transferred genetic information is copied and/or
25 expressed in the new environment. Commonly, the genetic
information exists in the form of complementary DNA
(cDNA) derived from messenger RNA (mRNA) coding for a
desired protein product. The carrier is frequently a
plasmid having the capacity to incorporate cDNA for later
30 replication in a host and, in some cases, actually to
control expression of the cDNA and thereby direct
synthesis of the encoded product in the host.

For some time, it has been known that the mammalian
immune response is based on a series of complex cellular
35 interactions, called the "immune network". Recent
research has provided new insights into the inner
workings of this network. While it remains clear that

much of the immune response does, in fact, revolve around the network-like interactions of lymphocytes, macrophages, granulocytes, and other cells, immunologists now generally hold the opinion that soluble proteins,
5 known as lymphokines, cytokines, or monokines, play critical roles in controlling these cellular interactions. Thus, there is considerable interest in the isolation, characterization, and mechanisms of action of cell modulatory factors, an understanding of which
10 will lead to significant advancements in the diagnosis and therapy of numerous medical abnormalities, e.g., immune system disorders.

Lymphokines apparently mediate cellular activities in a variety of ways. They have been shown to support
15 the proliferation, growth, and/or differentiation of pluripotential hematopoietic stem cells into vast numbers of progenitors comprising diverse cellular lineages which make up a complex immune system. Proper and balanced interactions between the cellular components are
20 necessary for a healthy immune response. The different cellular lineages often respond in a different manner when lymphokines are administered in conjunction with other agents.

Cell lineages especially important to the immune
25 response include two classes of lymphocytes: B-cells, which can produce and secrete immunoglobulins (proteins with the capability of recognizing and binding to foreign matter to effect its removal), and T-cells of various subsets that secrete lymphokines and induce or suppress
30 the B-cells and various other cells (including other T-cells) making up the immune network. These lymphocytes interact with many other cell types.

Another important cell lineage is the mast cell (which has not been positively identified in all
35 mammalian species), which is a granule-containing connective tissue cell located proximal to capillaries throughout the body. These cells are found in especially

high concentrations in the lungs, skin, and gastrointestinal and genitourinary tracts. Mast cells play a central role in allergy-related disorders, particularly anaphylaxis as follows: when selected
5 antigens crosslink one class of immunoglobulins bound to receptors on the mast cell surface, the mast cell degranulates and releases mediators, e.g., histamine, serotonin, heparin, and prostaglandins, which cause allergic reactions, e.g., anaphylaxis.

10 Research to better understand and treat various immune disorders has been hampered by the general inability to maintain cells of the immune system in vitro. Immunologists have discovered that culturing many of these cells can be accomplished through the use of T-
15 cell and other cell supernatants, which contain various growth factors, including many of the lymphokines.

The interleukin-1 family of proteins includes the IL-1 α , the IL-1 β , the IL-1RA, and recently the IL-1 γ (also designated Interferon-Gamma Inducing Factor, IGIF).
20 This related family of genes have been implicated in a broad range of biological functions. See Dinarello (1994) FASEB J. 8:1314-1325; Dinarello (1991) Blood 77:1627-1652; and Okamura, et al. (1995) Nature 378:88-91.

25 In addition, various growth and regulatory factors exist which modulate morphogenetic development. This includes, e.g., the Toll ligands, which signal through binding to receptors which share structural, and mechanistic, features characteristic of the IL-1
30 receptors. See, e.g., Lemaitre, et al. (1996) Cell 86:973-983; and Belvin and Anderson (1996) Ann. Rev. Cell & Devel. Biol. 12:393-416.

From the foregoing, it is evident that the discovery and development of new soluble proteins and their
35 receptors, including ones similar to lymphokines, should contribute to new therapies for a wide range of degenerative or abnormal conditions which directly or

indirectly involve development, differentiation, or function, e.g., of the immune system and/or hematopoietic cells. In particular, the discovery and understanding of novel receptors for lymphokine-like molecules which
5 enhance or potentiate the beneficial activities of other lymphokines would be highly advantageous. The present invention provides new receptors for ligands exhibiting similarity to interleukin-1 like compositions and related compounds, and methods for their use.

10

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a schematic comparison of the protein architectures of *Drosophila* and human DTLRs, and their relationship to vertebrate IL-1 receptors and plant
15 disease resistance proteins. Three *Drosophila* (Dm) DTLRs (Toll, 18w, and the Mst ORF fragment) (Morisato and Anderson (1995) Ann. Rev. Genet. 29:371-399; Chiang and Beachy (1994) Mech. Develop. 47:225-239; Mitcham, et al. (1996) J. Biol. Chem. 271:5777-5783; and Eldon, et al.
20 (1994) Develop. 120:885-899) are arrayed beside four complete (DTLRs 1-4) and one partial (DTLR5) human (Hu) receptors. Individual LRRs in the receptor ectodomains that are flagged by PRINTS (Attwood, et al. (1997) Nucleic Acids Res. 25:212-217) are explicitly noted by
25 boxes; 'top' and 'bottom' Cys-rich clusters that flank the C- or N-terminal ends of LRR arrays are respectively drawn by apposed half-circles. The loss of the internal Cys-rich region in DTLRs 1-5 largely accounts for their smaller ectodomains (558, 570, 690, and 652 aa,
30 respectively) when compared to the 784 and 977 aa extensions of Toll and 18w. The incomplete chains of DmMst and HuDTLR5 (519 and 153 aa ectodomains, respectively) are represented by dashed lines. The intracellular signaling module common to DTLRs, IL-1-type
35 receptors (IL-1Rs), the intracellular protein Myd88, and the tobacco disease resistance gene N product (DRgN) is indicated below the membrane. See, e.g., Hardiman, et

al. (1996) Oncogene 13:2467-2475; and Rock, et al. (1998) Proc. Nat'l Acad. Sci. USA 95:588-. Additional domains include the trio of Ig-like modules in IL-1Rs (disulfide-linked loops); the DRgN protein features an NTPase domain (box) and Myd88 has a death domain (black oval).

Figures 2A-2B show conserved structural patterns in the signaling domains of Toll- and IL-1-like cytokine receptors, and two divergent modular proteins. Figure 2A shows a sequence alignment of the common TH domain.

DTLRs are labeled as in Figure 1; the human (Hu) or mouse (Mo) IL-1 family receptors (IL-1R1-6) are sequentially numbered as earlier proposed (Hardiman, et al. (1996) Oncogene 13:2467-2475); Myd88 and the sequences from tobacco (To) and flax, *L. usitatissimum* (Lu), represent C- and N-terminal domains, respectively, of larger, multidomain molecules. Ungapped blocks of sequence (numbered 1-10) are boxed. Triangles indicate deleterious mutations, while truncations N-terminal of the arrow eliminate bioactivity in human IL-1R1 (Heguy, et al. (1992) J. Biol. Chem. 267:2605-2609). PHD (Rost and Sander (1994) Proteins 19:55-72) and DSC (King and Sternberg (1996) Protein Sci. 5:2298-2310) secondary structure predictions of α -helix (H), β -strand (E), or coil (L) are marked. The amino acid shading scheme depicts chemically similar residues: hydrophobic, acidic, basic, Cys, aromatic, structure-breaking, and tiny. Diagnostic sequence patterns for IL-1Rs, DTLRs, and full alignment (ALL) were derived by Consensus at a stringency of 75%. Symbols for amino acid subsets are (see internet site for detail): o, alcohol; l, aliphatic; ., any amino acid; a, aromatic; c, charged; h, hydrophobic; -, negative; p, polar; +, positive; s, small; u, tiny; t, turnlike. Figure 2B shows a topology diagram of the proposed TH β/α domain fold. The parallel β -sheet (with β -strands A-E as yellow triangles) is seen at its C-terminal end; α -helices (circles labeled 1-5) link the β -strands; chain connections are to the front (visible) or

back (hidden). Conserved, charged residues at the C-end of the β -sheet are noted in gray (Asp) or as a lone black (Arg) residue (see text).

Figure 3 shows evolution of a signaling domain superfamily. The multiple TH module alignment of Figure 2A was used to derive a phylogenetic tree by the Neighbor-Joining method (Thompson, et al. (1994) Nucleic Acids Res. 22:4673-4680). Proteins labeled as in the alignment; the tree was rendered with TreeView.

Figures 4A-4D show FISH chromosomal mapping of human DTLR genes. Denatured chromosomes from synchronous cultures of human lymphocytes were hybridized to biotinylated DTLR cDNA probes for localization. The assignment of the FISH mapping data (left, Figures 4A, DTLR2; 4B, DTLR3; 4C, DTLR4; 4D, DTLR5) with chromosomal bands was achieved by superimposing FISH signals with DAPI banded chromosomes (center panels). Heng and Tsui (1994) Meth. Molec. Biol. 33:109-122. Analyses are summarized in the form of human chromosome ideograms (right panels).

Figures 5A-5F show mRNA blot analyses of Human DTLRs. Human multiple tissue blots (He, heart; Br, brain; Pl, placenta; Lu, lung; Li, liver; Mu, muscle; Ki, kidney; Pn, Pancreas; Sp, spleen; Th, thymus; Pr, prostate; Te, testis; Ov, ovary, SI, small intestine; Co, colon; PBL, peripheral blood lymphocytes) and cancer cell line (promyelocytic leukemia, HL60; cervical cancer, HELAS3; chronic myelogenous leukemia, K562; lymphoblastic leukemia, Molt4; colorectal adenocarcinoma, SW480; melanoma, G361; Burkitt's Lymphoma Raji, Burkitt's; colorectal adenocarcinoma, SW480; lung carcinoma, A549) containing approximately 2 μ g of poly(A)⁺ RNA per lane were probed with radiolabeled cDNAs encoding DTLR1 (Figures 5A-5C), DTLR2 (Figure 5D), DTLR3 (Figure 5E), and DTLR4 (Figure 5F) as described. Blots were exposed to X-ray film for 2 days (Figures 5A-5C) or one week (Figure 5D-5F) at -70° C with intensifying screens. An

anomalous 0.3 kB species appears in some lanes;
hybridization experiments exclude a message encoding a
DTLR cytoplasmic fragment.

SUMMARY OF THE INVENTION

5 The present invention is directed to nine novel
related mammalian receptors, e.g., human, Toll receptor
like molecular structures, designated DTLR2, DTLR3,
DTLR4, DTLR5, DTLR6, DTLR7, DTLR8, DTLR9, and DTLR10, and
their biological activities. It includes nucleic acids
10 coding for the polypeptides themselves and methods for
their production and use. The nucleic acids of the
invention are characterized, in part, by their homology
to cloned complementary DNA (cDNA) sequences enclosed
herein.

15 In certain embodiments, the invention provides a
composition of matter selected from the group of: a
substantially pure or recombinant DTLR2 protein or
peptide exhibiting at least about 85% sequence identity
over a length of at least about 12 amino acids to SEQ ID
20 NO: 4; a natural sequence DTLR2 of SEQ ID NO: 4; a fusion
protein comprising DTLR2 sequence; a substantially pure
or recombinant DTLR3 protein or peptide exhibiting at
least about 85% sequence identity over a length of at
least about 12 amino acids to SEQ ID NO: 6; a natural
25 sequence DTLR3 of SEQ ID NO: 6; a fusion protein
comprising DTLR3 sequence; a substantially pure or
recombinant DTLR4 protein or peptide exhibiting at least
about 85% sequence identity over a length of at least
about 12 amino acids to SEQ ID NO: 26; a natural sequence
30 DTLR4 of SEQ ID NO: 26; a fusion protein comprising DTLR4
sequence; a substantially pure or recombinant DTLR5
protein or peptide exhibiting at least about 85% sequence
identity over a length of at least about 12 amino acids
to SEQ ID NO: 10; a natural sequence DTLR5 of SEQ ID NO:
35 10; and a fusion protein comprising DTLR5 sequence.

In other embodiments, the invention provides a
composition of matter selected from the group of: a

substantially pure or recombinant DTLR6 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 12; a natural sequence DTLR6 of SEQ ID NO: 12; a fusion protein comprising DTLR6 sequence; a substantially pure or recombinant DTLR7 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 16 or 18 or; a natural sequence DTLR7 of SEQ ID NO: 16 or 18; a fusion protein comprising DTLR7 sequence; a substantially pure or recombinant DTLR8 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 32; a natural sequence DTLR8 of SEQ ID NO: 32; a fusion protein comprising DTLR8 sequence; a substantially pure or recombinant DTLR9 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 22; a natural sequence DTLR9 of SEQ ID NO: 22; and a fusion protein comprising DTLR9 sequence; a substantially pure or recombinant DTLR10 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 34; a natural sequence DTLR10 of SEQ ID NO: 34; and a fusion protein comprising DTLR10 sequence.

Preferably, the substantially pure or isolated protein comprises a segment exhibiting sequence identity to a corresponding portion of a DTLR2, DTLR3, DTLR4, DTLR5, DTLR6, DTLR 7, DTLR8, DTLR9, or DTLR10, wherein: the homology is at least about 90% identity and the portion is at least about 9 amino acids; the homology is at least about 80% identity and the portion is at least about 17 amino acids; or the homology is at least about 70% identity and the portion is at least about 25 amino acids. In specific embodiments, the composition of matter: is DTLR2, which comprises a mature sequence of SEQ ID NO: 4; or exhibits a post-translational+

modification pattern distinct from natural DTLR2; is DTLR3, which comprises a mature sequence of SEQ ID NO: 6; or exhibits a post-translational modification pattern distinct from natural DTLR3; is DTLR4, which: comprises a mature sequence of SEQ ID NO: 26; or exhibits a post-translational modification pattern distinct from natural DTLR4; or is DTLR5, which: comprises the complete sequence of SEQ ID NO: 10; or exhibits a post-translational modification pattern distinct from natural DTLR5; or is DTLR6, which comprises a mature sequence of SEQ ID NO: 12; or exhibits a post-translational modification pattern distinct from natural DTLR6; is DTLR7, which comprises a mature sequence of SEQ ID NO: 16 or 18; or exhibits a post-translational modification pattern distinct from natural DTLR7; is DTLR8, which: comprises a mature sequence of SEQ ID NO: 32; or exhibits a post-translational modification pattern distinct from natural DTLR8; or is DTLR9, which: comprises the complete sequence of SEQ ID NO: 22; or exhibits a post-translational modification pattern distinct from natural DTLR9; or is DTLR10, which: comprises the complete sequence of SEQ ID NO: 34; or exhibits a post-translational modification pattern distinct from natural DTLR10; or the composition of matter may be a protein or peptide which: is from a warm blooded animal selected from a mammal, including a primate, such as a human; comprises at least one polypeptide segment of SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34; exhibits a plurality of portions exhibiting said identity; is a natural allelic variant of DTLR2, DTLR3, DTLR4, DTLR5, DTLR6, DTLR7, DTLR8, DTLR9, or DTLR10; has a length at least about 30 amino acids; exhibits at least two non-overlapping epitopes which are specific for a primate DTLR2, DTLR3, DTLR4, DTLR5, DTLR6, DTLR7, DTLR8, DTLR9, or DTLR10; exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a primate DTLR2, DTLR3, DTLR4, DTLR5, DTLR6; exhibits at

least two non-overlapping epitopes which are specific for a primate DTLR2, DTLR3, DTLR4, DTLR5, DTLR6, DTLR7, DTLR8, DTLR9, or DTLR10; exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a primate DTLR2, DTLR3, DTLR4, DTLR5, DTLR6, DTLR7, DTLR8, DTLR9, or DTLR10; is glycosylated; has a molecular weight of at least 100 kD with natural glycosylation; is a synthetic polypeptide; is attached to a solid substrate; is conjugated to another chemical moiety; is a 5-fold or less substitution from natural sequence; or is a deletion or insertion variant from a natural sequence.

Other embodiments include a composition comprising: a sterile DTLR2 protein or peptide; or the DTLR2 protein or peptide and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration; a sterile DTLR3 protein or peptide; or the DTLR3 protein or peptide and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration; a sterile DTLR4 protein or peptide; or the DTLR4 protein or peptide and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration; a sterile DTLR5 protein or peptide; or the DTLR5 protein or peptide and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration; a sterile DTLR6 protein or peptide; or the DTLR6 protein or peptide and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration; a sterile DTLR7 protein or peptide; or the DTLR7 protein or peptide and a carrier,

wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration; a sterile DTLR8 protein or peptide; or the DTLR8 protein or peptide and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration; a sterile DTLR9 protein or peptide; or the DTLR9 protein or peptide and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration; a sterile DTLR10 protein or peptide; or the DTLR10 protein or peptide and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration.

In certain fusion protein embodiments, the invention provides a fusion protein comprising: mature protein sequence of SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34; a detection or purification tag, including a FLAG, His6, or Ig sequence; or sequence of another receptor protein.

Various kit embodiments include a kit comprising a DTLR protein or polypeptide, and: a compartment comprising the protein or polypeptide; and/or instructions for use or disposal of reagents in the kit.

Binding compound embodiments include those comprising an antigen binding site from an antibody, which specifically binds to a natural DTLR2, DTLR3, DTLR4, DTLR5, DTLR6, DTLR7, DTLR8, DTLR9, or DTLR10 protein, wherein: the protein is a primate protein; the binding compound is an Fv, Fab, or Fab2 fragment; the binding compound is conjugated to another chemical moiety; or the antibody: is raised against a peptide sequence of a mature polypeptide of SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34; is raised against a mature

DTLR2, DTLR3, DTLR4, DTLR5, DTLR6, DTLR7, DTLR8, DTLR9 or DTLR10; is raised to a purified human DTLR2, DTLR3, DTLR4, DTLR5, DTLR6, DTLR7, DTLR8, DTLR9 or DTLR10; is immunoselected; is a polyclonal antibody; binds to a
5 denatured DTLR2, DTLR3, DTLR4, DTLR5, DTLR6, DTLR7, DTLR8, DTLR9 or DTLR10; exhibits a K_d to antigen of at least 30 μM ; is attached to a solid substrate, including a bead or plastic membrane; is in a sterile composition; or is detectably labeled, including a radioactive or
10 fluorescent label. A binding composition kit often comprises the binding compound, and: a compartment comprising said binding compound; and/or instructions for use or disposal of reagents in the kit. Often the kit is capable of making a qualitative or quantitative analysis.

15 Other compositions include a composition comprising: a sterile binding compound, or the binding compound and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral
20 administration.

Nucleic acid embodiments include an isolated or recombinant nucleic acid encoding a DTLR2-10 protein or peptide or fusion protein, wherein: the DTLR is from a mammal; or the nucleic acid: encodes an antigenic peptide
25 sequence of of SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34; encodes a plurality of antigenic peptide sequences of of SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34; exhibits at least about 80% identity to a natural cDNA encoding said segment; is an expression
30 vector; further comprises an origin of replication; is from a natural source; comprises a detectable label; comprises synthetic nucleotide sequence; is less than 6 kb, preferably less than 3 kb; is from a mammal, including a primate; comprises a natural full length
35 coding sequence; is a hybridization probe for a gene encoding said DTLR; or is a PCR primer, PCR product, or mutagenesis primer. A cell, tissue, or organ comprising

such a recombinant nucleic acid is also provided.
Preferably, the cell is: a prokaryotic cell; a eukaryotic
cell; a bacterial cell; a yeast cell; an insect cell; a
mammalian cell; a mouse cell; a primate cell; or a human
5 cell. Kits are provided comprising such nucleic acids,
and: a compartment comprising said nucleic acid; a
compartment further comprising a primate DTLR2, DTLR3,
DTLR4, DTLR5, DTLR6, DTLR7, DTLR8, DTLR9 or DTLR10
protein or polypeptide; and/or instructions for use or
10 disposal of reagents in the kit. Often, the kit is
capable of making a qualitative or quantitative analysis.

Other embodiments include a nucleic acid which:
hybridizes under wash conditions of 30° C and less than
2M salt to SEQ ID NO: 3; hybridizes under wash conditions
15 of 30° C and less than 2 M salt to SEQ ID NO: 5;
hybridizes under wash conditions of 30° C and less than
2M salt to SEQ ID NO: 25; hybridizes under wash
conditions of 30° C and less than 2 M salt to SEQ ID NO:
9; hybridizes under wash conditions of 30° C and less
20 than 2M salt to SEQ ID NO: 11; hybridizes under wash
conditions of 30° C and less than 2 M salt to SEQ ID NO:
15 or 17; hybridizes under wash conditions of 30° C and
less than 2M salt to SEQ ID NO: 31; hybridizes under wash
conditions of 30° C and less than 2 M salt to SEQ ID NO:
25 21; hybridizes under wash conditions of 30° C and less
than 2 M salt to SEQ ID NO: 33; exhibits at least about
85% identity over a stretch of at least about 30
nucleotides to a primate DTLR2 DTLR3, DTLR4, DTLR5,
DTLR6, DTLR7, DTLR8, DTLR9 or DTLR10.

30 Preferably, such nucleic acid will have such
properties, wherein: wash conditions are at 45° C and/or
500 mM salt; or the identity is at least 90% and/or the
stretch is at least 55 nucleotides. More preferably, the
wash conditions are at 55° C and/or 150 mM salt; or the
35 identity is at least 95% and/or the stretch is at least
75 nucleotides.

The invention also provides a method of modulating physiology or development of a cell or tissue culture cells comprising contacting the cell with an agonist or antagonist of a mammalian DTLR2, DTLR3, DTLR4, DTLR5,
5 DTLR6, DTLR7, DTLR8, DTLR9, or DTLR10.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

I. General

10 The present invention provides the amino acid sequence and DNA sequence of mammalian, herein primate DNAX Toll like receptor molecules (DTLR) having particular defined properties, both structural and biological. These have been designated herein as DTLR2,
15 DTLR3, DTLR4, DTLR5, DTLR6, DTLR7, DTLR8, DTLR9, and DTLR10, respectively, and increase the number of members of the human Toll like receptor family from 1 to 10. Various cDNAs encoding these molecules were obtained from primate, e.g., human, cDNA sequence libraries. Other
20 primate or other mammalian counterparts would also be desired.

Some of the standard methods applicable are described or referenced, e.g., in Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual, Cold Spring
25 Harbor Laboratory, Cold Spring Harbor Press; Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual, (2d ed.), vols 1-3, CSH Press, NY; Ausubel, et al., Biology, Greene Publishing Associates, Brooklyn, NY; or Ausubel, et al. (1987 and periodic supplements) Current Protocols
30 in Molecular Biology, Greene/Wiley, New York; each of which is incorporated herein by reference.

A complete nucleotide and corresponding amino acid sequence of a human DTLR1 coding segment is shown in SEQ ID NO: 1 and 2. See also Nomura, et al. (1994) DNA Res
35 1:27-35. A complete nucleotide and corresponding amino acid sequence of a human DTLR2 coding segment is shown in SEQ ID NO: 3 and 4. A complete nucleotide and

corresponding amino acid sequence of a human DTLR3 coding segment is shown in SEQ ID NO: 5 and 6. A complete nucleotide and corresponding amino acid sequence of a human DTLR4 coding segment is shown in SEQ ID NO: 7 and 8. An alternate nucleic acid and corresponding amino acid sequence of a human DTLR4 coding segment is provided in SEQ ID NO: 25 and 26. A partial nucleotide and corresponding amino acid sequence of a human DTLR5 coding segment is shown in SEQ ID NO: 9 and 10. A complete nucleotide and corresponding amino acid sequence of a human DTLR6 coding segment is shown in SEQ ID NO: 11 and 12 and a partial sequence of a mouse DTLR6 is provided in SEQ ID NO: 13 and 14. Additional mouse DTLR6 sequence is provided in SEQ ID NO: 27 and 29 (nucleotide sequence) and SEQ ID NO: 28 and 30 (amino acid sequence). Partial nucleotide (SEQ ID NO: 15 and 17) and corresponding amino acid sequence (SEQ ID NO: 16 and 18) of a human DTLR7 coding segment is also provided. Partial nucleotide and corresponding amino acid sequence of a human DTLR8 coding segment is shown in SEQ ID NO: 19 and 20. A more complete nucleotide and corresponding amino acid sequence of a human DTLR coding segment is shown in SEQ ID NO: 31 and 32. Partial nucleotide and corresponding amino acid sequence of a human DTLR9 coding segment is shown in SEQ ID NO: 21 and 22. Partial nucleotide and corresponding amino acid sequence of a human DTLR10 coding segment is shown in SEQ ID NO: 23 and 24. More complete nucleotide and corresponding amino acid sequence of a human DTLR10 coding segment is shown in SEQ ID NO: 33 and 34. A partial nucleotide sequence for a mouse DTLR10 coding segment is provided in SEQ ID NO: 35.

Table 1: Comparison of intracellular domains of human DTLRs.
 DTLR1 is SEQ ID NO: 2; DTLR2 is SEQ ID NO: 4; DTLR3 is SEQ ID NO: 6; DTLR4 is SEQ ID NO: 8; DTLR5 is SEQ ID NO: 10; and DTLR6 is SEQ ID NO: 12. Particularly important and conserved, e.g.,
 5 characteristic, residues correspond, across the DTLRs, to SEQ ID NO: 18 residues tyr10-tyr13; trp26; cys46; trp52; pro54-gly55; ser69; lys71; trp134-pro135; and phe144-trp145.

| | |
|-----------|---|
| DTLR1 | QRNLQFHAFISYSGHD---SFWVKNELLPNLEKEG-----MQICLHERNF |
| 10 DTLR9 | KENLQFHAFISYSEHD---SAWVKSELVPYLEKED-----IQICLHERNF |
| DTLR8 | -----NELIPNLEKEDGS---ILICLYESYF |
| DTLR2 | SRNICYDAFVSYSERD---AYWVENLMVQELFNFP---FKLCLHKRDF |
| DTLR6 | SPDCCYDAFIVYDTKDPVTEWVLAELVAKLEDPREK--HFNLCLLEERDW |
| DTLR7 | TSQTFYDAYISYDTKDSVTDWVINELRYHLEESRDK--NVLLCLEERDW |
| 15 DTLR10 | EDALPYDAFVVDKTXSAVADWVYNELRGQLEECRGRW-ALRLCLEERDW |
| DTLR4 | RGENIYDAFVIYSSQD---EDWVRNELVKNLEEGVPP---FQLCLHYRDF |
| DTLR5 | PDMYKYDAYLCFSSKD---FTWVQNALLKHLDTQYSDQNRFNLCFEERDF |
| DTLR3 | TEQFEYAAYIIHAYKD---KDWVWEHFSSMEKEDQS---LKFCLEERDF |
| | : . . : * : : |
| 20 DTLR1 | VPGKSIVENIITC-IEKSYKSIFVLSPNFVQSEWCH-YELYFAHHNLFHE |
| DTLR9 | VPGKSIVENIINC-IEKSYKSIFVLSPNFVQSEWCH-YELYFAHHNLFHE |
| DTLR8 | DPGKSISENIVSF-IEKSYKSIFVLSPNFVQNEWCH-YEFYFAHHNLFHE |
| DTLR2 | IPGKWIIDNIDS-IEKSHKTVFVLSENFVKSEWCK-YELDFSHFRLFEE |
| 25 DTLR6 | LPGQPVLENLSQS-IQLSKKTVFVMTDKYAKTENFK-IAFYLSHQRLMDE |
| DTLR7 | DPGLAIIDNLMQS-INQSKKTVFVLTKKYAKSWNFK-TAFYLXLQRLMGE |
| DTLR10 | LPGKTLFENLWAS-VYGSRKTLFVLAHTDRVSGLLR-AIFLLAQQRLL- |
| DTLR4 | IPGVAIAANIIHEGFHKSARKVIVVVSQHFQSRWCI-FEYEIAQTWQFLS |
| DTLR5 | VPGENRIANIQDA-IWNSRKIVCLVSRHFLRDGWCL-EAFSYAQGRCLSD |
| 30 DTLR3 | EAGVFELEAIVNS-IKRSRKIIFVITHHLLKDPLCKRFKVHHAVQQAIEQ |
| | . * : . * * : : : : |
| DTLR1 | GSNSLILILLEPIPQYSIPSSYHKLKSLMARRTYLEWPKEKSKRGLFWAN |
| DTLR9 | GSNNLILILLEPIPQNSIPNKYHKLKALMTQRTYLQWPKEKSKRGLFWA- |
| 35 DTLR8 | NSDHIILILLEPIPFYCIPTRYHKLEALLEKKAYLEWPKDRRKCGLFWAN |
| DTLR2 | NNDAAIILILLEPIEKKAIPQRFCKLRKIMNTKTYLEWPMDEAQREGFWVN |
| DTLR6 | KVDVIIILIFLEKPFQK---SKFLQLRKRLCGSSVLEWPTNPQAHFYFWQC |
| DTLR7 | NMDVIIIFILLEPVLQH---SPYLRLRQRICKSSILQWPDNPKAERLFWQT |
| DTLR10 | ----- |
| 40 DTLR4 | SRAGIIFIVLQKVEKT-LLRQQVELYRLLSRNTYLEWEDSVLGRHIFWRR |
| DTLR5 | LNSALIMVVVGSLSQY-QLMKHQSIIRGFVQKQQLRWPELDQVGWFLHK |
| DTLR3 | NLDSIILVFLEEIPDYKLNHALCLRRGMFKSHCILNWPVQKERIGAFRHK |
| 45 DTLR1 | LRAAINIKLTEQAKK----- |
| DTLR9 | ----- |
| DTLR8 | LRAAVNVNVLATREMYELQTFTELNEESRGSTISLMRTDCL |
| DTLR2 | LRAAIKS----- |
| DTLR6 | LKNALATDNHVAYSQVFKETV----- |
| 50 DTLR7 | LXNVVLTENDSRYNMYVDSIKQY----- |
| DTLR10 | ----- |
| DTLR4 | LRKALLDGKSWNPEGTVGTGCNWQEATSI----- |
| DTLR5 | LSQQILKKEKEKKDNNIPLQTVATIS----- |
| DTLR3 | LQVALGSKNSVH----- |
| 55 | |

As used herein, the term DNAX Toll like receptor 2 (DTLR2) shall be used to describe a protein comprising a protein or peptide segment having or sharing the amino acid sequence shown in SEQ ID NO: 4, or a substantial fragment thereof. Similarly, with a DTLR3 and SEQ ID NO: 6; DTLR4 and SEQ ID NO: 26; DTLR5 and SEQ ID NO: 10; DTLR6 and SEQ ID NO: 12; DTLR7 and SEQ ID NO: 16 and 18; DTLR8 and SEQ ID NO: 32; DTLR9 and SEQ ID NO: 22; and DTLR10 and SEQ ID NO: 34.

The invention also includes a protein variations of the respective DTLR allele whose sequence is provided, e.g., a mutein agonist or antagonist. Typically, such agonists or antagonists will exhibit less than about 10% sequence differences, and thus will often have between 1- and 11-fold substitutions, e.g., 2-, 3-, 5-, 7-fold, and others. It also encompasses allelic and other variants, e.g., natural polymorphic, of the protein described. Typically, it will bind to its corresponding biological receptor with high affinity, e.g., at least about 100 nM, usually better than about 30 nM, preferably better than about 10 nM, and more preferably at better than about 3 nM. The term shall also be used herein to refer to related naturally occurring forms, e.g., alleles, polymorphic variants, and metabolic variants of the mammalian protein.

This invention also encompasses proteins or peptides having substantial amino acid sequence identity with the amino acid sequence in SEQ ID NO: 4. It will include sequence variants with relatively few substitutions, e.g., preferably less than about 3-5. Similar features apply to the other DTLR sequences provided in SEQ ID NO: 6, 26, 10, 12, 16, 18, 32, 22 and 34.

A substantial polypeptide "fragment", or "segment", is a stretch of amino acid residues of at least about 8 amino acids, generally at least 10 amino acids, more generally at least 12 amino acids, often at least 14

amino acids, more often at least 16 amino acids, typically at least 18 amino acids, more typically at least 20 amino acids, usually at least 22 amino acids, more usually at least 24 amino acids, preferably at least 26 amino acids, more preferably at least 28 amino acids, and, in particularly preferred embodiments, at least about 30 or more amino acids. Sequences of segments of different proteins can be compared to one another over appropriate length stretches.

Amino acid sequence homology, or sequence identity, is determined by optimizing residue matches, if necessary, by introducing gaps as required. See, e.g., Needleham, et al., (1970) J. Mol. Biol. 48:443-453; Sankoff, et al., (1983) chapter one in Time Warps, String Edits, and Macromolecules: The Theory and Practice of Sequence Comparison, Addison-Wesley, Reading, MA; and software packages from IntelliGenetics, Mountain View, CA; and the University of Wisconsin Genetics Computer Group (GCG), Madison, WI; each of which is incorporated herein by reference. This changes when considering conservative substitutions as matches. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Homologous amino acid sequences are intended to include natural allelic and interspecies variations in the cytokine sequence. Typical homologous proteins or peptides will have from 50-100% homology (if gaps can be introduced), to 60-100% homology (if conservative substitutions are included) with an amino acid sequence segment of SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34. Homology measures will be at least about 70%, generally at least 76%, more generally at least 81%, often at least 85%, more often at least 88%, typically at least 90%, more typically at least 92%, usually at least 94%, more usually at least 95%,

preferably at least 96%, and more preferably at least 97%, and in particularly preferred embodiments, at least 98% or more. The degree of homology will vary with the length of the compared segments. Homologous proteins or peptides, such as the allelic variants, will share most biological activities with the embodiments described in SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34. Particularly interesting regions of comparison, at the amino acid or nucleotide levels, correspond to those within each of the blocks 1-10, or intrablock regions, corresponding to those indicated in Figure 2A.

As used herein, the term "biological activity" is used to describe, without limitation, effects on inflammatory responses, innate immunity, and/or morphogenic development by respective ligands. For example, these receptors should, like IL-1 receptors, mediate phosphatase or phosphorylase activities, which activities are easily measured by standard procedures. See, e.g., Hardie, et al. (eds. 1995) The Protein Kinase FactBook vols. I and II, Academic Press, San Diego, CA; Hanks, et al. (1991) Meth. Enzymol. 200:38-62; Hunter, et al. (1992) Cell 70:375-388; Lewin (1990) Cell 61:743-752; Pines, et al. (1991) Cold Spring Harbor Symp. Quant. Biol. 56:449-463; and Parker, et al. (1993) Nature 363:736-738. The receptors exhibit biological activities much like regulatable enzymes, regulated by ligand binding. However, the enzyme turnover number is more close to an enzyme than a receptor complex. Moreover, the numbers of occupied receptors necessary to induce such enzymatic activity is less than most receptor systems, and may number closer to dozens per cell, in contrast to most receptors which will trigger at numbers in the thousands per cell. The receptors, or portions thereof, may be useful as phosphate labeling enzymes to label general or specific substrates.

The terms ligand, agonist, antagonist, and analog of, e.g., a DTLR, include molecules that modulate the

characteristic cellular responses to Toll ligand like proteins, as well as molecules possessing the more standard structural binding competition features of ligand-receptor interactions, e.g., where the receptor is
5 a natural receptor or an antibody. The cellular responses likely are mediated through binding of various Toll ligands to cellular receptors related to, but possibly distinct from, the type I or type II IL-1 receptors. See, e.g., Belvin and Anderson (1996) Ann.
10 Rev. Cell Dev. Biol. 12:393-416; Morisato and Anderson (1995) Ann. Rev. Genetics 29:371-3991 and Hultmark (1994) Nature 367:116-117.

Also, a ligand is a molecule which serves either as a natural ligand to which said receptor, or an analog
15 thereof, binds, or a molecule which is a functional analog of the natural ligand. The functional analog may be a ligand with structural modifications, or may be a wholly unrelated molecule which has a molecular shape which interacts with the appropriate ligand binding
20 determinants. The ligands may serve as agonists or antagonists, see, e.g., Goodman, et al. (eds) (1990) Goodman & Gilman's: The Pharmacological Bases of Therapeutics, Pergamon Press, New York.

Rational drug design may also be based upon
25 structural studies of the molecular shapes of a receptor or antibody and other effectors or ligands. Effectors may be other proteins which mediate other functions in response to ligand binding, or other proteins which normally interact with the receptor. One means for
30 determining which sites interact with specific other proteins is a physical structure determination, e.g., x-ray crystallography or 2 dimensional NMR techniques. These will provide guidance as to which amino acid residues form molecular contact regions. For a detailed
35 description of protein structural determination, see, e.g., Blundell and Johnson (1976) Protein

Crystallography, Academic Press, New York, which is hereby incorporated herein by reference.

II. Activities

5 The Toll like receptor proteins will have a number of different biological activities, e.g., in phosphate metabolism, being added to or removed from specific substrates, typically proteins. Such will generally result in modulation of an inflammatory function, other
10 innate immunity response, or a morphological effect. The DTLR2, 3, 4, 5, 6, 7, 8, 9, or 10 proteins are homologous to other Toll like receptor proteins, but each have structural differences. For example, a human DTLR2 gene coding sequence probably has about 70% identity with the
15 nucleotide coding sequence of mouse DTLR2. At the amino acid level, there is also likely to be reasonable identity.

 The biological activities of the DTLRs will be related to addition or removal of phosphate moieties to
20 substrates, typically in a specific manner, but occasionally in a non specific manner. Substrates may be identified, or conditions for enzymatic activity may be assayed by standard methods, e.g., as described in Hardie, et al. (eds. 1995) The Protein Kinase FactBook
25 vols. I and II, Academic Press, San Diego, CA; Hanks, et al. (1991) Meth. Enzymol. 200:38-62; Hunter, et al. (1992) Cell 70:375-388; Lewin (1990) Cell 61:743-752; Pines, et al. (1991) Cold Spring Harbor Symp. Quant. Biol. 56:449-463; and Parker, et al. (1993) Nature
30 363:736-738.

III. Nucleic Acids

 This invention contemplates use of isolated nucleic acid or fragments, e.g., which encode these or closely
35 related proteins, or fragments thereof, e.g., to encode a corresponding polypeptide, preferably one which is biologically active. In addition, this invention covers

isolated or recombinant DNA which encodes such proteins or polypeptides having characteristic sequences of the respective DTLRs, individually or as a group. Typically, the nucleic acid is capable of hybridizing, under
5 appropriate conditions, with a nucleic acid sequence segment shown in SEQ ID NOS: 3, 5, 25, 9, 11, 15, 17, 31, 21, or 33, but preferably not with a corresponding segment of SEQ ID NO: 1. Said biologically active protein or polypeptide can be a full length protein, or
10 fragment, and will typically have a segment of amino acid sequence highly homologous to one shown in SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34. Further, this invention covers the use of isolated or recombinant nucleic acid, or fragments thereof, which encode proteins
15 having fragments which are equivalent to the DTLR2-10 proteins. The isolated nucleic acids can have the respective regulatory sequences in the 5' and 3' flanks, e.g., promoters, enhancers, poly-A addition signals, and others from the natural gene.

20 An "isolated" nucleic acid is a nucleic acid, e.g., an RNA, DNA, or a mixed polymer, which is substantially pure, e.g., separated from other components which naturally accompany a native sequence, such as ribosomes, polymerases, and flanking genomic sequences from the
25 originating species. The term embraces a nucleic acid sequence which has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates, which are thereby distinguishable from naturally occurring compositions, and chemically
30 synthesized analogs or analogs biologically synthesized by heterologous systems. A substantially pure molecule includes isolated forms of the molecule, either completely or substantially pure.

An isolated nucleic acid will generally be a
35 homogeneous composition of molecules, but will, in some embodiments, contain heterogeneity, preferably minor. This heterogeneity is typically found at the polymer ends

or portions not critical to a desired biological function or activity.

A "recombinant" nucleic acid is typically defined either by its method of production or its structure. In
5 reference to its method of production, e.g., a product made by a process, the process is use of recombinant nucleic acid techniques, e.g., involving human intervention in the nucleotide sequence. Typically this intervention involves in vitro manipulation, although
10 under certain circumstances it may involve more classical animal breeding techniques. Alternatively, it can be a nucleic acid made by generating a sequence comprising fusion of two fragments which are not naturally contiguous to each other, but is meant to exclude
15 products of nature, e.g., naturally occurring mutants as found in their natural state. Thus, for example, products made by transforming cells with any unnaturally occurring vector is encompassed, as are nucleic acids comprising sequence derived using any synthetic
20 oligonucleotide process. Such a process is often done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a restriction enzyme sequence recognition site. Alternatively, the process is performed to join
25 together nucleic acid segments of desired functions to generate a single genetic entity comprising a desired combination of functions not found in the commonly available natural forms, e.g., encoding a fusion protein. Restriction enzyme recognition sites are often the target
30 of such artificial manipulations, but other site specific targets, e.g., promoters, DNA replication sites, regulation sequences, control sequences, or other useful features may be incorporated by design. A similar concept is intended for a recombinant, e.g., fusion,
35 polypeptide. This will include a dimeric repeat. Specifically included are synthetic nucleic acids which, by genetic code redundancy, encode equivalent

polypeptides to fragments of DTLR2-10 and fusions of sequences from various different related molecules, e.g., other IL-1 receptor family members.

A "fragment" in a nucleic acid context is a
5 contiguous segment of at least about 17 nucleotides, generally at least 21 nucleotides, more generally at least 25 nucleotides, ordinarily at least 30 nucleotides, more ordinarily at least 35 nucleotides, often at least 39 nucleotides, more often at least 45 nucleotides,
10 typically at least 50 nucleotides, more typically at least 55 nucleotides, usually at least 60 nucleotides, more usually at least 66 nucleotides, preferably at least 72 nucleotides, more preferably at least 79 nucleotides, and in particularly preferred embodiments will be at
15 least 85 or more nucleotides. Typically, fragments of different genetic sequences can be compared to one another over appropriate length stretches, particularly defined segments such as the domains described below.

A nucleic acid which codes for a DTLR2-10 will be
20 particularly useful to identify genes, mRNA, and cDNA species which code for itself or closely related proteins, as well as DNAs which code for polymorphic, allelic, or other genetic variants, e.g., from different individuals or related species. Preferred probes for
25 such screens are those regions of the interleukin which are conserved between different polymorphic variants or which contain nucleotides which lack specificity, and will preferably be full length or nearly so. In other situations, polymorphic variant specific sequences will
30 be more useful.

This invention further covers recombinant nucleic acid molecules and fragments having a nucleic acid sequence identical to or highly homologous to the isolated DNA set forth herein. In particular, the
35 sequences will often be operably linked to DNA segments which control transcription, translation, and DNA

replication. These additional segments typically assist in expression of the desired nucleic acid segment.

Homologous, or highly identical, nucleic acid sequences, when compared to one another or the sequences shown in SEQ ID NO: 3, 5, 25, 9, 11, 15, 17, 31, 21, or 33 exhibit significant similarity. The standards for homology in nucleic acids are either measures for homology generally used in the art by sequence comparison or based upon hybridization conditions. Comparative hybridization conditions are described in greater detail below.

Substantial identity in the nucleic acid sequence comparison context means either that the segments, or their complementary strands, when compared, are identical when optimally aligned, with appropriate nucleotide insertions or deletions, in at least about 60% of the nucleotides, generally at least 66%, ordinarily at least 71%, often at least 76%, more often at least 80%, usually at least 84%, more usually at least 88%, typically at least 91%, more typically at least about 93%, preferably at least about 95%, more preferably at least about 96 to 98% or more, and in particular embodiments, as high at about 99% or more of the nucleotides, including, e.g., segments encoding structural domains such as the segments described below. Alternatively, substantial identity will exist when the segments will hybridize under selective hybridization conditions, to a strand or its complement, typically using a sequence derived from SEQ ID NO: 3, 5, 25, 9, 11, 15, 17, 31, 21, or 33. Typically, selective hybridization will occur when there is at least about 55% homology over a stretch of at least about 14 nucleotides, more typically at least about 65%, preferably at least about 75%, and more preferably at least about 90%. See, Kanehisa (1984) Nuc. Acids Res. 12:203-213, which is incorporated herein by reference. The length of homology comparison, as described, may be over longer stretches, and in certain embodiments will be

over a stretch of at least about 17 nucleotides,
generally at least about 20 nucleotides, ordinarily at
least about 24 nucleotides, usually at least about 28
nucleotides, typically at least about 32 nucleotides,
5 more typically at least about 40 nucleotides, preferably
at least about 50 nucleotides, and more preferably at
least about 75 to 100 or more nucleotides.

Stringent conditions, in referring to homology in
the hybridization context, will be stringent combined
10 conditions of salt, temperature, organic solvents, and
other parameters typically controlled in hybridization
reactions. Stringent temperature conditions will usually
include temperatures in excess of about 30° C, more
usually in excess of about 37° C, typically in excess of
15 about 45° C, more typically in excess of about 55° C,
preferably in excess of about 65° C, and more preferably
in excess of about 70° C. Stringent salt conditions will
ordinarily be less than about 500 mM, usually less than
about 400 mM, more usually less than about 300 mM,
20 typically less than about 200 mM, preferably less than
about 100 mM, and more preferably less than about 80 mM,
even down to less than about 20 mM. However, the
combination of parameters is much more important than the
measure of any single parameter. See, e.g., Wetmur and
25 Davidson (1968) J. Mol. Biol. 31:349-370, which is hereby
incorporated herein by reference.

Alternatively, for sequence comparison, typically
one sequence acts as a reference sequence, to which test
sequences are compared. When using a sequence comparison
30 algorithm, test and reference sequences are input into a
computer, subsequence coordinates are designated, if
necessary, and sequence algorithm program parameters are
designated. The sequence comparison algorithm then
calculates the percent sequence identity for the test
35 sequence(s) relative to the reference sequence, based on
the designated program parameters.

Optical alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'l Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally Ausubel et al., supra).

One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle (1987) J. Mol. Evol. 35:351-360. The method used is similar to the method described by Higgins and Sharp (1989) CABIOS 5:151-153. The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. For example, a reference sequence can be compared to other test sequences to determine the percent sequence identity relationship using the following

parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps.

Another example of algorithm that is suitable for determining percent sequence identity and sequence
5 similarity is the BLAST algorithm, which is described Altschul, et al. (1990) J. Mol. Biol. 215:403-410. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm
10 involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is
15 referred to as the neighborhood word score threshold (Altschul, et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as
20 far as the cumulative alignment score can be increased. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the
25 accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the
30 BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Nat'l Acad. Sci. USA 89:10915) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

In addition to calculating percent sequence
35 identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Nat'l Acad. Sci.

USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

A further indication that two nucleic acid sequences of polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions, as described below.

The isolated DNA can be readily modified by nucleotide substitutions, nucleotide deletions, nucleotide insertions, and inversions of nucleotide stretches. These modifications result in novel DNA sequences which encode this protein or its derivatives. These modified sequences can be used to produce mutant proteins (muteins) or to enhance the expression of variant species. Enhanced expression may involve gene amplification, increased transcription, increased translation, and other mechanisms. Such mutant DTLR-like derivatives include predetermined or site-specific mutations of the protein or its fragments, including silent mutations using genetic code degeneracy. "Mutant DTLR" as used herein encompasses a polypeptide otherwise falling within the homology definition of the DTLR as set

forth above, but having an amino acid sequence which differs from that of other DTLR-like proteins as found in nature, whether by way of deletion, substitution, or insertion. In particular, "site specific mutant DTLR" encompasses a protein having substantial homology with a protein of SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34, and typically shares most of the biological activities or effects of the forms disclosed herein.

Although site specific mutation sites are predetermined, mutants need not be site specific. Mammalian DTLR mutagenesis can be achieved by making amino acid insertions or deletions in the gene, coupled with expression. Substitutions, deletions, insertions, or any combinations may be generated to arrive at a final construct. Insertions include amino- or carboxy-terminal fusions. Random mutagenesis can be conducted at a target codon and the expressed mammalian DTLR mutants can then be screened for the desired activity. Methods for making substitution mutations at predetermined sites in DNA having a known sequence are well known in the art, e.g., by M13 primer mutagenesis. See also Sambrook, et al. (1989) and Ausubel, et al. (1987 and periodic Supplements).

The mutations in the DNA normally should not place coding sequences out of reading frames and preferably will not create complementary regions that could hybridize to produce secondary mRNA structure such as loops or hairpins.

The phosphoramidite method described by Beaucage and Carruthers (1981) Tetra. Letts. 22:1859-1862, will produce suitable synthetic DNA fragments. A double stranded fragment will often be obtained either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

Polymerase chain reaction (PCR) techniques can often be applied in mutagenesis. Alternatively, mutagenesis primers are commonly used methods for generating defined mutations at predetermined sites. See, e.g, Innis, et al. (eds. 1990) PCR Protocols: A Guide to Methods and Applications Academic Press, San Diego, CA; and Dieffenbach and Dveksler (1995; eds.) PCR Primer: A Laboratory Manual Cold Spring Harbor Press, CSH, NY.

10 IV. Proteins, Peptides

As described above, the present invention encompasses primate DTLR2-10, e.g., whose sequences are disclosed in SEQ ID NOS: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34, and described above. Allelic and other variants are also contemplated, including, e.g., fusion proteins combining portions of such sequences with others, including epitope tags and functional domains.

The present invention also provides recombinant proteins, e.g., heterologous fusion proteins using segments from these rodent proteins. A heterologous fusion protein is a fusion of proteins or segments which are naturally not normally fused in the same manner. Thus, the fusion product of a DTLR with an IL-1 receptor is a continuous protein molecule having sequences fused in a typical peptide linkage, typically made as a single translation product and exhibiting properties, e.g., sequence or antigenicity, derived from each source peptide. A similar concept applies to heterologous nucleic acid sequences.

30 In addition, new constructs may be made from combining similar functional or structural domains from other related proteins, e.g., IL-1 receptors or other DTLRs, including species variants. For example, ligand-binding or other segments may be "swapped" between different new fusion polypeptides or fragments. See, e.g., Cunningham, et al. (1989) Science 243:1330-1336; and O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992,

each of which is incorporated herein by reference. Thus, new chimeric polypeptides exhibiting new combinations of specificities will result from the functional linkage of receptor-binding specificities. For example, the ligand
5 binding domains from other related receptor molecules may be added or substituted for other domains of this or related proteins. The resulting protein will often have hybrid function and properties. For example, a fusion protein may include a targetting domain which may serve
10 to provide sequestering of the fusion protein to a particular subcellular organelle.

Candidate fusion partners and sequences can be selected from various sequence data bases, e.g., GenBank, c/o IntelliGenetics, Mountain View, CA; and BCG,
15 University of Wisconsin Biotechnology Computing Group, Madison, WI, which are each incorporated herein by reference.

The present invention particularly provides muteins which bind Toll ligands, and/or which are affected in
20 signal transduction. Structural alignment of human DTLR1-10 with other members of the IL-1 family show conserved features/residues. See, e.g., Figure 3A. Alignment of the human DTLR sequences with other members of the IL-1 family indicates various structural and
25 functionally shared features. See also, Bazan, et al. (1996) Nature 379:591; Lodi, et al. (1994) Science 263:1762-1766; Sayle and Milner-White (1995) TIBS 20:374-376; and Gronenberg, et al. (1991) Protein Engineering 4:263-269.

30 The IL-1 α and IL-1 β ligands bind an IL-1 receptor type I as the primary receptor and this complex then forms a high affinity receptor complex with the IL-1 receptor type III. Such receptor subunits are probably shared with the new IL-1 family members.

35 Similar variations in other species counterparts of DTLR2-10 sequences, e.g., in the corresponding regions, should provide similar interactions with ligand or

substrate. Substitutions with either mouse sequences or human sequences are particularly preferred. Conversely, conservative substitutions away from the ligand binding interaction regions will probably preserve most signaling activities.

"Derivatives" of the primate DTLR2-10 include amino acid sequence mutants, glycosylation variants, metabolic derivatives and covalent or aggregative conjugates with other chemical moieties. Covalent derivatives can be prepared by linkage of functionalities to groups which are found in the DTLR amino acid side chains or at the N- or C- termini, e.g., by means which are well known in the art. These derivatives can include, without limitation, aliphatic esters or amides of the carboxyl terminus, or of residues containing carboxyl side chains, O-acyl derivatives of hydroxyl group-containing residues, and N-acyl derivatives of the amino terminal amino acid or amino-group containing residues, e.g., lysine or arginine. Acyl groups are selected from the group of alkyl-moieties including C3 to C18 normal alkyl, thereby forming alkanoyl aroyl species.

In particular, glycosylation alterations are included, e.g., made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing, or in further processing steps. Particularly preferred means for accomplishing this are by exposing the polypeptide to glycosylating enzymes derived from cells which normally provide such processing, e.g., mammalian glycosylation enzymes. Deglycosylation enzymes are also contemplated. Also embraced are versions of the same primary amino acid sequence which have other minor modifications, including phosphorylated amino acid residues, e.g., phosphotyrosine, phosphoserine, or phosphothreonine.

A major group of derivatives are covalent conjugates of the receptors or fragments thereof with other proteins of polypeptides. These derivatives can be synthesized in

recombinant culture such as N- or C-terminal fusions or by the use of agents known in the art for their usefulness in cross-linking proteins through reactive side groups. Preferred derivatization sites with cross-linking agents are at free amino groups, carbohydrate moieties, and cysteine residues.

Fusion polypeptides between the receptors and other homologous or heterologous proteins are also provided. Homologous polypeptides may be fusions between different receptors, resulting in, for instance, a hybrid protein exhibiting binding specificity for multiple different Toll ligands, or a receptor which may have broadened or weakened specificity of substrate effect. Likewise, heterologous fusions may be constructed which would exhibit a combination of properties or activities of the derivative proteins. Typical examples are fusions of a reporter polypeptide, e.g., luciferase, with a segment or domain of a receptor, e.g., a ligand-binding segment, so that the presence or location of a desired ligand may be easily determined. See, e.g., Dull, et al., U.S. Patent No. 4,859,609, which is hereby incorporated herein by reference. Other gene fusion partners include glutathione-S-transferase (GST), bacterial β -galactosidase, trpE, Protein A, β -lactamase, alpha amylase, alcohol dehydrogenase, and yeast alpha mating factor. See, e.g., Godowski, et al. (1988) Science 241:812-816.

The phosphoramidite method described by Beaucage and Carruthers (1981) Tetra. Letts. 22:1859-1862, will produce suitable synthetic DNA fragments. A double stranded fragment will often be obtained either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

Such polypeptides may also have amino acid residues which have been chemically modified by phosphorylation,

sulfonation, biotinylation, or the addition or removal of other moieties, particularly those which have molecular shapes similar to phosphate groups. In some embodiments, the modifications will be useful labeling reagents, or
5 serve as purification targets, e.g., affinity ligands.

Fusion proteins will typically be made by either recombinant nucleic acid methods or by synthetic polypeptide methods. Techniques for nucleic acid manipulation and expression are described generally, for
10 example, in Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.), Vols. 1-3, Cold Spring Harbor Laboratory, and Ausubel, et al. (eds. 1987 and periodic supplements) Current Protocols in Molecular Biology,
Greene/Wiley, New York, which are each incorporated
15 herein by reference. Techniques for synthesis of polypeptides are described, for example, in Merrifield (1963) J. Amer. Chem. Soc. 85:2149-2156; Merrifield (1986) Science 232: 341-347; and Atherton, et al. (1989) Solid Phase Peptide Synthesis: A Practical Approach, IRL
20 Press, Oxford; each of which is incorporated herein by reference. See also Dawson, et al. (1994) Science 266:776-779 for methods to make larger polypeptides.

This invention also contemplates the use of derivatives of a DTLR2-10 other than variations in amino
25 acid sequence or glycosylation. Such derivatives may involve covalent or aggregative association with chemical moieties. These derivatives generally fall into three classes: (1) salts, (2) side chain and terminal residue covalent modifications, and (3) adsorption complexes, for
30 example with cell membranes. Such covalent or aggregative derivatives are useful as immunogens, as reagents in immunoassays, or in purification methods such as for affinity purification of a receptor or other binding molecule, e.g., an antibody. For example, a Toll
35 ligand can be immobilized by covalent bonding to a solid support such as cyanogen bromide-activated Sepharose, by methods which are well known in the art, or adsorbed onto

polyolefin surfaces, with or without glutaraldehyde cross-linking, for use in the assay or purification of a DTLR receptor, antibodies, or other similar molecules. The ligand can also be labeled with a detectable group, for example radioiodinated by the chloramine T procedure, covalently bound to rare earth chelates, or conjugated to another fluorescent moiety for use in diagnostic assays.

A DTLR of this invention can be used as an immunogen for the production of antisera or antibodies specific, e.g., capable of distinguishing between other IL-1 receptor family members, for the DTLR or various fragments thereof. The purified DTLR can be used to screen monoclonal antibodies or antigen-binding fragments prepared by immunization with various forms of impure preparations containing the protein. In particular, the term "antibodies" also encompasses antigen binding fragments of natural antibodies, e.g., Fab, Fab2, Fv, etc. The purified DTLR can also be used as a reagent to detect antibodies generated in response to the presence of elevated levels of expression, or immunological disorders which lead to antibody production to the endogenous receptor. Additionally, DTLR fragments may also serve as immunogens to produce the antibodies of the present invention, as described immediately below. For example, this invention contemplates antibodies having binding affinity to or being raised against the amino acid sequences shown in SEQ ID NOS: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34, fragments thereof, or various homologous peptides. In particular, this invention contemplates antibodies having binding affinity to, or having been raised against, specific fragments which are predicted to be, or actually are, exposed at the exterior protein surface of the native DTLR.

The blocking of physiological response to the receptor ligands may result from the inhibition of binding of the ligand to the receptor, likely through competitive inhibition. Thus, in vitro assays of the

present invention will often use antibodies or antigen binding segments of these antibodies, or fragments attached to solid phase substrates. These assays will also allow for the diagnostic determination of the effects of either ligand binding region mutations and modifications, or other mutations and modifications, e.g., which affect signaling or enzymatic function.

This invention also contemplates the use of competitive drug screening assays, e.g., where neutralizing antibodies to the receptor or fragments compete with a test compound for binding to a ligand or other antibody. In this manner, the neutralizing antibodies or fragments can be used to detect the presence of a polypeptide which shares one or more binding sites to a receptor and can also be used to occupy binding sites on a receptor that might otherwise bind a ligand.

V. Making Nucleic Acids and Protein

DNA which encodes the protein or fragments thereof can be obtained by chemical synthesis, screening cDNA libraries, or by screening genomic libraries prepared from a wide variety of cell lines or tissue samples. Natural sequences can be isolated using standard methods and the sequences provided herein. Other species counterparts can be identified by hybridization techniques, or by various PCR techniques, combined with or by searching in sequence databases, e.g., GenBank.

This DNA can be expressed in a wide variety of host cells for the synthesis of a full-length receptor or fragments which can in turn, for example, be used to generate polyclonal or monoclonal antibodies; for binding studies; for construction and expression of modified ligand binding or kinase/phosphatase domains; and for structure/function studies. Variants or fragments can be expressed in host cells that are transformed or transfected with appropriate expression vectors. These

molecules can be substantially free of protein or cellular contaminants, other than those derived from the recombinant host, and therefore are particularly useful in pharmaceutical compositions when combined with a
5 pharmaceutically acceptable carrier and/or diluent. The protein, or portions thereof, may be expressed as fusions with other proteins.

Expression vectors are typically self-replicating DNA or RNA constructs containing the desired receptor
10 gene or its fragments, usually operably linked to suitable genetic control elements that are recognized in a suitable host cell. These control elements are capable of effecting expression within a suitable host. The specific type of control elements necessary to effect
15 expression will depend upon the eventual host cell used. Generally, the genetic control elements can include a prokaryotic promoter system or a eukaryotic promoter expression control system, and typically include a transcriptional promoter, an optional operator to control
20 the onset of transcription, transcription enhancers to elevate the level of mRNA expression, a sequence that encodes a suitable ribosome binding site, and sequences that terminate transcription and translation. Expression vectors also usually contain an origin of replication
25 that allows the vector to replicate independently of the host cell.

The vectors of this invention include those which contain DNA which encodes a protein, as described, or a fragment thereof encoding a biologically active
30 equivalent polypeptide. The DNA can be under the control of a viral promoter and can encode a selection marker. This invention further contemplates use of such expression vectors which are capable of expressing eukaryotic cDNA coding for such a protein in a
35 prokaryotic or eukaryotic host, where the vector is compatible with the host and where the eukaryotic cDNA coding for the receptor is inserted into the vector such

that growth of the host containing the vector expresses the cDNA in question. Usually, expression vectors are designed for stable replication in their host cells or for amplification to greatly increase the total number of
5 copies of the desirable gene per cell. It is not always necessary to require that an expression vector replicate in a host cell, e.g., it is possible to effect transient expression of the protein or its fragments in various hosts using vectors that do not contain a replication
10 origin that is recognized by the host cell. It is also possible to use vectors that cause integration of the protein encoding portion or its fragments into the host DNA by recombination.

Vectors, as used herein, comprise plasmids, viruses,
15 bacteriophage, integratable DNA fragments, and other vehicles which enable the integration of DNA fragments into the genome of the host. Expression vectors are specialized vectors which contain genetic control elements that effect expression of operably linked genes.
20 Plasmids are the most commonly used form of vector but all other forms of vectors which serve an equivalent function and which are, or become, known in the art are suitable for use herein. See, e.g., Pouwels, et al. (1985 and Supplements) Cloning Vectors: A Laboratory
25 Manual, Elsevier, N.Y., and Rodriguez, et al. (eds) Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworth, Boston, 1988, which are incorporated herein by reference.

Transformed cells are cells, preferably mammalian,
30 that have been transformed or transfected with receptor vectors constructed using recombinant DNA techniques. Transformed host cells usually express the desired protein or its fragments, but for purposes of cloning, amplifying, and manipulating its DNA, do not need to
35 express the subject protein. This invention further contemplates culturing transformed cells in a nutrient medium, thus permitting the receptor to accumulate in the

cell membrane. The protein can be recovered, either from the culture or, in certain instances, from the culture medium.

For purposes of this invention, nucleic sequences
5 are operably linked when they are functionally related to each other. For example, DNA for a presequence or secretory leader is operably linked to a polypeptide if it is expressed as a preprotein or participates in directing the polypeptide to the cell membrane or in
10 secretion of the polypeptide. A promoter is operably linked to a coding sequence if it controls the transcription of the polypeptide; a ribosome binding site is operably linked to a coding sequence if it is positioned to permit translation. Usually, operably
15 linked means contiguous and in reading frame, however, certain genetic elements such as repressor genes are not contiguously linked but still bind to operator sequences that in turn control expression.

Suitable host cells include prokaryotes, lower
20 eukaryotes, and higher eukaryotes. Prokaryotes include both gram negative and gram positive organisms, e.g., E. coli and B. subtilis. Lower eukaryotes include yeasts, e.g., S. cerevisiae and Pichia, and species of the genus Dictyostelium. Higher eukaryotes include established
25 tissue culture cell lines from animal cells, both of non-mammalian origin, e.g., insect cells, and birds, and of mammalian origin, e.g., human, primates, and rodents.

Prokaryotic host-vector systems include a wide variety of vectors for many different species. As used
30 herein, E. coli and its vectors will be used generically to include equivalent vectors used in other prokaryotes. A representative vector for amplifying DNA is pBR322 or many of its derivatives. Vectors that can be used to express the receptor or its fragments include, but are
35 not limited to, such vectors as those containing the lac promoter (pUC-series); trp promoter (pBR322-trp); Ipp promoter (the pIN-series); lambda-pP or pR promoters

(pOTS); or hybrid promoters such as ptac (pDR540). See Brosius, et al. (1988) "Expression Vectors Employing Lambda-, trp-, lac-, and Ipp-derived Promoters", in Vectors: A Survey of Molecular Cloning Vectors and Their
5 Uses, (eds. Rodriguez and Denhardt), Butterworth, Boston, Chapter 10, pp. 205-236, which is incorporated herein by reference.

Lower eukaryotes, e.g., yeasts and Dictyostelium, may be transformed with DTLR sequence containing vectors.
10 For purposes of this invention, the most common lower eukaryotic host is the baker's yeast, Saccharomyces cerevisiae. It will be used to generically represent lower eukaryotes although a number of other strains and species are also available. Yeast vectors typically
15 consist of a replication origin (unless of the integrating type), a selection gene, a promoter, DNA encoding the receptor or its fragments, and sequences for translation termination, polyadenylation, and transcription termination. Suitable expression vectors
20 for yeast include such constitutive promoters as 3-phosphoglycerate kinase and various other glycolytic enzyme gene promoters or such inducible promoters as the alcohol dehydrogenase 2 promoter or metallothionine promoter. Suitable vectors include derivatives of the
25 following types: self-replicating low copy number (such as the YRp-series), self-replicating high copy number (such as the YEp-series); integrating types (such as the YIp-series), or mini-chromosomes (such as the YCp-series).

30 Higher eukaryotic tissue culture cells are normally the preferred host cells for expression of the functionally active interleukin protein. In principle, any higher eukaryotic tissue culture cell line is workable, e.g., insect baculovirus expression systems,
35 whether from an invertebrate or vertebrate source. However, mammalian cells are preferred. Transformation or transfection and propagation of such cells has become

a routine procedure. Examples of useful cell lines include HeLa cells, Chinese hamster ovary (CHO) cell lines, baby rat kidney (BRK) cell lines, insect cell lines, bird cell lines, and monkey (COS) cell lines.

5 Expression vectors for such cell lines usually include an origin of replication, a promoter, a translation initiation site, RNA splice sites (if genomic DNA is used), a polyadenylation site, and a transcription termination site. These vectors also usually contain a
10 selection gene or amplification gene. Suitable expression vectors may be plasmids, viruses, or retroviruses carrying promoters derived, e.g., from such sources as from adenovirus, SV40, parvoviruses, vaccinia virus, or cytomegalovirus. Representative examples of
15 suitable expression vectors include pCDNA1; pCD, see Okayama, et al. (1985) Mol. Cell Biol. 5:1136-1142; pMC1neo PolyA, see Thomas, et al. (1987) Cell 51:503-512; and a baculovirus vector such as pAC 373 or pAC 610.

For secreted proteins, an open reading frame usually
20 encodes a polypeptide that consists of a mature or secreted product covalently linked at its N-terminus to a signal peptide. The signal peptide is cleaved prior to secretion of the mature, or active, polypeptide. The cleavage site can be predicted with a high degree of
25 accuracy from empirical rules, e.g., von-Heijne (1986) Nucleic Acids Research 14:4683-4690, and the precise amino acid composition of the signal peptide does not appear to be critical to its function, e.g., Randall, et al. (1989) Science 243:1156-1159; Kaiser et al. (1987)
30 Science 235:312-317.

It will often be desired to express these polypeptides in a system which provides a specific or defined glycosylation pattern. In this case, the usual pattern will be that provided naturally by the expression
35 system. However, the pattern will be modifiable by exposing the polypeptide, e.g., an unglycosylated form, to appropriate glycosylating proteins introduced into a

heterologous expression system. For example, the receptor gene may be co-transformed with one or more genes encoding mammalian or other glycosylating enzymes. Using this approach, certain mammalian glycosylation
5 patterns will be achievable in prokaryote or other cells.

The source of DTLR can be a eukaryotic or prokaryotic host expressing recombinant DTLR, such as is described above. The source can also be a cell line such as mouse Swiss 3T3 fibroblasts, but other mammalian cell
10 lines are also contemplated by this invention, with the preferred cell line being from the human species.

Now that the sequences are known, the primate DTLRs, fragments, or derivatives thereof can be prepared by conventional processes for synthesizing peptides. These
15 include processes such as are described in Stewart and Young (1984) Solid Phase Peptide Synthesis, Pierce Chemical Co., Rockford, IL; Bodanszky and Bodanszky (1984) The Practice of Peptide Synthesis, Springer-Verlag, New York; and Bodanszky (1984) The
20 Principles of Peptide Synthesis, Springer-Verlag, New York; all of each which are incorporated herein by reference. For example, an azide process, an acid chloride process, an acid anhydride process, a mixed anhydride process, an active ester process (e.g.,
25 p-nitrophenyl ester, N-hydroxysuccinimide ester, or cyanomethyl ester), a carbodiimidazole process, an oxidative-reductive process, or a dicyclohexylcarbodiimide (DCCD)/additive process can be used. Solid phase and solution phase syntheses are both
30 applicable to the foregoing processes. Similar techniques can be used with partial DTLR sequences.

The DTLR proteins, fragments, or derivatives are suitably prepared in accordance with the above processes as typically employed in peptide synthesis, generally
35 either by a so-called stepwise process which comprises condensing an amino acid to the terminal amino acid, one by one in sequence, or by coupling peptide fragments to

the terminal amino acid. Amino groups that are not being used in the coupling reaction typically must be protected to prevent coupling at an incorrect location.

If a solid phase synthesis is adopted, the
5 C-terminal amino acid is bound to an insoluble carrier or support through its carboxyl group. The insoluble carrier is not particularly limited as long as it has a binding capability to a reactive carboxyl group. Examples of such insoluble carriers include halomethyl
10 resins, such as chloromethyl resin or bromomethyl resin, hydroxymethyl resins, phenol resins, tert-alkyloxycarbonylhydrazidated resins, and the like.

An amino group-protected amino acid is bound in sequence through condensation of its activated carboxyl
15 group and the reactive amino group of the previously formed peptide or chain, to synthesize the peptide step by step. After synthesizing the complete sequence, the peptide is split off from the insoluble carrier to produce the peptide. This solid-phase approach is
20 generally described by Merrifield, et al. (1963) in J. Am. Chem. Soc. 85:2149-2156, which is incorporated herein by reference.

The prepared protein and fragments thereof can be isolated and purified from the reaction mixture by means
25 of peptide separation, for example, by extraction, precipitation, electrophoresis, various forms of chromatography, and the like. The receptors of this invention can be obtained in varying degrees of purity depending upon desired uses. Purification can be
30 accomplished by use of the protein purification techniques disclosed herein, see below, or by the use of the antibodies herein described in methods of immunoabsorbant affinity chromatography. This immunoabsorbant affinity chromatography is carried out by
35 first linking the antibodies to a solid support and then contacting the linked antibodies with solubilized lysates of appropriate cells, lysates of other cells expressing

the receptor, or lysates or supernatants of cells producing the protein as a result of DNA techniques, see below.

Generally, the purified protein will be at least
5 about 40% pure, ordinarily at least about 50% pure,
usually at least about 60% pure, typically at least about
70% pure, more typically at least about 80% pure,
preferable at least about 90% pure and more preferably at
least about 95% pure, and in particular embodiments, 97%-
10 99% or more. Purity will usually be on a weight basis,
but can also be on a molar basis. Different assays will
be applied as appropriate.

VI. Antibodies

15 Antibodies can be raised to the various mammalian,
e.g., primate DTLR proteins and fragments thereof, both
in naturally occurring native forms and in their
recombinant forms, the difference being that antibodies
to the active receptor are more likely to recognize
20 epitopes which are only present in the native
conformations. Denatured antigen detection can also be
useful in, e.g., Western analysis. Anti-idiotypic
antibodies are also contemplated, which would be useful
as agonists or antagonists of a natural receptor or an
25 antibody.

Antibodies, including binding fragments and single
chain versions, against predetermined fragments of the
protein can be raised by immunization of animals with
conjugates of the fragments with immunogenic proteins.
30 Monoclonal antibodies are prepared from cells secreting
the desired antibody. These antibodies can be screened
for binding to normal or defective protein, or screened
for agonistic or antagonistic activity. These monoclonal
antibodies will usually bind with at least a K_D of about
35 1 mM, more usually at least about 300 μ M, typically at
least about 100 μ M, more typically at least about 30 μ M,

preferably at least about 10 μM , and more preferably at least about 3 μM or better.

The antibodies, including antigen binding fragments, of this invention can have significant diagnostic or therapeutic value. They can be potent antagonists that bind to the receptor and inhibit binding to ligand or inhibit the ability of the receptor to elicit a biological response, e.g., act on its substrate. They also can be useful as non-neutralizing antibodies and can be coupled to toxins or radionuclides to bind producing cells, or cells localized to the source of the interleukin. Further, these antibodies can be conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker.

The antibodies of this invention can also be useful in diagnostic applications. As capture or non-neutralizing antibodies, they might bind to the receptor without inhibiting ligand or substrate binding. As neutralizing antibodies, they can be useful in competitive binding assays. They will also be useful in detecting or quantifying ligand. They may be used as reagents for Western blot analysis, or for immunoprecipitation or immunopurification of the respective protein.

Protein fragments may be joined to other materials, particularly polypeptides, as fused or covalently joined polypeptides to be used as immunogens. Mammalian DTLR and its fragments may be fused or covalently linked to a variety of immunogens, such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc. See Microbiology, Hoeber Medical Division, Harper and Row, 1969; Landsteiner (1962) Specificity of Serological Reactions, Dover Publications, New York; and Williams, et al. (1967) Methods in Immunology and Immunochemistry, Vol. 1, Academic Press, New York; each of which are incorporated herein by reference, for descriptions of methods of preparing polyclonal antisera. A typical

method involves hyperimmunization of an animal with an antigen. The blood of the animal is then collected shortly after the repeated immunizations and the gamma globulin is isolated.

5 In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies may be found in, e.g., Stites, et al. (eds) Basic and
10 Clinical Immunology (4th ed.), Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York;
15 and particularly in Kohler and Milstein (1975) in Nature 256: 495-497, which discusses one method of generating monoclonal antibodies. Each of these references is incorporated herein by reference. Summarized briefly, this method involves injecting an animal with an
20 immunogen. The animal is then sacrificed and cells taken from its spleen, which are then fused with myeloma cells. The result is a hybrid cell or "hybridoma" that is capable of reproducing in vitro. The population of hybridomas is then screened to isolate individual clones,
25 each of which secrete a single antibody species to the immunogen. In this manner, the individual antibody species obtained are the products of immortalized and cloned single B cells from the immune animal generated in response to a specific site recognized on the immunogenic
30 substance.

Other suitable techniques involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors. See, Huse, et al. (1989)
35 "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281; and Ward, et al. (1989) Nature 341:544-

546, each of which is hereby incorporated herein by reference. The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies.

5 Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific
10 and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents, teaching the use of such labels include U.S. Patent Nos.
15 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant or chimeric immunoglobulins may be produced, see Cabilly, U.S. Patent No. 4,816,567; or made in transgenic mice, see Mendez, et al. (1997) Nature Genetics 15:146-156. These references
20 are incorporated herein by reference.

The antibodies of this invention can also be used for affinity chromatography in isolating the DTLRs. Columns can be prepared where the antibodies are linked to a solid support, e.g., particles, such as agarose,
25 Sephadex, or the like, where a cell lysate may be passed through the column, the column washed, followed by increasing concentrations of a mild denaturant, whereby the purified protein will be released. The protein may be used to purify antibody.

30 The antibodies may also be used to screen expression libraries for particular expression products. Usually the antibodies used in such a procedure will be labeled with a moiety allowing easy detection of presence of antigen by antibody binding.

35 Antibodies raised against a DTLR will also be used to raise anti-idiotypic antibodies. These will be useful in detecting or diagnosing various immunological

conditions related to expression of the protein or cells which express the protein. They also will be useful as agonists or antagonists of the ligand, which may be competitive inhibitors or substitutes for naturally occurring ligands.

A DTLR protein that specifically binds to or that is specifically immunoreactive with an antibody generated against a defined immunogen, such as an immunogen consisting of the amino acid sequence of SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34, is typically determined in an immunoassay. The immunoassay typically uses a polyclonal antiserum which was raised, e.g., to a protein of SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34. This antiserum is selected to have low crossreactivity against other IL-1R family members, e.g., DTLR1, preferably from the same species, and any such crossreactivity is removed by immunoabsorption prior to use in the immunoassay.

In order to produce antisera for use in an immunoassay, the protein of SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34, or a combination thereof, is isolated as described herein. For example, recombinant protein may be produced in a mammalian cell line. An appropriate host, e.g., an inbred strain of mice such as balb/c, is immunized with the selected protein, typically using a standard adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol (see Harlow and Lane, supra). Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used as an immunogen. Polyclonal sera are collected and titered against the immunogen protein in an immunoassay, e.g., a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of 10^4 or greater are selected and tested for their cross reactivity against other IL-1R family members, e.g., mouse DTLRs or human DTLR1, using a competitive binding

immunoassay such as the one described in Harlow and Lane, supra, at pages 570-573. Preferably at least two DTLR family members are used in this determination in conjunction with either or some of the human DTLR2-10.

5 These IL-1R family members can be produced as recombinant proteins and isolated using standard molecular biology and protein chemistry techniques as described herein.

Immunoassays in the competitive binding format can be used for the crossreactivity determinations. For
10 example, the proteins of SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34, or various fragments thereof, can be immobilized to a solid support. Proteins added to the assay compete with the binding of the antisera to the immobilized antigen. The ability of the above proteins
15 to compete with the binding of the antisera to the immobilized protein is compared to the protein of SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 and/or 34. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera
20 with less than 10% crossreactivity with each of the proteins listed above are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorbtion with the above-listed proteins.

25 The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein to the immunogen protein (e.g., the IL-1R like protein of SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 and/or 34). In order to make this
30 comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required is less than twice the amount
35 of the protein of the selected protein or proteins that is required, then the second protein is said to

specifically bind to an antibody generated to the immunogen.

It is understood that these DTLR proteins are members of a family of homologous proteins that comprise at least 10 so far identified genes. For a particular gene product, such as the DTLR2-10, the term refers not only to the amino acid sequences disclosed herein, but also to other proteins that are allelic, non-allelic or species variants. It also understood that the terms include nonnatural mutations introduced by deliberate mutation using conventional recombinant technology such as single site mutation, or by excising short sections of DNA encoding the respective proteins, or by substituting new amino acids, or adding new amino acids. Such minor alterations must substantially maintain the immunoidentity of the original molecule and/or its biological activity. Thus, these alterations include proteins that are specifically immunoreactive with a designated naturally occurring IL-1R related protein, for example, the DTLR proteins shown in SEQ ID NO: 4, 6, 26, 10, 12, 16, 18, 32, 22 or 34. The biological properties of the altered proteins can be determined by expressing the protein in an appropriate cell line and measuring the appropriate effect upon lymphocytes. Particular protein modifications considered minor would include conservative substitution of amino acids with similar chemical properties, as described above for the IL-1R family as a whole. By aligning a protein optimally with the protein of DTLR2-10 and by using the conventional immunoassays described herein to determine immunoidentity, one can determine the protein compositions of the invention.

VII. Kits and quantitation

Both naturally occurring and recombinant forms of the IL-1R like molecules of this invention are particularly useful in kits and assay methods. For example, these methods would also be applied to screening

for binding activity, e.g., ligands for these proteins. Several methods of automating assays have been developed in recent years so as to permit screening of tens of thousands of compounds per year. See, e.g., a BIOMEK
5 automated workstation, Beckman Instruments, Palo Alto, California, and Fodor, et al. (1991) Science 251:767-773, which is incorporated herein by reference. The latter describes means for testing binding by a plurality of defined polymers synthesized on a solid substrate. The
10 development of suitable assays to screen for a ligand or agonist/antagonist homologous proteins can be greatly facilitated by the availability of large amounts of purified, soluble DTLRs in an active state such as is provided by this invention.

15 Purified DTLR can be coated directly onto plates for use in the aforementioned ligand screening techniques. However, non-neutralizing antibodies to these proteins can be used as capture antibodies to immobilize the respective receptor on the solid phase, useful, e.g., in
20 diagnostic uses.

This invention also contemplates use of DTLR2-10, fragments thereof, peptides, and their fusion products in a variety of diagnostic kits and methods for detecting the presence of the protein or its ligand.
25 Alternatively, or additionally, antibodies against the molecules may be incorporated into the kits and methods. Typically the kit will have a compartment containing either a defined DTLR peptide or gene segment or a reagent which recognizes one or the other. Typically,
30 recognition reagents, in the case of peptide, would be a receptor or antibody, or in the case of a gene segment, would usually be a hybridization probe.

A preferred kit for determining the concentration of, e.g., DTLR4, a sample would typically comprise a
35 labeled compound, e.g., ligand or antibody, having known binding affinity for DTLR4, a source of DTLR4 (naturally occurring or recombinant) as a positive control, and a

means for separating the bound from free labeled compound, for example a solid phase for immobilizing the DTLR4 in the test sample. Compartments containing reagents, and instructions, will normally be provided.

5 Antibodies, including antigen binding fragments, specific for mammalian DTLR or a peptide fragment, or receptor fragments are useful in diagnostic applications to detect the presence of elevated levels of ligand and/or its fragments. Diagnostic assays may be
10 homogeneous (without a separation step between free reagent and antibody-antigen complex) or heterogeneous (with a separation step). Various commercial assays exist, such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA),
15 enzyme-multiplied immunoassay technique (EMIT), substrate-labeled fluorescent immunoassay (SLFIA) and the like. For example, unlabeled antibodies can be employed by using a second antibody which is labeled and which recognizes the antibody to DTLR4 or to a particular
20 fragment thereof. These assays have also been extensively discussed in the literature. See, e.g., Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH., and Coligan (Ed.) (1991) and periodic supplements, Current Protocols In Immunology Greene/Wiley, New York.

25 Anti-idiotypic antibodies may have similar use to serve as agonists or antagonists of DTLR4. These should be useful as therapeutic reagents under appropriate circumstances.

30 Frequently, the reagents for diagnostic assays are supplied in kits, so as to optimize the sensitivity of the assay. For the subject invention, depending upon the nature of the assay, the protocol, and the label, either labeled or unlabeled antibody, or labeled ligand is provided. This is usually in conjunction with other
35 additives, such as buffers, stabilizers, materials necessary for signal production such as substrates for enzymes, and the like. Preferably, the kit will also

contain instructions for proper use and disposal of the contents after use. Typically the kit has compartments for each useful reagent, and will contain instructions for proper use and disposal of reagents. Desirably, the reagents are provided as a dry lyophilized powder, where the reagents may be reconstituted in an aqueous medium having appropriate concentrations for performing the assay.

The aforementioned constituents of the diagnostic assays may be used without modification or may be modified in a variety of ways. For example, labeling may be achieved by covalently or non-covalently joining a moiety which directly or indirectly provides a detectable signal. In any of these assays, a test compound, DTLR, or antibodies thereto can be labeled either directly or indirectly. Possibilities for direct labeling include label groups: radiolabels such as ^{125}I , enzymes (U.S. Pat. No. 3,645,090) such as peroxidase and alkaline phosphatase, and fluorescent labels (U.S. Pat. No. 3,940,475) capable of monitoring the change in fluorescence intensity, wavelength shift, or fluorescence polarization. Both of the patents are incorporated herein by reference. Possibilities for indirect labeling include biotinylation of one constituent followed by binding to avidin coupled to one of the above label groups.

There are also numerous methods of separating the bound from the free ligand, or alternatively the bound from the free test compound. The DTLR can be immobilized on various matrixes followed by washing. Suitable matrices include plastic such as an ELISA plate, filters, and beads. Methods of immobilizing the receptor to a matrix include, without limitation, direct adhesion to plastic, use of a capture antibody, chemical coupling, and biotin-avidin. The last step in this approach involves the precipitation of antibody/antigen complex by any of several methods including those utilizing, e.g.,

an organic solvent such as polyethylene glycol or a salt such as ammonium sulfate. Other suitable separation techniques include, without limitation, the fluorescein antibody magnetizable particle method described in
5 Rattle, et al. (1984) Clin. Chem. 30(9):1457-1461, and the double antibody magnetic particle separation as described in U.S. Pat. No. 4,659,678, each of which is incorporated herein by reference.

The methods for linking protein or fragments to
10 various labels have been extensively reported in the literature and do not require detailed discussion here. Many of the techniques involve the use of activated carboxyl groups either through the use of carbodiimide or active esters to form peptide bonds, the formation of
15 thioethers by reaction of a mercapto group with an activated halogen such as chloroacetyl, or an activated olefin such as maleimide, for linkage, or the like. Fusion proteins will also find use in these applications.

Another diagnostic aspect of this invention involves
20 use of oligonucleotide or polynucleotide sequences taken from the sequence of a DTLR. These sequences can be used as probes for detecting levels of the respective DTLR in patients suspected of having an immunological disorder. The preparation of both RNA and DNA nucleotide sequences,
25 the labeling of the sequences, and the preferred size of the sequences has received ample description and discussion in the literature. Normally an oligonucleotide probe should have at least about 14 nucleotides, usually at least about 18 nucleotides, and
30 the polynucleotide probes may be up to several kilobases. Various labels may be employed, most commonly radionuclides, particularly ^{32}P . However, other techniques may also be employed, such as using biotin modified nucleotides for introduction into a
35 polynucleotide. The biotin then serves as the site for binding to avidin or antibodies, which may be labeled with a wide variety of labels, such as radionuclides,

fluorescers, enzymes, or the like. Alternatively, antibodies may be employed which can recognize specific duplexes, including DNA duplexes, RNA duplexes, DNA-RNA hybrid duplexes, or DNA-protein duplexes. The antibodies
5 in turn may be labeled and the assay carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected. The use of probes to the novel anti-sense RNA may be carried out in
10 any conventional techniques such as nucleic acid hybridization, plus and minus screening, recombinational probing, hybrid released translation (HRT), and hybrid arrested translation (HART). This also includes amplification techniques such as polymerase chain
15 reaction (PCR).

Diagnostic kits which also test for the qualitative or quantitative presence of other markers are also contemplated. Diagnosis or prognosis may depend on the combination of multiple indications used as markers.
20 Thus, kits may test for combinations of markers. See, e.g., Viallet, et al. (1989) Progress in Growth Factor Res. 1:89-97.

VIII. Therapeutic Utility

25 This invention provides reagents with significant therapeutic value. The DTLRs (naturally occurring or recombinant), fragments thereof, mutein receptors, and antibodies, along with compounds identified as having binding affinity to the receptors or antibodies, should
30 be useful in the treatment of conditions exhibiting abnormal expression of the receptors or their ligands. Such abnormality will typically be manifested by immunological disorders. Additionally, this invention should provide therapeutic value in various diseases or
35 disorders associated with abnormal expression or abnormal triggering of response to the ligand. The Toll ligands have been suggested to be involved in morphologic

development, e.g., dorso-ventral polarity determination, and immune responses, particularly the primitive innate responses. See, e.g., Sun, et al. (1991) Eur. J. Biochem. 196:247-254; Hultmark (1994) Nature 367:116-117.

5 Recombinant DTLRs, muteins, agonist or antagonist antibodies thereto, or antibodies can be purified and then administered to a patient. These reagents can be combined for therapeutic use with additional active ingredients, e.g., in conventional pharmaceutically
10 acceptable carriers or diluents, along with physiologically innocuous stabilizers and excipients. These combinations can be sterile, e.g., filtered, and placed into dosage forms as by lyophilization in dosage vials or storage in stabilized aqueous preparations.
15 This invention also contemplates use of antibodies or binding fragments thereof which are not complement binding.

 Ligand screening using DTLR or fragments thereof can be performed to identify molecules having binding
20 affinity to the receptors. Subsequent biological assays can then be utilized to determine if a putative ligand can provide competitive binding, which can block intrinsic stimulating activity. Receptor fragments can be used as a blocker or antagonist in that it blocks the
25 activity of ligand. Likewise, a compound having intrinsic stimulating activity can activate the receptor and is thus an agonist in that it simulates the activity of ligand, e.g., inducing signaling. This invention further contemplates the therapeutic use of antibodies to
30 DTLRs as antagonists.

 The quantities of reagents necessary for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medicants
35 administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts

useful for in situ administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Various considerations are described, e.g., in Gilman, et al. (eds) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, (current edition), Mack Publishing Co., Easton, Penn.; each of which is hereby incorporated herein by reference. Methods for administration are discussed therein and below, e.g., for oral, intravenous, intraperitoneal, or intramuscular administration, transdermal diffusion, and others. Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds described, e.g., in the Merck Index, Merck & Co., Rahway, New Jersey. Because of the likely high affinity binding, or turnover numbers, between a putative ligand and its receptors, low dosages of these reagents would be initially expected to be effective. And the signaling pathway suggests extremely low amounts of ligand may have effect. Thus, dosage ranges would ordinarily be expected to be in amounts lower than 1 mM concentrations, typically less than about 10 μ M concentrations, usually less than about 100 nM, preferably less than about 10 pM (picomolar), and most preferably less than about 1 fM (femtomolar), with an appropriate carrier. Slow release formulations, or slow release apparatus will often be utilized for continuous administration.

DTLRs, fragments thereof, and antibodies or its fragments, antagonists, and agonists, may be administered directly to the host to be treated or, depending on the size of the compounds, it may be desirable to conjugate them to carrier proteins such as ovalbumin or serum albumin prior to their administration. Therapeutic formulations may be administered in any conventional dosage formulation. While it is possible for the active

ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation. Formulations comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof. Each carrier must be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient. Formulations include those suitable for oral, rectal, nasal, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman, et al. (eds) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Penn.; Avis, et al. (eds. 1993) Pharmaceutical Dosage Forms: Parenteral Medications Dekker, NY; Lieberman, et al. (eds. 1990) Pharmaceutical Dosage Forms: Tablets Dekker, NY; and Lieberman, et al. (eds. 1990) Pharmaceutical Dosage Forms: Disperse Systems Dekker, NY. The therapy of this invention may be combined with or used in association with other therapeutic agents, particularly agonists or antagonists of other IL-1 family members.

IX. Ligands

The description of the Toll receptors herein provide means to identify ligands, as described above. Such ligand should bind specifically to the respective receptor with reasonably high affinity. Various constructs are made available which allow either labeling of the receptor to detect its ligand. For example, directly labeling DTLR, fusing onto it markers for secondary labeling, e.g., FLAG or other epitope tags, etc., will allow detection of receptor. This can be histological, as an affinity method for biochemical

purification, or labeling or selection in an expression cloning approach. A two-hybrid selection system may also be applied making appropriate constructs with the available DTLR sequences. See, e.g., Fields and Song
5 (1989) Nature 340:245-246.

Generally, descriptions of DTLRs will be analogously applicable to individual specific embodiments directed to DTLR2, DTLR3, DTLR4, DTLR5, DTLR6, DTLR7, DTLR8, DTLR9, and/or DTLR10 reagents and compositions.

10 The broad scope of this invention is best understood with reference to the following examples, which are not intended to limit the inventions to the specific embodiments.

15 EXAMPLES

I. General Methods

Some of the standard methods are described or referenced, e.g., in Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor
20 Laboratory, Cold Spring Harbor Press; Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual, (2d ed.), vols 1-3, CSH Press, NY; Ausubel, et al., Biology, Greene Publishing Associates, Brooklyn, NY; or Ausubel, et al. (1987 and Supplements) Current Protocols in Molecular Biology,
25 Greene/Wiley, New York. Methods for protein purification include such methods as ammonium sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and
30 others. See, e.g., Ausubel, et al. (1987 and periodic supplements); Coligan, et al. (ed. 1996) and periodic supplements, Current Protocols In Protein Science Greene/Wiley, New York; Deutscher (1990) "Guide to Protein Purification" in Methods in Enzymology, vol. 182,
35 and other volumes in this series; and manufacturer's literature on use of protein purification products, e.g., Pharmacia, Piscataway, N.J., or Bio-Rad, Richmond, CA.

Combination with recombinant techniques allow fusion to appropriate segments, e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence. See, e.g., Hochuli (1989) Chemische Industrie 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow (ed.) Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, N.Y.; and Crowe, et al. (1992) QIAexpress: The High Level Expression & Protein Purification System QUIAGEN, Inc., Chatsworth, CA.

Standard immunological techniques and assays are described, e.g., in Hertenberg, et al. (eds. 1996) Weir's Handbook of Experimental Immunology vols. 1-4, Blackwell Science; Coligan (1991) Current Protocols in Immunology Wiley/Greene, NY; and Methods in Enzymology volumes. 70, 73, 74, 84, 92, 93, 108, 116, 121, 132, 150, 162, and 163.

Assays for vascular biological activities are well known in the art. They will cover angiogenic and angiostatic activities in tumor, or other tissues, e.g., arterial smooth muscle proliferation (see, e.g., Koyoma, et al. (1996) Cell 87:1069-1078), monocyte adhesion to vascular epithelium (see McEvoy, et al. (1997) J. Exp. Med. 185:2069-2077), etc. See also Ross (1993) Nature 362:801-809; Reikter and Gordon (1995) Am. J. Pathol. 147:668-677; Thyberg, et al. (1990) Atherosclerosis 10:966-990; and Gumbiner (1996) Cell 84:345-357.

Assays for neural cell biological activities are described, e.g., in Wouterlood (ed. 1995) Neuroscience Protocols modules 10, Elsevier; Methods in Neurosciences Academic Press; and Neuromethods Humana Press, Totowa, NJ. Methodology of developmental systems is described, e.g., in Meisami (ed.) Handbook of Human Growth and Developmental Biology CRC Press; and Chrispeels (ed.) Molecular Techniques and Approaches in Developmental Biology Interscience.

Computer sequence analysis is performed, e.g., using available software programs, including those from the GCG (U. Wisconsin) and GenBank sources. Public sequence databases were also used, e.g., from GenBank, NCBI, EMBO, and others.

Many techniques applicable to IL-10 receptors may be applied to DTLRs, as described, e.g., in USSN 08/110,683 (IL-10 receptor), which is incorporated herein by reference for all purposes.

10

II. Novel Family of Human Receptors

Abbreviations: DTLR, Toll-like receptor; IL-1R, interleukin-1 receptor; TH, Toll homology; LRR, leucine-rich repeat; EST, expressed sequence tag; STS, sequence tagged site; FISH, fluorescence in situ hybridization.

The discovery of sequence homology between the cytoplasmic domains of *Drosophila* Toll and human interleukin-1 (IL-1) receptors has sown the conviction that both molecules trigger related signaling pathways tied to the nuclear translocation of Rel-type transcription factors. This conserved signaling scheme governs an evolutionarily ancient immune response in both insects and vertebrates. We report the molecular cloning of a novel class of putative human receptors with a protein architecture that is closely similar to *Drosophila* Toll in both intra- and extra-cellular segments. Five human Toll-like receptors, designated DTLRs 1-5, are likely the direct homologs of the fly molecule, and as such could constitute an important and unrecognized component of innate immunity in humans; intriguingly, the evolutionary retention of DTLRs in vertebrates may indicate another role, akin to Toll in the dorso-ventralization of the *Drosophila* embryo, as regulators of early morphogenetic patterning. Multiple tissue mRNA blots indicate markedly different patterns of

expression for the human DTLRs. Using fluorescence in situ hybridization and Sequence-Tagged Site database analyses, we also show that the cognate DTLR genes reside on chromosomes 4 (DTLRs 1, 2, and 3), 9 (DTLR4), and 1
5 (DTLR5). Structure prediction of the aligned Toll-homology (TH) domains from varied insect and human DTLRs, vertebrate IL-1 receptors, and MyD88 factors, and plant disease resistance proteins, recognizes a parallel β/α fold with an acidic active site; a similar structure
10 notably recurs in a class of response regulators broadly involved in transducing sensory information in bacteria.

The seeds of the morphogenetic gulf that so dramatically separates flies from humans are planted in
15 familiar embryonic shapes and patterns, but give rise to very different cell complexities. DeRobertis and Sasai (1996) Nature 380:37-40; and Arendt and Nübler-Jung (1997) Mech. Develop. 61:7-21. This divergence of developmental plans between insects and vertebrates is
20 choreographed by remarkably similar signaling pathways, underscoring a greater conservation of protein networks and biochemical mechanisms from unequal gene repertoires. Miklos and Rubin (1996) Cell 86:521-529; and Chothia (1994) Develop. 1994 Suppl., 27-33. A powerful way to
25 chart the evolutionary design of these regulatory pathways is by inferring their likely molecular components (and biological functions) through interspecies comparisons of protein sequences and structures. Miklos and Rubin (1996) Cell 86:521-529;
30 Chothia (1994) Develop. 1994 Suppl., 27-33 (3-5); and Banfi, et al. (1996) Nature Genet. 13:167-174.

A universally critical step in embryonic development is the specification of body axes, either born from innate asymmetries or triggered by external cues.
35 DeRobertis and Sasai (1996) Nature 380:37-40; and Arendt and Nübler-Jung (1997) Mech. Develop. 61:7-21. As a model system, particular attention has been focused on

the phylogenetic basis and cellular mechanisms of dorsoventral polarization . DeRobertis and Sasai (1996) Nature 380:37-40; and Arendt and Nübler-Jung (1997) Mech. Develop. 61:7-21. A prototype molecular strategy for this transformation has emerged from the *Drosophila* embryo, where the sequential action of a small number of genes results in a ventralizing gradient of the transcription factor Dorsal. St. Johnston and Nüsslein-Volhard (1992) Cell 68:201-219; and Morisato and Anderson (1995) Ann. Rev. Genet. 29:371-399.

This signaling pathway centers on Toll, a transmembrane receptor that transduces the binding of a maternally-secreted ventral factor, Spätzle, into the cytoplasmic engagement of Tube, an accessory molecule, and the activation of Pelle, a Ser/Thr kinase that catalyzes the dissociation of Dorsal from the inhibitor Cactus and allows migration of Dorsal to ventral nuclei (Morisato and Anderson (1995) Ann. Rev. Genet. 29:371-399; and Belvin and Anderson (1996) Ann. Rev. Cell Develop. Biol. 12:393-416. The Toll pathway also controls the induction of potent antimicrobial factors in the adult fly (Lemaitre, et al. (1996) Cell 86:973-983); this role in *Drosophila* immune defense strengthens mechanistic parallels to IL-1 pathways that govern a host of immune and inflammatory responses in vertebrates. Belvin and Anderson (1996) Ann. Rev. Cell Develop. Biol. 12:393-416; and Wasserman (1993) Molec. Biol. Cell 4:767-771. A Toll-related cytoplasmic domain in IL-1 receptors directs the binding of a Pelle-like kinase, IRAK, and the activation of a latent NF- κ B/I- κ B complex that mirrors the embrace of Dorsal and Cactus. Belvin and Anderson (1996) Ann. Rev. Cell Develop. Biol. 12:393-416; and Wasserman (1993) Molec. Biol. Cell 4:767-771.

We describe the cloning and molecular characterization of four new Toll-like molecules in humans, designated DTLRs 2-5 (following Chiang & Beachy (1994) Mech. Develop. 47:225-239), that reveal a receptor

family more closely tied to *Drosophila* Toll homologs than to vertebrate IL-1 receptors. The DTLR sequences are derived from human ESTs; these partial cDNAs were used to draw complete expression profiles in human tissues for the five DTLRs, map the chromosomal locations of cognate genes, and narrow the choice of cDNA libraries for full-length cDNA retrievals. Spurred by other efforts (Banfi, et al. (1996) Nature Genet. 13:167-174; and Wang, et al. (1996) J. Biol. Chem. 271:4468-4476), we are assembling, by structural conservation and molecular parsimony, a biological system in humans that is the counterpart of a compelling regulatory scheme in *Drosophila*. In addition, a biochemical mechanism driving Toll signaling is suggested by the proposed tertiary fold of the Toll-homology (TH) domain, a core module shared by DTLRs, a broad family of IL-1 receptors, mammalian MyD88 factors and plant disease resistance proteins. Mitcham, et al. (1996) J. Biol. Chem. 271:5777-5783; and Hardiman, et al. (1996) Oncogene 13:2467-2475. We propose that a signaling route coupling morphogenesis and primitive immunity in insects, plants, and animals (Belvin and Anderson (1996) Ann. Rev. Cell Develop. Biol. 12:393-416; and Wilson, et al. (1997) Curr. Biol. 7:175-178) may have roots in bacterial two-component pathways.

25

Computational Analysis.

Human sequences related to insect DTLRs were identified from the EST database (dbEST) at the National Center for Biotechnology Information (NCBI) using the BLAST server (Altschul, et al. (1994) Nature Genet. 6:119-129). More sensitive pattern- and profile-based methods (Bork and Gibson (1996) Meth. Enzymol. 266:162-184) were used to isolate the signaling domains of the DTLR family that are shared with vertebrate and plant proteins present in nonredundant databases. The progressive alignment of DTLR intra- or extracellular domain sequences was carried out by ClustalW (Thompson,

et al. (1994) Nucleic Acids Res. 22:4673-4680); this program also calculated the branching order of aligned sequences by the Neighbor-Joining algorithm (5000 bootstrap replications provided confidence values for the tree groupings).

Conserved alignment patterns, discerned at several degrees of stringency, were drawn by the Consensus program (internet URL <http://www.bork.embl-heidelberg.de/Alignment/consensus.html>). The PRINTS library of protein fingerprints (<http://www.biochem.ucl.ac.uk/bsm/dbbrowser/PRINTS/PRINTS.html>) (Attwood, et al. (1997) Nucleic Acids Res. 25:212-217) reliably identified the myriad leucine-rich repeats (LRRs) present in the extracellular segments of DTLRs with a compound motif (PRINTS code Leurichrpt) that flexibly matches N- and C-terminal features of divergent LRRs. Two prediction algorithms whose three-state accuracy is above 72% were used to derive a consensus secondary structure for the intracellular domain alignment, as a bridge to fold recognition efforts (Fischer, et al. (1996) FASEB J. 10:126-136). Both the neural network program PHD (Rost and Sander (1994) Proteins 19:55-72) and the statistical prediction method DSC (King and Sternberg (1996) Protein Sci. 5:2298-2310) have internet servers (URLs http://www.embl-heidelberg.de/predictprotein/phd_pred.html and http://bonsai.lif.icnet.uk/bmm/dsc/dsc_read_align.html, respectively). The intracellular region encodes the THD region discussed, e.g., in Hardiman, et al. (1996) Oncogene 13:2467-2475; and Rock, et al. (1998) Proc. Nat'l Acad. Sci. USA 95:588-593, each of which is incorporated herein by reference. This domain is very important in the mechanism of signaling by the receptors, which transfers a phosphate group to a substrate.

35

Cloning of full-length human DTLR cDNAs.

PCR primers derived from the Toll-like Humrsc786 sequence (Genbank accession code D13637) (Nomura, et al. (1994) DNA Res 1:27-35) were used to probe a human erythroleukemic, TF-1 cell line-derived cDNA library (Kitamura, et al. (1989) Blood 73:375-380) to yield the DTLR1 cDNA sequence. The remaining DTLR sequences were flagged from dbEST, and the relevant EST clones obtained from the I.M.A.G.E. consortium (Lennon, et al. (1996) Genomics 33:151-152) via Research Genetics (Huntsville, AL): CloneID#'s 80633 and 117262 (DTLR2), 144675 (DTLR3), 202057 (DTLR4) and 277229 (DTLR5). Full length cDNAs for human DTLRs 2-4 were cloned by DNA hybridization screening of λ gt10 phage, human adult lung, placenta, and fetal liver 5'-Stretch Plus cDNA libraries (Clontech), respectively; the DTLR5 sequence is derived from a human multiple-sclerosis plaque EST. All positive clones were sequenced and aligned to identify individual DTLR ORFs: DTLR1 (2366 bp clone, 786 aa ORF), DTLR2 (2600 bp, 784 aa), DTLR3 (3029 bp, 904 aa), DTLR4 (3811 bp, 879 aa) and DTLR5 (1275 bp, 370 aa). Probes for DTLR3 and DTLR4 hybridizations were generated by PCR using human placenta (Stratagene) and adult liver (Clontech) cDNA libraries as templates, respectively; primer pairs were derived from the respective EST sequences. PCR reactions were conducted using T. aquaticus Taqplus DNA polymerase (Stratagene) under the following conditions: 1 x (94° C, 2 min) 30 x (55° C, 20 sec; 72° C 30 sec; 94° C 20 sec), 1 x (72° C, 8 min). For DTLR2 full-length cDNA screening, a 900 bp fragment generated by EcoRI/XbaI digestion of the first EST clone (ID# 80633) was used as a probe.

mRNA blots and chromosomal localization.

Human multiple tissue (Cat# 1, 2) and cancer cell line blots (Cat# 7757-1), containing approximately 2 μ g of poly(A)⁺ RNA per lane, were purchased from Clontech (Palo Alto, CA). For DTLRs 1-4, the isolated full-length

cDNAs served as probes, for DTLR5 the EST clone (ID #277229) plasmid insert was used. Briefly, the probes were radiolabeled with [α -³²P] dATP using the Amersham Rediprime random primer labeling kit (RPN1633).

- 5 Prehybridization and hybridizations were performed at 65° C in 0.5 M Na₂HPO₄, 7% SDS, 0.5 M EDTA (pH 8.0). All stringency washes were conducted at 65° C with two initial washes in 2 x SSC, 0.1% SDS for 40 min followed by a subsequent wash in 0.1 x SSC, 0.1% SDS for 20 min.
- 10 Membranes were then exposed at -70° C to X-Ray film (Kodak) in the presence of intensifying screens. More detailed studies by cDNA library Southern (14) were performed with selected human DTLR clones to examine their expression in hemopoietic cell subsets.
- 15 Human chromosomal mapping was conducted by the method of fluorescence in situ hybridization (FISH) as described in Heng and Tsui (1994) Meth. Molec. Biol. 33:109-122, using the various full-length (DTLRs 2-4) or partial (DTLR5) cDNA clones as probes. These analyses
- 20 were performed as a service by SeedNA Biotech Inc. (Ontario, Canada). A search for human syndromes (or mouse defects in syntenic loci) associated with the mapped DTLR genes was conducted in the Dysmorphic Human-Mouse Homology Database by internet server
- 25 (http://www.hgmp.mrc.ac.uk/DHMHHD/hum_chromel.html).

Conserved architecture of insect and human DTLR ectodomains.

- 30 The Toll family in *Drosophila* comprises at least four distinct gene products: Toll, the prototype receptor involved in dorsoventral patterning of the fly embryo (Morisato and Anderson (1995) Ann. Rev. Genet. 29:371-399) and a second named '18 Wheeler' (18w) that may also be involved in early embryonic development (Chiang and
- 35 Beachy (1994) Mech. Develop. 47:225-239; Eldon, et al. (1994) Develop. 120:885-899); two additional receptors are predicted by incomplete, Toll-like ORFs downstream of

the male-specific-transcript (Mst) locus (Genbank code X67703) or encoded by the 'sequence-tagged-site' (STS) Dm2245 (Genbank code G01378) (Mitcham, et al. (1996) J. Biol. Chem. 271:5777-5783). The extracellular segments
5 of Toll and 18w are distinctively composed of imperfect, ~24 amino acid LRR motifs (Chiang and Beachy (1994) Mech. Develop. 47:225-239; and Eldon, et al. (1994) Develop. 120:885-899). Similar tandem arrays of LRRs commonly form the adhesive antennae of varied cell surface
10 molecules and their generic tertiary structure is presumed to mimic the horseshoe-shaped cradle of a ribonuclease inhibitor fold, where seventeen LRRs show a repeating β/α -hairpin, 28 residue motif (Buchanan and Gay (1996) Prog. Biophys. Molec. Biol. 65:1-44). The
15 specific recognition of Spätzle by Toll may follow a model proposed for the binding of cystine-knot fold glycoprotein hormones by the multi-LRR ectodomains of serpentine receptors, using the concave side of the curved β -sheet (Kajava, et al. (1995) Structure 3:867-
20 877); intriguingly, the pattern of cysteines in Spätzle, and an orphan Drosophila ligand, Trunk, predict a similar cystine-knot tertiary structure (Belvin and Anderson (1996) Ann. Rev. Cell Develop. Biol. 12:393-416; and Casanova, et al. (1995) Genes Develop. 9:2539-2544).
25 The 22 and 31 LRR ectodomains of Toll and 18w, respectively (the Mst ORF fragment displays 16 LRRs), are most closely related to the comparable 18, 19, 24, and 22 LRR arrays of DTLRs 1-4 (the incomplete DTLR5 chain presently includes four membrane-proximal LRRs) by
30 sequence and pattern analysis (Altschul, et al. (1994) Nature Genet. 6:119-129; and Bork and Gibson (1996) Meth. Enzymol. 266:162-184) (Fig. 1). However, a striking difference in the human DTLR chains is the common loss of a ~90 residue cysteine-rich region that is variably
35 embedded in the ectodomains of Toll, 18w and the Mst ORF (distanced four, six and two LRRs, respectively, from the membrane boundary). These cysteine clusters are

bipartite, with distinct 'top' (ending an LRR) and 'bottom' (stacked atop an LRR) halves (Chiang and Beachy (1994) Mech. Develop. 47:225-239; Eldon, et al. (1994) Develop. 120:885-899; and ,Buchanan and Gay (1996) Prog. Biophys. Molec. Biol. 65:1-44); the 'top' module recurs in both Drosophila and human DTLRs as a conserved juxtamembrane spacer (Fig. 1). We suggest that the flexibly located cysteine clusters in Drosophila receptors (and other LRR proteins), when mated 'top' to 'bottom', form a compact module with paired termini that can be inserted between any pair of LRRs without altering the overall fold of DTLR ectodomains; analogous 'extruded' domains decorate the structures of other proteins (Russell (1994) Protein Engin. 7:1407-1410).

Molecular design of the TH signaling domain.

Sequence comparison of Toll and IL-1 type-I (IL-1R1) receptors has disclosed a distant resemblance of a ~200 amino acid cytoplasmic domain that presumably mediates signaling by similar Rel-type transcription factors. Belvin and Anderson (1996) Ann. Rev. Cell Develop. Biol. 12:393-416; and (Belvin and Anderson (1996) Ann. Rev. Cell Develop. Biol. 12:393-416; and Wasserman (1993) Molec. Biol. Cell 4:767-771). More recent additions to this functional paradigm include a pair of plant disease resistance proteins from tobacco and flax that feature an N-terminal TH module followed by nucleotide-binding (NTPase) and LRR segments (Wilson, et al. (1997) Curr. Biol. 7:175-178); by contrast, a 'death domain' preceeds the TH chain of MyD88, an intracellular myeloid differentiation marker (Mitcham, et al. (1996) J. Biol. Chem. 271:5777-5783; and Hardiman, et al. (1996) Oncogene 13:2467-2475) (Fig. 1). New IL-1-type receptors include IL-1R3, an accessory signaling molecule, and orphan receptors IL-1R4 (also called ST2/Fit-1/T1), IL-1R5 (IL-1R-related protein), and IL-1R6 (IL-1R-related protein-2) (Mitcham, et al. (1996) J. Biol. Chem. 271:5777-

5783;Hardiman, et al. (1996) Oncogene 13:2467-2475).

With the new human DTLR sequences, we have sought a structural definition of this evolutionary thread by analyzing the conformation of the common TH module: ten
5 blocks of conserved sequence comprising 128 amino acids form the minimal TH domain fold; gaps in the alignment mark the likely location of sequence and length-variable loops (Fig. 2a).

Two prediction algorithms that take advantage of the
10 patterns of conservation and variation in multiply aligned sequences, PHD (Rost and Sander (1994) Proteins 19:55-72) and DSC (King and Sternberg (1996) Protein Sci. 5:2298-2310), produced strong, concordant results for the TH signaling module (Fig. 2a). Each block contains a
15 discrete secondary structural element: the imprint of alternating β -strands (labeled A-E) and α -helices (numbered 1-5) is diagnostic of an β/α -class fold with α -helices on both faces of a parallel β -sheet. Hydrophobic β -strands A, C and D are predicted to form 'interior'
20 staves in the β -sheet, while the shorter, amphipathic β -strands B and E resemble typical 'edge' units (Fig. 2a). This assignment is consistent with a strand order of B-A-C-D-E in the core β -sheet (Fig. 2b); fold comparison ('mapping') and recognition ('threading') programs
25 (Fischer, et al. (1996) FASEB J. 10:126-136) strongly return this doubly wound β/α topology. A surprising, functional prediction of this outline structure for the TH domain is that many of the conserved, charged residues in the multiple alignment map to the C-terminal end of
30 the β -sheet: residue Asp16 (block numbering scheme - Fig. 2a) at the end of β A, Arg39 and Asp40 following β B, Glu75 in the first turn of α 3, and the more loosely conserved Glu/Asp residues in the β D- α 4 loop, or after β E (Fig. 2a). The location of four other conserved residues
35 (Asp7, Glu28, and the Arg57-Arg/Lys58 pair) is compatible with a salt bridge network at the opposite, N-terminal end of the β -sheet (Fig. 2a).

Signaling function depends on the structural integrity of the TH domain. Inactivating mutations or deletions within the module boundaries (Fig. 2a) have been catalogued for IL-1R1 and Toll. Heguy, et al. (1992) J. Biol. Chem. 267:2605-2609; Croston, et al. (1995) J. Biol. Chem. 270:16514-16517; Schneider, et al. (1991) Genes Develop. 5:797-807; Norris and Manley. (1992) Genes Develop. 6:1654-1667; Norris and Manley (1995) Genes Develop. 9:358-369; and Norris and Manley (1996) Genes Develop. 10:862-872. The human DTLR1-5 chains extending past the minimal TH domain (8, 0, 6, 22 and 18 residue lengths, respectively) are most closely similar to the stubby, 4 aa 'tail' of the Mst ORF. Toll and 18w display unrelated 102 and 207 residue tails (Fig. 2a) that may negatively regulate the signaling of the fused TH domains. Norris and Manley (1995) Genes Develop. 9:358-369; and Norris and Manley (1996) Genes Develop. 10:862-872.

The evolutionary relationship between the disparate proteins that carry the TH domain can best be discerned by a phylogenetic tree derived from the multiple alignment (Fig. 3). Four principal branches segregate the plant proteins, the MyD88 factors, IL-1 receptors and Toll-like molecules; the latter branch clusters the *Drosophila* and human DTLRs.

Chromosomal dispersal of human DTLR genes.

In order to investigate the genetic linkage of the nascent human DTLR gene family, we mapped the chromosomal loci of four of the five genes by FISH (Fig. 4). The DTLR1 gene has previously been charted by the human genome project: an STS database locus (dbSTS accession number G06709, corresponding to STS WI-7804 or SHGC-12827) exists for the Humrsc786 cDNA (Nomura, et al. (1994) DNA Res 1:27-35) and fixes the gene to chromosome 4 marker interval D4S1587-D42405 (50-56 cM) circa 4p14. This assignment has recently been corroborated by FISH

analysis. Taguchi, et al. (1996) Genomics 32:486-488.
In the present work, we reliably assign the remaining
DTLR genes to loci on chromosome 4q32 (DTLR2), 4q35
(DTLR3), 9q32-33 (DTLR4) and 1q33.3 (DTLR5). During the
5 course of this work, an STS for the parent DTLR2 EST
(cloneID # 80633) has been generated (dbSTS accession
number T57791 for STS SHGC-33147) and maps to the
chromosome 4 marker interval D4S424-D4S1548 (143-153 cM)
at 4q32 -in accord with our findings. There is a ~50 cM
10 gap between DTLR2 and DTLR3 genes on the long arm of
chromosome 4.

DTLR genes are differentially expressed.

Both Toll and 18w have complex spatial and temporal
15 patterns of expression in Drosophila that may point to
functions beyond embryonic patterning. St. Johnston and
Nüsslein-Volhard (1992) Cell 68:201-219; Morisato and
Anderson (1995) Ann. Rev. Genet. 29:371-399; Belvin and
Anderson (1996) Ann. Rev. Cell Develop. Biol. 12:393-416;
20 Lemaitre, et al. (1996) Cell 86:973-983; Chiang and
Beachy (1994) Mech. Develop. 47:225-239; and Eldon, et
al. (1994) Develop. 120:885-899. We have examined the
spatial distribution of DTLR transcripts by mRNA blot
analysis with varied human tissue and cancer cell lines
25 using radioabeled DTLR cDNAs (Fig. 5). DTLR1 is found to
be ubiquitously expressed, and at higher levels than the
other receptors. Presumably reflecting alternative
splicing, 'short' 3.0 kB and 'long' 8.0 kB DTLR1
transcript forms are present in ovary and spleen,
30 respectively (Fig. 5, panels A & B). A cancer cell mRNA
panel also shows the prominent overexpression of DTLR1 in
a Burkitt's Lymphoma Raji cell line (Fig. 5, panel C).
DTLR2 mRNA is less widely expressed than DTLR1, with a
4.0 kB species detected in lung and a 4.4 kB transcript
35 evident in heart, brain and muscle. The tissue
distribution pattern of DTLR3 echoes that of DTLR2 (Fig.
5, panel E). DTLR3 is also present as two major

transcripts of approximately 4.0 and 6.0 kB in size, and the highest levels of expression are observed in placenta and pancreas. By contrast, DTLR4 and DTLR5 messages appear to be extremely tissue-specific. DTLR4 was
5 detected only in placenta as a single transcript of ~7.0 kB in size. A faint 4.0 kB signal was observed for DTLR5 in ovary and peripheral blood monocytes.

Components of an evolutionarily ancient regulatory
10 system.

The original molecular blueprints and divergent fates of signaling pathways can be reconstructed by comparative genomic approaches. Miklos and Rubin (1996) Cell 86:521-529; Chothia (1994) Develop. 1994 Suppl., 27-
15 33; Banfi, et al. (1996) Nature Genet. 13:167-174; and Wang, et al. (1996) J. Biol. Chem. 271:4468-4476. We have used this logic to identify an emergent gene family in humans, encoding five receptor paralogs at present, DTLRs 1-5, that are the direct evolutionary counterparts
20 of a *Drosophila* gene family headed by Toll (Figs. 1-3). The conserved architecture of human and fly DTLRs, conserved LRR ectodomains and intracellular TH modules (Fig. 1), intimates that the robust pathway coupled to Toll in *Drosophila* (6, 7) survives in vertebrates. The
25 best evidence borrows from a reiterated pathway: the manifold IL-1 system and its repertoire of receptor-fused TH domains, IRAK, NF- κ B and I- κ B homologs (Belvin and Anderson (1996) Ann. Rev. Cell Develop. Biol. 12:393-416; Wasserman (1993) Molec. Biol. Cell 4:767-771; Hardiman,
30 et al. (1996) Oncogene 13:2467-2475; and Cao, et al. (1996) Science 271:1128-1131); a Tube-like factor has also been characterized. It is not known whether DTLRs can productively couple to the IL-1R signaling machinery, or instead, a parallel set of proteins is used.
35 Differently from IL-1 receptors, the LRR cradle of human DTLRs is predicted to retain an affinity for Spätzle/Trunk-related cystine-knot factors; candidate

DTLR ligands (called PENS) that fit this mold have been isolated.

Biochemical mechanisms of signal transduction can be gauged by the conservation of interacting protein folds in a pathway. Miklos and Rubin (1996) Cell 86:521-529; Chothia (1994) Develop. 1994 Suppl., 27-33. At present, the Toll signaling paradigm involves some molecules whose roles are narrowly defined by their structures, actions or fates: Pelle is a Ser/Thr kinase (phosphorylation), Dorsal is an NF- κ B-like transcription factor (DNA-binding) and Cactus is an ankyrin-repeat inhibitor (Dorsal binding, degradation). Belvin and Anderson (1996) Ann. Rev. Cell Develop. Biol. 12:393-416. By contrast, the functions of the Toll TH domain and Tube remain enigmatic. Like other cytokine receptors (Heldin (1995) Cell 80:213-223), ligand-mediated dimerization of Toll appears to be the triggering event: free cysteines in the juxtamembrane region of Toll create constitutively active receptor pairs (Schneider, et al. (1991) Genes Develop. 5:797-807), and chimeric Torso-Toll receptors signal as dimers (Galindo, et al. (1995) Develop. 121:2209-2218); yet, severe truncations or wholesale loss of the Toll ectodomain results in promiscuous intracellular signaling (Norris and Manley (1995) Genes Develop. 9:358-369; and Winans and Hashimoto (1995) Molec. Biol. Cell 6:587-596), reminiscent of oncogenic receptors with catalytic domains (Heldin (1995) Cell 80:213-223). Tube is membrane-localized, engages the N-terminal (death) domain of Pelle and is phosphorylated, but neither Toll-Tube or Toll-Pelle interactions are registered by two-hybrid analysis (Galindo, et al. (1995) Develop. 121:2209-2218; and Großhans, et al. (1994) Nature 372:563-566); this latter result suggests that the conformational 'state' of the Toll TH domain somehow affects factor recruitment. Norris and Manley (1996) Genes Develop. 10:862-872; and Galindo, et al. (1995) Develop. 121:2209-2218.

At the heart of these vexing issues is the structural nature of the Toll TH module. To address this question, we have taken advantage of the evolutionary diversity of TH sequences from insects, plants and
5 vertebrates, incorporating the human DTLR chains, and extracted the minimal, conserved protein core for structure prediction and fold recognition (Fig. 2). The strongly predicted (β/α)₅ TH domain fold with its asymmetric cluster of acidic residues is topologically
10 identical to the structures of response regulators in bacterial two-component signaling pathways (Volz (1993) Biochemistry 32:11741-11753; and Parkinson (1993) Cell 73:857-871) (Fig. 2). The prototype chemotaxis regulator CheY transiently binds a divalent cation in an 'aspartate pocket' at the C-end of the core β -sheet; this cation
15 provides electrostatic stability and facilitates the activating phosphorylation of an invariant Asp. Volz (1993) Biochemistry 32:11741-11753. Likewise, the TH domain may capture cations in its acidic nest, but
20 activation, and downstream signaling, could depend on the specific binding of a negatively charged moiety: anionic ligands can overcome intensely negative binding-site potentials by locking into precise hydrogen-bond networks. Ledvina, et al. (1996) Proc. Natl. Acad. Sci.
25 USA 93:6786-6791. Intriguingly, the TH domain may not simply act as a passive scaffold for the assembly of a Tube/Pelle complex for Toll, or homologous systems in plants and vertebrates, but instead actively participate as a true conformational trigger in the signal
30 transducing machinery. Perhaps explaining the conditional binding of a Tube/Pelle complex, Toll dimerization could promote unmasking, by regulatory receptor tails (Norris and Manley (1995) Genes Develop. 9:358-369; Norris and Manley (1996) Genes Develop.
35 10:862-872), or binding by small molecule activators of the 'TH pocket'. However, 'free' TH modules inside the cell (Norris and Manley (1995) Genes Develop. 9:358-369;

Winans and Hashimoto (1995) Molec. Biol. Cell 6:587-596) could act as catalytic, CheY-like triggers by activating and docking with errant Tube/Pelle complexes.

5 Morphogenetic receptors and immune defense.

The evolutionary link between insect and vertebrate immune systems is stamped in DNA: genes encoding antimicrobial factors in insects display upstream motifs similar to acute phase response elements known to bind NF- κ B transcription factors in mammals. Hultmark (1993) Trends Genet. 9:178-183. Dorsal, and two Dorsal-related factors, Dif and Relish, help induce these defense proteins after bacterial challenge (Reichhart, et al. (1993) C. R. Acad. Sci. Paris 316:1218-1224; Ip, et al. (1993) Cell 75:753-763; and Dushay, et al. (1996) Proc. Natl. Acad. Sci. USA 93:10343-10347); Toll, or other DTLRs, likely modulate these rapid immune responses in adult *Drosophila* (Lemaitre, et al. (1996) Cell 86:973-983; and Rosetto, et al. (1995) Biochem. Biophys. Res. Commun. 209:111-116). These mechanistic parallels to the IL-1 inflammatory response in vertebrates are evidence of the functional versatility of the Toll signaling pathway, and suggest an ancient synergy between embryonic patterning and innate immunity (Belvin and Anderson (1996) Ann. Rev. Cell Develop. Biol. 12:393-416; Lemaitre, et al. (1996) Cell 86:973-983; Wasserman (1993) Molec. Biol. Cell 4:767-771; Wilson, et al. (1997) Curr. Biol. 7:175-178; Hultmark (1993) Trends Genet. 9:178-183; Reichhart, et al. (1993) C. R. Acad. Sci. Paris 316:1218-1224; Ip, et al. (1993) Cell 75:753-763; Dushay, et al. (1996) Proc. Natl. Acad. Sci. USA 93:10343-10347; Rosetto, et al. (1995) Biochem. Biophys. Res. Commun. 209:111-116; Medzhitov and Janeway (1997) Curr. Opin. Immunol. 9:4-9; and Medzhitov and Janeway (1997) Curr. Opin. Immunol. 9:4-9). The closer homology of insect and human DTLR proteins invites an even stronger overlap of biological functions that supersedes the purely immune

parallels to IL-1 systems, and lends potential molecular regulators to dorso-ventral and other transformations of vertebrate embryos. DeRobertis and Sasai (1996) Nature 380:37-40; and Arendt and Nübler-Jung (1997) Mech.

5 Develop. 61:7-21.

The present description of an emergent, robust receptor family in humans mirrors the recent discovery of the vertebrate Frizzled receptors for Wnt patterning factors. Wang, et al. (1996) J. Biol. Chem. 271:4468-
10 4476. As numerous other cytokine-receptor systems have roles in early development (Lemaire and Kodjabachian (1996) Trends Genet. 12:525-531), perhaps the distinct cellular contexts of compact embryos and gangly adults simply result in familiar signaling pathways and their
15 diffusible triggers having different biological outcomes at different times, e.g., morphogenesis versus immune defense for DTLRs. For insect, plant, and human Toll-related systems (Hardiman, et al. (1996) Oncogene 13:2467-2475; Wilson, et al. (1997) Curr. Biol. 7:175-
20 178), these signals course through a regulatory TH domain that intriguingly resembles a bacterial transducing engine (Parkinson (1993) Cell 73:857-871).

In particular, the DTLR6 exhibits structural features which establish its membership in the family.
25 Moreover, members of the family have been implicated in a number of significant developmental disease conditions and with function of the innate immune system. In particular, the DTLR6 has been mapped to the X chromosome to a location which is a hot spot for major developmental
30 abnormalities. See, e.g., The Sanger Center: human X chromosome website <http://www.sanger.ac.uk/HGP/ChrX/index.shtml>; and the Baylor College of Medicine Human Genome Sequencing website <http://gc.bcm.tmc.edu:8088/cgi-bin/seq/home>.

35 The accession number for the deposited PAC is AC003046. This accession number contains sequence from two PACs: RPC-164K3 and RPC-263P4. These two PAC

sequences mapped on human chromosome Xp22 at the Baylor web site between STS markers DXS704 and DXS7166. This region is a "hot spot" for severe developmental abnormalities.

5

III. Amplification of DTLR fragment by PCR

Two appropriate primer sequences are selected (see Tables 1 through 10). RT-PCR is used on an appropriate mRNA sample selected for the presence of message to
10 produce a partial or full length cDNA, e.g., a sample which expresses the gene. See, e.g., Innis, et al. (eds. 1990) PCR Protocols: A Guide to Methods and Applications Academic Press, San Diego, CA; and Dieffenbach and Dveksler (1995; eds.) PCR Primer: A Laboratory Manual
15 Cold Spring Harbor Press, CSH, NY. Such will allow determination of a useful sequence to probe for a full length gene in a cDNA library. The TLR6 is a contiguous sequence in the genome, which may suggest that the other TLRs are also. Thus, PCR on genomic DNA may yield full
20 length contiguous sequence, and chromosome walking methodology would then be applicable. Alternatively, sequence databases will contain sequence corresponding to portions of the described embodiments, or closely related forms, e.g., alternative splicing, etc. Expression
25 cloning techniques also may be applied on cDNA libraries.

IV. Tissue distribution of DTLRs

Message for each gene encoding these DTLRs has been detected. See Figures 5A-5F. Other cells and tissues
30 will be assayed by appropriate technology, e.g., PCR, immunoassay, hybridization, or otherwise. Tissue and organ cDNA preparations are available, e.g., from Clontech, Mountain View, CA. Identification of sources of natural expression are useful, as described.

35 Southern Analysis: DNA (5 µg) from a primary amplified cDNA library is digested with appropriate restriction enzymes to release the inserts, run on a 1% agarose gel and

transferred to a nylon membrane (Schleicher and Schuell, Keene, NH).

Samples for human mRNA isolation would typically include, e.g.: peripheral blood mononuclear cells
5 (monocytes, T cells, NK cells, granulocytes, B cells), resting (T100); peripheral blood mononuclear cells, activated with anti-CD3 for 2, 6, 12 h pooled (T101); T cell, TH0 clone Mot 72, resting (T102); T cell, TH0 clone Mot 72, activated with anti-CD28 and anti-CD3 for 3, 6,
10 12 h pooled (T103); T cell, TH0 clone Mot 72, anergic treated with specific peptide for 2, 7, 12 h pooled (T104); T cell, TH1 clone HY06, resting (T107); T cell, TH1 clone HY06, activated with anti-CD28 and anti-CD3 for 3, 6, 12 h pooled (T108); T cell, TH1 clone HY06, anergic
15 treated with specific peptide for 2, 6, 12 h pooled (T109); T cell, TH2 clone HY935, resting (T110); T cell, TH2 clone HY935, activated with anti-CD28 and anti-CD3 for 2, 7, 12 h pooled (T111); T cells CD4+CD45RO- T cells polarized 27 days in anti-CD28, IL-4, and anti IFN- γ , TH2
20 polarized, activated with anti-CD3 and anti-CD28 4 h (T116); T cell tumor lines Jurkat and Hut78, resting (T117); T cell clones, pooled AD130.2, Tc783.12, Tc783.13, Tc783.58, Tc782.69, resting (T118); T cell random $\gamma\delta$ T cell clones, resting (T119); Splenocytes,
25 resting (B100); Splenocytes, activated with anti-CD40 and IL-4 (B101); B cell EBV lines pooled WT49, RSB, JY, CVIR, 721.221, RM3, HSY, resting (B102); B cell line JY, activated with PMA and ionomycin for 1, 6 h pooled (B103); NK 20 clones pooled, resting (K100); NK 20 clones
30 pooled, activated with PMA and ionomycin for 6 h (K101); NK1 clone, derived from peripheral blood of LGL leukemia patient, IL-2 treated (K106); NK cytotoxic clone 640-A30-1, resting (K107); hematopoietic precursor line TF1, activated with PMA and ionomycin for 1, 6 h pooled
35 (C100); U937 premonocytic line, resting (M100); U937 premonocytic line, activated with PMA and ionomycin for 1, 6 h pooled (M101); elutriated monocytes, activated

with LPS, IFN γ , anti-IL-10 for 1, 2, 6, 12, 24 h pooled (M102); elutriated monocytes, activated with LPS, IFN γ , IL-10 for 1, 2, 6, 12, 24 h pooled (M103); elutriated monocytes, activated with LPS, IFN γ , anti-IL-10 for 4, 16 h pooled (M106); elutriated monocytes, activated with LPS, IFN γ , IL-10 for 4, 16 h pooled (M107); elutriated monocytes, activated LPS for 1 h (M108); elutriated monocytes, activated LPS for 6 h (M109); DC 70% CD1a+, from CD34+ GM-CSF, TNF α 12 days, resting (D101); DC 70% CD1a+, from CD34+ GM-CSF, TNF α 12 days, activated with PMA and ionomycin for 1 hr (D102); DC 70% CD1a+, from CD34+ GM-CSF, TNF α 12 days, activated with PMA and ionomycin for 6 hr (D103); DC 95% CD1a+, from CD34+ GM-CSF, TNF α 12 days FACS sorted, activated with PMA and ionomycin for 1, 6 h pooled (D104); DC 95% CD14+, ex CD34+ GM-CSF, TNF α 12 days FACS sorted, activated with PMA and ionomycin 1, 6 hr pooled (D105); DC CD1a+ CD86+, from CD34+ GM-CSF, TNF α 12 days FACS sorted, activated with PMA and ionomycin for 1, 6 h pooled (D106); DC from monocytes GM-CSF, IL-4 5 days, resting (D107); DC from monocytes GM-CSF, IL-4 5 days, resting (D108); DC from monocytes GM-CSF, IL-4 5 days, activated LPS 4, 16 h pooled (D109); DC from monocytes GM-CSF, IL-4 5 days, activated TNF α , monocyte supe for 4, 16 h pooled (D110); leiomyoma L11 benign tumor (X101); normal myometrium M5 (O115); malignant leiomyosarcoma GS1 (X103); lung fibroblast sarcoma line MRC5, activated with PMA and ionomycin for 1, 6 h pooled (C101); kidney epithelial carcinoma cell line CHA, activated with PMA and ionomycin for 1, 6 h pooled (C102); kidney fetal 28 wk male (O100); lung fetal 28 wk male (O101); liver fetal 28 wk male (O102); heart fetal 28 wk male (O103); brain fetal 28 wk male (O104); gallbladder fetal 28 wk male (O106); small intestine fetal 28 wk male (O107); adipose tissue fetal 28 wk male (O108); ovary fetal 25 wk female (O109); uterus fetal 25 wk female (O110); testes fetal 28 wk male

(O111); spleen fetal 28 wk male (O112); adult placenta 28 wk (O113); and tonsil inflamed, from 12 year old (X100).

Samples for mouse mRNA isolation can include, e.g.:
resting mouse fibroblastic L cell line (C200); Braf:ER
5 (Braf fusion to estrogen receptor) transfected cells,
control (C201); T cells, TH1 polarized (Mel14 bright,
CD4+ cells from spleen, polarized for 7 days with IFN- γ
and anti IL-4; T200); T cells, TH2 polarized (Mel14
bright, CD4+ cells from spleen, polarized for 7 days with
10 IL-4 and anti-IFN- γ ; T201); T cells, highly TH1 polarized
(see Openshaw, et al. (1995) J. Exp. Med. 182:1357-1367;
activated with anti-CD3 for 2, 6, 16 h pooled; T202); T
cells, highly TH2 polarized (see Openshaw, et al. (1995)
J. Exp. Med. 182:1357-1367; activated with anti-CD3 for
15 2, 6, 16 h pooled; T203); CD44- CD25+ pre T cells, sorted
from thymus (T204); TH1 T cell clone D1.1, resting for 3
weeks after last stimulation with antigen (T205); TH1 T
cell clone D1.1, 10 μ g/ml ConA stimulated 15 h (T206);
TH2 T cell clone CDC35, resting for 3 weeks after last
20 stimulation with antigen (T207); TH2 T cell clone CDC35,
10 μ g/ml ConA stimulated 15 h (T208); Mel14+ naive T
cells from spleen, resting (T209); Mel14+ T cells,
polarized to Th1 with IFN- γ /IL-12/anti-IL-4 for 6, 12, 24
h pooled (T210); Mel14+ T cells, polarized to Th2 with
25 IL-4/anti-IFN- γ for 6, 13, 24 h pooled (T211);
unstimulated mature B cell leukemia cell line A20 (B200);
unstimulated B cell line CH12 (B201); unstimulated large
B cells from spleen (B202); B cells from total spleen,
LPS activated (B203); metrizamide enriched dendritic
30 cells from spleen, resting (D200); dendritic cells from
bone marrow, resting (D201); monocyte cell line RAW 264.7
activated with LPS 4 h (M200); bone-marrow macrophages
derived with GM and M-CSF (M201); macrophage cell line
J774, resting (M202); macrophage cell line J774 + LPS +
35 anti-IL-10 at 0.5, 1, 3, 6, 12 h pooled (M203);
macrophage cell line J774 + LPS + IL-10 at 0.5, 1, 3, 5,
12 h pooled (M204); aerosol challenged mouse lung tissue,

Th2 primers, aerosol OVA challenge 7, 14, 23 h pooled
(see Garlisi, et al. (1995) Clinical Immunology and
Immunopathology 75:75-83; X206); Nippostrongylus-infected
lung tissue (see Coffman, et al. (1989) Science 245:308-
5 310; X200); total adult lung, normal (O200); total lung,
rag-1 (see Schwarz, et al. (1993) Immunodeficiency 4:249-
252; O205); IL-10 K.O. spleen (see Kuhn, et al. (1991)
Cell 75:263-274; X201); total adult spleen, normal
(O201); total spleen, rag-1 (O207); IL-10 K.O. Peyer's
10 patches (O202); total Peyer's patches, normal (O210); IL-
10 K.O. mesenteric lymph nodes (X203); total mesenteric
lymph nodes, normal (O211); IL-10 K.O. colon (X203);
total colon, normal (O212); NOD mouse pancreas (see
Makino, et al. (1980) Jikken Dobutsu 29:1-13; X205);
15 total thymus, rag-1 (O208); total kidney, rag-1 (O209);
total heart, rag-1 (O202); total brain, rag-1 (O203);
total testes, rag-1 (O204); total liver, rag-1 (O206);
rat normal joint tissue (O300); and rat arthritic joint
tissue (X300).

20

V. Cloning of species counterparts of DTLRs

Various strategies are used to obtain species
counterparts of these DTLRs, preferably from other
25 primates. One method is by cross hybridization using
closely related species DNA probes. It may be useful to
go into evolutionarily similar species as intermediate
steps. Another method is by using specific PCR primers
based on the identification of blocks of similarity or
30 difference between particular species, e.g., human,
genes, e.g., areas of highly conserved or nonconserved
polypeptide or nucleotide sequence. Alternatively,
antibodies may be used for expression cloning.

35 VI. Production of mammalian DTLR protein

An appropriate, e.g., GST, fusion construct is
engineered for expression, e.g., in E. coli. For

example, a mouse IGIF pGex plasmid is constructed and transformed into *E. coli*. Freshly transformed cells are grown in LB medium containing 50 µg/ml ampicillin and induced with IPTG (Sigma, St. Louis, MO). After
5 overnight induction, the bacteria are harvested and the pellets containing the DTLR protein are isolated. The pellets are homogenized in TE buffer (50 mM Tris-base pH 8.0, 10 mM EDTA and 2 mM pefabloc) in 2 liters. This material is passed through a microfluidizer
10 (Microfluidics, Newton, MA) three times. The fluidized supernatant is spun down on a Sorvall GS-3 rotor for 1 h at 13,000 rpm. The resulting supernatant containing the DTLR protein is filtered and passed over a glutathione-SEPHAROSE column equilibrated in 50 mM Tris-base pH 8.0.
15 The fractions containing the DTLR-GST fusion protein are pooled and cleaved with thrombin (Enzyme Research Laboratories, Inc., South Bend, IN). The cleaved pool is then passed over a Q-SEPHAROSE column equilibrated in 50 mM Tris-base. Fractions containing DTLR are pooled and
20 diluted in cold distilled H₂O, to lower the conductivity, and passed back over a fresh Q-Sepharose column, alone or in succession with an immunoaffinity antibody column.. Fractions containing the DTLR protein are pooled, aliquoted, and stored in the -70° C freezer.
25 Comparison of the CD spectrum with DTLR1 protein may suggest that the protein is correctly folded. See Hazuda, et al. (1969) J. Biol. Chem. 264:1689-1693.

VII. Biological Assays with DTLRs

30 Biological assays will generally be directed to the ligand binding feature of the protein or to the kinase/phosphatase activity of the receptor. The activity will typically be reversible, as are many other enzyme actions. mediate phosphatase or phosphorylase
35 activities, which activities are easily measured by standard procedures. See, e.g., Hardie, et al. (eds. 1995) The Protein Kinase FactBook vols. I and II,

Academic Press, San Diego, CA; Hanks, et al. (1991) Meth. Enzymol. 200:38-62; Hunter, et al. (1992) Cell 70:375-388; Lewin (1990) Cell 61:743-752; Pines, et al. (1991) Cold Spring Harbor Symp. Quant. Biol. 56:449-463; and
5 Parker, et al. (1993) Nature 363:736-738.

The family of interleukins 1 contains molecules, each of which is an important mediator of inflammatory disease. For a comprehensive review, see Dinarello (1996) "Biologic basis for interleukin-1 in disease"
10 Blood 87:2095-2147. There are suggestions that the various Toll ligands may play important roles in the initiation of disease, particularly inflammatory responses. The finding of novel proteins related to the IL-1 family furthers the identification of molecules that
15 provide the molecular basis for initiation of disease and allow for the development of therapeutic strategies of increased range and efficacy.

VIII. Preparation of antibodies specific for, e.g.,
20 DTLR4

Inbred Balb/c mice are immunized intraperitoneally with recombinant forms of the protein, e.g., purified DTLR4 or stable transfected NIH-3T3 cells. Animals are boosted at appropriate time points with protein, with or
25 without additional adjuvant, to further stimulate antibody production. Serum is collected, or hybridomas produced with harvested spleens.

Alternatively, Balb/c mice are immunized with cells transformed with the gene or fragments thereof, either
30 endogenous or exogenous cells, or with isolated membranes enriched for expression of the antigen. Serum is collected at the appropriate time, typically after numerous further administrations. Various gene therapy techniques may be useful, e.g., in producing protein in
35 situ, for generating an immune response.

Monoclonal antibodies may be made. For example, splenocytes are fused with an appropriate fusion partner

and hybridomas are selected in growth medium by standard procedures. Hybridoma supernatants are screened for the presence of antibodies which bind to the desired DTLR, e.g., by ELISA or other assay. Antibodies which
5 specifically recognize specific DTLR embodiments may also be selected or prepared.

In another method, synthetic peptides or purified protein are presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan
10 (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press. In appropriate situations, the binding reagent is either labeled as described above, e.g., fluorescence or otherwise, or immobilized to a
15 substrate for panning methods. Nucleic acids may also be introduced into cells in an animal to produce the antigen, which serves to elicit an immune response. See, e.g., Wang, et al. (1993) Proc. Nat'l. Acad. Sci. 90:4156-4160; Barry, et al. (1994) BioTechniques 16:616-
20 619; and Xiang, et al. (1995) Immunity 2: 129-135.

IX. Production of fusion proteins with, e.g., DTLR5

Various fusion constructs are made with DTLR5. This portion of the gene is fused to an epitope tag, e.g., a
25 FLAG tag, or to a two hybrid system construct. See, e.g., Fields and Song (1989) Nature 340:245-246.

The epitope tag may be used in an expression cloning procedure with detection with anti-FLAG antibodies to detect a binding partner, e.g., ligand for the respective
30 DTLR5. The two hybrid system may also be used to isolate proteins which specifically bind to DTLR5.

X. Chromosomal mapping of DTLRs

Chromosome spreads are prepared. In situ
35 hybridization is performed on chromosome preparations obtained from phytohemagglutinin-stimulated lymphocytes cultured for 72 h. 5-bromodeoxyuridine is added for the

final seven hours of culture (60 µg/ml of medium), to ensure a posthybridization chromosomal banding of good quality.

5 An appropriate fragment, e.g., a PCR fragment, amplified with the help of primers on total B cell cDNA template, is cloned into an appropriate vector. The vector is labeled by nick-translation with ³H. The radiolabeled probe is hybridized to metaphase spreads as described in Mattei, et al. (1985) Hum. Genet. 69:327-
10 331.

After coating with nuclear track emulsion (KODAK NTB2), slides are exposed, e.g., for 18 days at 4° C. To avoid any slipping of silver grains during the banding procedure, chromosome spreads are first stained with
15 buffered Giemsa solution and metaphase photographed. R-banding is then performed by the fluorochrome-photolysis-Giemsa (FPG) method and metaphases rephotographed before analysis.

Alternatively, FISH can be performed, as described
20 above. The DTLR genes are located on different chromosomes. DTLR2 and DTLR3 are localized to human chromosome 4; DTLR4 is localized to human chromosome 9, and DTLR5 is localized to human chromosome 1. See Figures 4A-4D.

25

XI. Structure activity relationship

Information on the criticality of particular residues is determined using standard procedures and analysis. Standard mutagenesis analysis is performed,
30 e.g., by generating many different variants at determined positions, e.g., at the positions identified above, and evaluating biological activities of the variants. This may be performed to the extent of determining positions which modify activity, or to focus on specific positions
35 to determine the residues which can be substituted to either retain, block, or modulate biological activity.

Alternatively, analysis of natural variants can indicate what positions tolerate natural mutations. This may result from populational analysis of variation among individuals, or across strains or species. Samples from
5 selected individuals are analysed, e.g., by PCR analysis and sequencing. This allows evaluation of population polymorphisms.

XI. Isolation of a ligand for a DTLR

10 A DTLR can be used as a specific binding reagent to identify its binding partner, by taking advantage of its specificity of binding, much like an antibody would be used. A binding reagent is either labeled as described above, e.g., fluorescence or otherwise, or immobilized to
15 a substrate for panning methods.

The binding composition is used to screen an expression library made from a cell line which expresses a binding partner, i.e., ligand, preferably membrane associated. Standard staining techniques are used to
20 detect or sort surface expressed ligand, or surface expressing transformed cells are screened by panning. Screening of intracellular expression is performed by various staining or immunofluorescence procedures. See also McMahan, et al. (1991) EMBO J. 10:2821-2832.

25 For example, on day 0, precoat 2-chamber permanox slides with 1 ml per chamber of fibronectin, 10 ng/ml in PBS, for 30 min at room temperature. Rinse once with PBS. Then plate COS cells at $2-3 \times 10^5$ cells per chamber in 1.5 ml of growth media. Incubate overnight at 37° C.

30 On day 1 for each sample, prepare 0.5 ml of a solution of 66 µg/ml DEAE-dextran, 66 µM chloroquine, and 4 µg DNA in serum free DME. For each set, a positive control is prepared, e.g., of DTLR-FLAG cDNA at 1 and 1/200 dilution, and a negative mock. Rinse cells with
35 serum free DME. Add the DNA solution and incubate 5 hr at 37° C. Remove the medium and add 0.5 ml 10% DMSO in

DME for 2.5 min. Remove and wash once with DME. Add 1.5 ml growth medium and incubate overnight.

On day 2, change the medium. On days 3 or 4, the cells are fixed and stained. Rinse the cells twice with
5 Hank's Buffered Saline Solution (HBSS) and fix in 4% paraformaldehyde (PFA)/glucose for 5 min. Wash 3X with HBSS. The slides may be stored at -80° C after all liquid is removed. For each chamber, 0.5 ml incubations are performed as follows. Add HBSS/saponin (0.1%) with
10 32 µl/ml of 1 M NaN₃ for 20 min. Cells are then washed with HBSS/saponin 1X. Add appropriate DTLR or DTLR/antibody complex to cells and incubate for 30 min. Wash cells twice with HBSS/saponin. If appropriate, add first antibody for 30 min. Add second antibody, e.g.,
15 Vector anti-mouse antibody, at 1/200 dilution, and incubate for 30 min. Prepare ELISA solution, e.g., Vector Elite ABC horseradish peroxidase solution, and preincubate for 30 min. Use, e.g., 1 drop of solution A (avidin) and 1 drop solution B (biotin) per 2.5 ml
20 HBSS/saponin. Wash cells twice with HBSS/saponin. Add ABC HRP solution and incubate for 30 min. Wash cells twice with HBSS, second wash for 2 min, which closes cells. Then add Vector diaminobenzoic acid (DAB) for 5 to 10 min. Use 2 drops of buffer plus 4 drops DAB plus 2
25 drops of H₂O₂ per 5 ml of glass distilled water. Carefully remove chamber and rinse slide in water. Air dry for a few minutes, then add 1 drop of Crystal Mount and a cover slip. Bake for 5 min at 85-90° C.

Evaluate positive staining of pools and
30 progressively subclone to isolation of single genes responsible for the binding.

Alternatively, DTLR reagents are used to affinity purify or sort out cells expressing a putative ligand. See, e.g., Sambrook, et al. or Ausubel, et al.

35 Another strategy is to screen for a membrane bound receptor by panning. The receptor cDNA is constructed as described above. The ligand can be immobilized and used

to immobilize expressing cells. Immobilization may be achieved by use of appropriate antibodies which recognize, e.g., a FLAG sequence of a DTLR fusion construct, or by use of antibodies raised against the first antibodies. Recursive cycles of selection and amplification lead to enrichment of appropriate clones and eventual isolation of receptor expressing clones.

Phage expression libraries can be screened by mammalian DTLRs. Appropriate label techniques, e.g., anti-FLAG antibodies, will allow specific labeling of appropriate clones.

All citations herein are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled; and the invention is not to be limited by the specific embodiments that have been presented herein by way of example.

SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- 5 (i) APPLICANT: (A) NAME: Schering Corporation
(B) STREET: 2000 Galloping Hill Road
(C) CITY: Kenilworth
10 (D) STATE: New Jersey
(E) COUNTRY: USA
(F) POSTAL CODE: 07033
(G) TELEPHONE: (908) 298-4000
(H) TELEFAX: (908) 298-5388
- 15 (ii) TITLE OF INVENTION: HUMAN RECEPTOR PROTEINS; RELATED
REAGENTS AND METHODS
- (iii) NUMBER OF SEQUENCES: 35
- 20 (iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: Macintosh Power PC
(C) OPERATING SYSTEM: 8.0
25 (D) SOFTWARE: Microsoft Word 6.0
- (v) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
30 (C) CLASSIFICATION:
- (vi) PRIOR APPLICATION DATA:
(A) APPLICATION NO.: USSN 60/044,293
(B) FILING DATE: 07-MAY-1997
- 35 (A) APPLICATION NO.: USSN 60/072,212
(B) FILING DATE: 22-JAN-1998
- (A) APPLICATION NO.: USSN 60/076,947
40 (B) FILING DATE: 05-MAR-1998
- (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
45 (A) LENGTH: 2367 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- 50 (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..2358
- 55 (ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 67..2358

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

| | | |
|----|---|-----|
| 5 | ATG ACT AGC ATC TTC CAT TTT GCC ATT ATC TTC ATG TTA ATA CTT CAG Met Thr Ser Ile Phe His Phe Ala Ile Ile Phe Met Leu Ile Leu Gln -22 -20 -15 -10 | 48 |
| 10 | ATC AGA ATA CAA TTA TCT GAA GAA AGT GAA TTT TTA GTT GAT AGG TCA Ile Arg Ile Gln Leu Ser Glu Glu Ser Glu Phe Leu Val Asp Arg Ser -5 1 5 10 | 96 |
| 15 | AAA AAC GGT CTC ATC CAC GTT CCT AAA GAC CTA TCC CAG AAA ACA ACA Lys Asn Gly Leu Ile His Val Pro Lys Asp Leu Ser Gln Lys Thr Thr 15 20 25 | 144 |
| 20 | ATC TTA AAT ATA TCG CAA AAT TAT ATA TCT GAG CTT TGG ACT TCT GAC Ile Leu Asn Ile Ser Gln Asn Tyr Ile Ser Glu Leu Trp Thr Ser Asp 30 35 40 | 192 |
| 25 | ATC TTA TCA CTG TCA AAA CTG AGG ATT TTG ATA ATT TCT CAT AAT AGA Ile Leu Ser Leu Ser Lys Leu Arg Ile Leu Ile Ile Ser His Asn Arg 45 50 55 | 240 |
| 30 | ATC CAG TAT CTT GAT ATC AGT GTT TTC AAA TTC AAC CAG GAA TTG GAA Ile Gln Tyr Leu Asp Ile Ser Val Phe Lys Phe Asn Gln Glu Leu Glu 60 65 70 | 288 |
| 35 | TAC TTG GAT TTG TCC CAC AAC AAG TTG GTG AAG ATT TCT TGC CAC CCT Tyr Leu Asp Leu Ser His Asn Lys Leu Val Lys Ile Ser Cys His Pro 75 80 85 90 | 336 |
| 40 | ACT GTG AAC CTC AAG CAC TTG GAC CTG TCA TTT AAT GCA TTT GAT GCC Thr Val Asn Leu Lys His Leu Asp Leu Ser Phe Asn Ala Phe Asp Ala 95 100 105 | 384 |
| 45 | CTG CCT ATA TGC AAA GAG TTT GGC AAT ATG TCT CAA CTA AAA TTT CTG Leu Pro Ile Cys Lys Glu Phe Gly Asn Met Ser Gln Leu Lys Phe Leu 110 115 120 | 432 |
| 50 | GGG TTG AGC ACC ACA CAC TTA GAA AAA TCT AGT GTG CTG CCA ATT GCT Gly Leu Ser Thr Thr His Leu Glu Lys Ser Ser Val Leu Pro Ile Ala 125 130 135 | 480 |
| 55 | CAT TTG AAT ATC AGC AAG GTC TTG CTG GTC TTA GGA GAG ACT TAT GGG His Leu Asn Ile Ser Lys Val Leu Leu Val Leu Gly Glu Thr Tyr Gly 140 145 150 | 528 |
| 60 | GAA AAA GAA GAC CCT GAG GGC CTT CAA GAC TTT AAC ACT GAG AGT CTG Glu Lys Glu Asp Pro Glu Gly Leu Gln Asp Phe Asn Thr Glu Ser Leu 155 160 165 170 | 576 |
| 65 | CAC ATT GTG TTC CCC ACA AAC AAA GAA TTC CAT TTT ATT TTG GAT GTG His Ile Val Phe Pro Thr Asn Lys Glu Phe His Phe Ile Leu Asp Val 175 180 185 | 624 |
| 70 | TCA GTC AAG ACT GTA GCA AAT CTG GAA CTA TCT AAT ATC AAA TGT GTG Ser Val Lys Thr Val Ala Asn Leu Glu Leu Ser Asn Ile Lys Cys Val 190 195 200 | 672 |
| 75 | CTA GAA GAT AAC AAA TGT TCT TAC TTC CTA AGT ATT CTG GCG AAA CTT Leu Glu Asp Asn Lys Cys Ser Tyr Phe Leu Ser Ile Leu Ala Lys Leu | 720 |

| | 205 | | | | | 210 | | | | | 215 | | | | | | |
|----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------|
| 5 | CAA Gln | ACA Thr | AAT Asn | CCA Pro | AAG Lys | TTA Leu | TCA Ser | AGT Ser | CTT Leu | ACC Thr | TTA Leu | AAC Asn | AAC Asn | ATT Ile | GAA Glu | ACA Thr | 768 |
| | 220 | | | | | | 225 | | | | | 230 | | | | | |
| 10 | ACT Thr | TGG Trp | AAT Asn | TCT Ser | TTC Phe | ATT Ile | AGG Arg | ATC Ile | CTC Leu | CAA Gln | CTA Leu | GTT Val | TGG Trp | CAT His | ACA Thr | ACT Thr | 816 |
| | 235 | | | | | 240 | | | | | 245 | | | | | 250 | |
| | GTA Val | TGG Trp | TAT Tyr | TTC Phe | TCA Ser | ATT Ile | TCA Ser | AAC Asn | GTG Val | AAG Lys | CTA Leu | CAG Gln | GGT Gly | CAG Gln | CTG Leu | GAC Asp | 864 |
| | | | | | 255 | | | | | 260 | | | | | 265 | | |
| 15 | TTC Phe | AGA Arg | GAT Asp | TTT Phe | GAT Asp | TAT Tyr | TCT Ser | GGC Gly | ACT Thr | TCC Ser | TTG Leu | AAG Lys | GCC Ala | TTG Leu | TCT Ser | ATA Ile | 912 |
| | | | | 270 | | | | | 275 | | | | 280 | | | | |
| 20 | CAC His | CAA Gln | GTT Val | GTC Val | AGC Ser | GAT Asp | GTG Val | TTC Phe | GGT Gly | TTT Phe | CCG Pro | CAA Gln | AGT Ser | TAT Tyr | ATC Ile | TAT Tyr | 960 |
| | | | 285 | | | | | 290 | | | | 295 | | | | | |
| 25 | GAA Glu | ATC Ile | TTT Phe | TCG Ser | AAT Asn | ATG Met | AAC Asn | ATC Ile | AAA Lys | AAT Asn | TTC Phe | ACA Thr | GTG Val | TCT Ser | GGT Gly | ACA Thr | 1008 |
| | 300 | | | | | | 305 | | | | | 310 | | | | | |
| 30 | CGC Arg | ATG Met | GTC Val | CAC His | ATG Met | CTT Leu | TGC Cys | CCA Pro | TCC Ser | AAA Lys | ATT Ile | AGC Ser | CCG Pro | TTC Phe | CTG Leu | CAT His | 1056 |
| | 315 | | | | | 320 | | | | | 325 | | | | | 330 | |
| | TTG Leu | GAT Asp | TTT Phe | TCC Ser | AAT Asn | AAT Asn | CTC Leu | TTA Leu | ACA Thr | GAC Asp | ACG Thr | GTT Val | TTT Phe | GAA Glu | AAT Asn | TGT Cys | 1104 |
| | | | | | 335 | | | | | 340 | | | | | 345 | | |
| 35 | GGG Gly | CAC His | CTT Leu | ACT Thr | GAG Glu | TTG Leu | GAG Glu | ACA Thr | CTT Leu | ATT Ile | TTA Leu | CAA Gln | ATG Met | AAT Asn | CAA Gln | TTA Leu | 1152 |
| | | | | 350 | | | | 355 | | | | | 360 | | | | |
| 40 | AAA Lys | GAA Glu | CTT Leu | TCA Ser | AAA Lys | ATA Ile | GCT Ala | GAA Glu | ATG Met | ACT Thr | ACA Thr | CAG Gln | ATG Met | AAG Lys | TCT Ser | CTG Leu | 1200 |
| | | | 365 | | | | 370 | | | | | 375 | | | | | |
| 45 | CAA Gln | CAA Gln | TTG Leu | GAT Asp | ATT Ile | AGC Ser | CAG Gln | AAT Asn | TCT Ser | GTA Val | AGC Ser | TAT Tyr | GAT Asp | GAA Glu | AAG Lys | AAA Lys | 1248 |
| | 380 | | | | | | 385 | | | | | 390 | | | | | |
| 50 | GGA Gly | GAC Asp | TGT Cys | TCT Ser | TGG Trp | ACT Thr | AAA Lys | AGT Ser | TTA Leu | TTA Leu | AGT Ser | TTA Leu | AAT Asn | ATG Met | TCT Ser | TCA Ser | 1296 |
| | 395 | | | | | 400 | | | | | 405 | | | | | 410 | |
| | AAT Asn | ATA Ile | CTT Leu | ACT Thr | GAC Asp | ACT Thr | ATT Ile | TTC Phe | AGA Arg | TGT Cys | TTA Leu | CCT Pro | CCC Pro | AGG Arg | ATC Ile | AAG Lys | 1344 |
| | | | | | 415 | | | | | 420 | | | | | 425 | | |
| 55 | GTA Val | CTT Leu | GAT Asp | CTT Leu | CAC His | AGC Ser | AAT Asn | AAA Lys | ATA Ile | AAG Lys | AGC Ser | ATT Ile | CCT Pro | AAA Lys | CAA Gln | GTC Val | 1392 |
| | | | | 430 | | | | 435 | | | | | 440 | | | | |
| 60 | GTA Val | AAA Lys | CTG Leu | GAA Glu | GCT Ala | TTG Leu | CAA Gln | GAA Glu | CTC Leu | AAT Asn | GTT Val | GCT Ala | TTC Phe | AAT Asn | TCT Ser | TTA Leu | 1440 |
| | | | 445 | | | | 450 | | | | | 455 | | | | | |

| | | | | | | | | | | | | | | | | | |
|----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------|
| 5 | ACT Thr | GAC Asp | CTT Leu | CCT Pro | GGA Gly | TGT Cys | GGC Gly | AGC Ser | TTT Phe | AGC Ser | AGC Ser | CTT Leu | TCT Ser | GTA Val | TTG Leu | ATC Ile | 1488 |
| | 460 | | | | | | 465 | | | | | 470 | | | | | |
| 10 | ATT Ile | GAT Asp | CAC His | AAT Asn | TCA Ser | GTT Val | TCC Ser | CAC His | CCA Pro | TCA Ser | GCT Ala | GAT Asp | TTC Phe | TTC Phe | CAG Gln | AGC Ser | 1536 |
| | 475 | | | | | 480 | | | | | 485 | | | | | 490 | |
| 15 | TGC Cys | CAG Gln | AAG Lys | ATG Met | AGG Arg | TCA Ser | ATA Ile | AAA Lys | GCA Ala | GGG Gly | GAC Asp | AAT Asn | CCA Pro | TTC Phe | CAA Gln | TGT Cys | 1584 |
| | | | | | 495 | | | | | 500 | | | | | 505 | | |
| 20 | ACC Thr | TGT Cys | GAG Glu | CTC Leu | GGA Gly | GAA Glu | TTT Phe | GTC Val | AAA Lys | AAT Asn | ATA Ile | GAC Asp | CAA Gln | GTA Val | TCA Ser | AGT Ser | 1632 |
| | | | | 510 | | | | | 515 | | | | | 520 | | | |
| 25 | GAA Glu | GTG Val | TTA Leu | GAG Glu | GGC Gly | TGG Trp | CCT Pro | GAT Asp | TCT Ser | TAT Tyr | AAG Lys | TGT Cys | GAC Asp | TAC Tyr | CCG Pro | GAA Glu | 1680 |
| | | | 525 | | | | 530 | | | | | | 535 | | | | |
| 30 | AGT Ser | TAT Tyr | AGA Arg | GGA Gly | ACC Thr | CTA Leu | CTA Leu | AAG Lys | GAC Asp | TTT Phe | CAC His | ATG Met | TCT Ser | GAA Glu | TTA Leu | TCC Ser | 1728 |
| | | 540 | | | | | 545 | | | | | 550 | | | | | |
| 35 | TGC Cys | AAC Asn | ATA Ile | ACT Thr | CTG Leu | CTG Leu | ATC Ile | GTC Val | ACC Thr | ATC Ile | GTT Val | GCC Ala | ACC Thr | ATG Met | CTG Leu | GTG Val | 1776 |
| | 555 | | | | 560 | | | | | | 565 | | | | | 570 | |
| 40 | TTG Leu | GCT Ala | GTG Val | ACT Thr | GTG Val | ACC Thr | TCC Ser | CTC Leu | TGC Cys | ATC Ile | TAC Tyr | TTG Leu | GAT Asp | CTG Leu | CCC Pro | TGG Trp | 1824 |
| | | | | | 575 | | | | | 580 | | | | | 585 | | |
| 45 | TAT Tyr | CTC Leu | AGG Arg | ATG Met | GTG Val | TGC Cys | CAG Gln | TGG Trp | ACC Thr | CAG Gln | ACC Thr | CGG Arg | CGC Arg | AGG Arg | GCC Ala | AGG Arg | 1872 |
| | | | | 590 | | | | | 595 | | | | | 600 | | | |
| 50 | AAC Asn | ATA Ile | CCC Pro | TTA Leu | GAA Glu | GAA Glu | CTC Leu | CAA Gln | AGA Arg | AAT Asn | CTC Leu | CAG Gln | TTT Phe | CAT His | GCA Ala | TTT Phe | 1920 |
| | | | 605 | | | | | 610 | | | | | 615 | | | | |
| 55 | ATT Ile | TCA Ser | TAT Tyr | AGT Ser | GGG Gly | CAC His | GAT Asp | TCT Ser | TTC Phe | TGG Trp | GTG Val | AAG Lys | AAT Asn | GAA Glu | TTA Leu | TTG Leu | 1968 |
| | | 620 | | | | | 625 | | | | | 630 | | | | | |
| 60 | CCA Pro | AAC Asn | CTA Leu | GAG Glu | AAA Lys | GAA Glu | GGT Gly | ATG Met | CAG Gln | ATT Ile | TGC Cys | CTT Leu | CAT His | GAG Glu | AGA Arg | AAC Asn | 2016 |
| | 635 | | | | 640 | | | | | | 645 | | | | | 650 | |
| 65 | TTT Phe | GTT Val | CCT Pro | GGC Gly | AAG Lys | AGC Ser | ATT Ile | GTG Val | GAA Glu | AAT Asn | ATC Ile | ATC Ile | ACC Thr | TGC Cys | ATT Ile | GAG Glu | 2064 |
| | | | | | 655 | | | | | 660 | | | | | 665 | | |
| 70 | AAG Lys | AGT Ser | TAC Tyr | AAG Lys | TCC Ser | ATC Ile | TTT Phe | GTT Val | TTG Leu | TCT Ser | CCC Pro | AAC Asn | TTT Phe | GTC Val | CAG Gln | AGT Ser | 2112 |
| | | | | 670 | | | | | 675 | | | | | 680 | | | |
| 75 | GAA Glu | TGG Trp | TGC Cys | CAT His | TAT Tyr | GAA Glu | CTC Leu | TAC Tyr | TTT Phe | GCC Ala | CAT His | CAC His | AAT Asn | CTC Leu | TTT Phe | CAT His | 2160 |
| | | | 685 | | | | | 690 | | | | | 695 | | | | |

GAA GGA TCT AAT AGC TTA ATC CTG ATC TTG CTG GAA CCC ATT CCG CAG 2208
 Glu Gly Ser Asn Ser Leu Ile Leu Ile Leu Leu Glu Pro Ile Pro Gln
 700 705 710

5 TAC TCC ATT CCT AGC AGT TAT CAC AAG CTC AAA AGT CTC ATG GCC AGG 2256
 Tyr Ser Ile Pro Ser Ser Tyr His Lys Leu Lys Ser Leu Met Ala Arg
 715 720 725 730

10 AGG ACT TAT TTG GAA TGG CCC AAG GAA AAG AGC AAA CGT GGC CTT TTT 2304
 Arg Thr Tyr Leu Glu Trp Pro Lys Glu Lys Ser Lys Arg Gly Leu Phe
 735 740 745

15 TGG GCT AAC TTA AGG GCA GCC ATT AAT ATT AAG CTG ACA GAG CAA GCA 2352
 Trp Ala Asn Leu Arg Ala Ala Ile Asn Ile Lys Leu Thr Glu Gln Ala
 750 755 760

AAG AAA TAGTCTAGA 2367
 Lys Lys

20

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
 25 (A) LENGTH: 786 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
 30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

35 Met Thr Ser Ile Phe His Phe Ala Ile Ile Phe Met Leu Ile Leu Gln
 -22 -20 -15 -10
 Ile Arg Ile Gln Leu Ser Glu Glu Ser Glu Phe Leu Val Asp Arg Ser
 -5 1 5 10

40 Lys Asn Gly Leu Ile His Val Pro Lys Asp Leu Ser Gln Lys Thr Thr
 15 20 25
 Ile Leu Asn Ile Ser Gln Asn Tyr Ile Ser Glu Leu Trp Thr Ser Asp
 30 35 40

45 Ile Leu Ser Leu Ser Lys Leu Arg Ile Leu Ile Ile Ser His Asn Arg
 45 50 55

50 Ile Gln Tyr Leu Asp Ile Ser Val Phe Lys Phe Asn Gln Glu Leu Glu
 60 65 70
 Tyr Leu Asp Leu Ser His Asn Lys Leu Val Lys Ile Ser Cys His Pro
 75 80 85 90

55 Thr Val Asn Leu Lys His Leu Asp Leu Ser Phe Asn Ala Phe Asp Ala
 95 100 105
 Leu Pro Ile Cys Lys Glu Phe Gly Asn Met Ser Gln Leu Lys Phe Leu
 110 115 120

60 Gly Leu Ser Thr Thr His Leu Glu Lys Ser Ser Val Leu Pro Ile Ala
 125 130 135

| | | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| | His | Leu | Asn | Ile | Ser | Lys | Val | Leu | Leu | Val | Leu | Gly | Glu | Thr | Tyr | Gly | |
| | 140 | | | | | | 145 | | | | | 150 | | | | | |
| 5 | Glu | Lys | Glu | Asp | Pro | Glu | Gly | Leu | Gln | Asp | Phe | Asn | Thr | Glu | Ser | Leu | |
| | 155 | | | | | 160 | | | | | 165 | | | | | 170 | |
| | His | Ile | Val | Phe | Pro | Thr | Asn | Lys | Glu | Phe | His | Phe | Ile | Leu | Asp | Val | |
| | | | | | 175 | | | | | 180 | | | | | 185 | | |
| 10 | Ser | Val | Lys | Thr | Val | Ala | Asn | Leu | Glu | Leu | Ser | Asn | Ile | Lys | Cys | Val | |
| | | | | 190 | | | | | 195 | | | | | 200 | | | |
| | Leu | Glu | Asp | Asn | Lys | Cys | Ser | Tyr | Phe | Leu | Ser | Ile | Leu | Ala | Lys | Leu | |
| 15 | | | 205 | | | | | 210 | | | | | 215 | | | | |
| | Gln | Thr | Asn | Pro | Lys | Leu | Ser | Ser | Leu | Thr | Leu | Asn | Asn | Ile | Glu | Thr | |
| | 220 | | | | | | 225 | | | | | 230 | | | | | |
| 20 | Thr | Trp | Asn | Ser | Phe | Ile | Arg | Ile | Leu | Gln | Leu | Val | Trp | His | Thr | Thr | |
| | 235 | | | | | 240 | | | | | 245 | | | | | 250 | |
| | Val | Trp | Tyr | Phe | Ser | Ile | Ser | Asn | Val | Lys | Leu | Gln | Gly | Gln | Leu | Asp | |
| | | | | | 255 | | | | | 260 | | | | | 265 | | |
| 25 | Phe | Arg | Asp | Phe | Asp | Tyr | Ser | Gly | Thr | Ser | Leu | Lys | Ala | Leu | Ser | Ile | |
| | | | | 270 | | | | 275 | | | | | | 280 | | | |
| | His | Gln | Val | Val | Ser | Asp | Val | Phe | Gly | Phe | Pro | Gln | Ser | Tyr | Ile | Tyr | |
| 30 | | | 285 | | | | | 290 | | | | | 295 | | | | |
| | Glu | Ile | Phe | Ser | Asn | Met | Asn | Ile | Lys | Asn | Phe | Thr | Val | Ser | Gly | Thr | |
| | 300 | | | | | | 305 | | | | | 310 | | | | | |
| 35 | Arg | Met | Val | His | Met | Leu | Cys | Pro | Ser | Lys | Ile | Ser | Pro | Phe | Leu | His | |
| | 315 | | | | | 320 | | | | | 325 | | | | | 330 | |
| | Leu | Asp | Phe | Ser | Asn | Asn | Leu | Leu | Thr | Asp | Thr | Val | Phe | Glu | Asn | Cys | |
| | | | | | 335 | | | | | 340 | | | | | 345 | | |
| 40 | Gly | His | Leu | Thr | Glu | Leu | Glu | Thr | Leu | Ile | Leu | Gln | Met | Asn | Gln | Leu | |
| | | | | 350 | | | | | 355 | | | | | 360 | | | |
| | Lys | Glu | Leu | Ser | Lys | Ile | Ala | Glu | Met | Thr | Thr | Gln | Met | Lys | Ser | Leu | |
| 45 | | | 365 | | | | | 370 | | | | | 375 | | | | |
| | Gln | Gln | Leu | Asp | Ile | Ser | Gln | Asn | Ser | Val | Ser | Tyr | Asp | Glu | Lys | Lys | |
| | 380 | | | | | | 385 | | | | | 390 | | | | | |
| 50 | Gly | Asp | Cys | Ser | Trp | Thr | Lys | Ser | Leu | Leu | Ser | Leu | Asn | Met | Ser | Ser | |
| | 395 | | | | | 400 | | | | | 405 | | | | | 410 | |
| | Asn | Ile | Leu | Thr | Asp | Thr | Ile | Phe | Arg | Cys | Leu | Pro | Pro | Arg | Ile | Lys | |
| | | | | | 415 | | | | | 420 | | | | | 425 | | |
| 55 | Val | Leu | Asp | Leu | His | Ser | Asn | Lys | Ile | Lys | Ser | Ile | Pro | Lys | Gln | Val | |
| | | | | 430 | | | | | 435 | | | | | 440 | | | |
| | Val | Lys | Leu | Glu | Ala | Leu | Gln | Glu | Leu | Asn | Val | Ala | Phe | Asn | Ser | Leu | |
| 60 | | | 445 | | | | | 450 | | | | | 455 | | | | |

Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser Leu Ser Val Leu Ile
 460 465 470
 5 Ile Asp His Asn Ser Val Ser His Pro Ser Ala Asp Phe Phe Gln Ser
 475 480 485 490
 Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp Asn Pro Phe Gln Cys
 495 500 505
 10 Thr Cys Glu Leu Gly Glu Phe Val Lys Asn Ile Asp Gln Val Ser Ser
 510 515 520
 Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys Cys Asp Tyr Pro Glu
 525 530 535
 15 Ser Tyr Arg Gly Thr Leu Leu Lys Asp Phe His Met Ser Glu Leu Ser
 540 545 550
 20 Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Val Ala Thr Met Leu Val
 555 560 565 570
 Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr Leu Asp Leu Pro Trp
 575 580 585
 25 Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr Arg Arg Arg Ala Arg
 590 595 600
 Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe
 605 610 615
 30 Ile Ser Tyr Ser Gly His Asp Ser Phe Trp Val Lys Asn Glu Leu Leu
 620 625 630
 35 Pro Asn Leu Glu Lys Glu Gly Met Gln Ile Cys Leu His Glu Arg Asn
 635 640 645 650
 Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Thr Cys Ile Glu
 655 660 665
 40 Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Ser
 670 675 680
 Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His
 685 690 695
 45 Glu Gly Ser Asn Ser Leu Ile Leu Ile Leu Leu Glu Pro Ile Pro Gln
 700 705 710
 50 Tyr Ser Ile Pro Ser Ser Tyr His Lys Leu Lys Ser Leu Met Ala Arg
 715 720 725 730
 Arg Thr Tyr Leu Glu Trp Pro Lys Glu Lys Ser Lys Arg Gly Leu Phe
 735 740 745
 55 Trp Ala Asn Leu Arg Ala Ala Ile Asn Ile Lys Leu Thr Glu Gln Ala
 750 755 760
 Lys Lys

60

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2355 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..2352

(ix) FEATURE:
 (A) NAME/KEY: mat_peptide
 (B) LOCATION: 67..2352

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

| | |
|---|-----|
| ATG CCA CAT ACT TTG TGG ATG GTG TGG GTC TTG GGG GTC ATC ATC AGC | 48 |
| Met Pro His Thr Leu Trp Met Val Trp Val Leu Gly Val Ile Ile Ser | |
| -22 -20 -15 -10 | |
| CTC TCC AAG GAA GAA TCC TCC AAT CAG GCT TCT CTG TCT TGT GAC CGC | 96 |
| Leu Ser Lys Glu Glu Ser Ser Asn Gln Ala Ser Leu Ser Cys Asp Arg | |
| -5 1 5 10 | |
| AAT GGT ATC TGC AAG GGC AGC TCA GGA TCT TTA AAC TCC ATT CCC TCA | 144 |
| Asn Gly Ile Cys Lys Gly Ser Ser Gly Ser Leu Asn Ser Ile Pro Ser | |
| 15 20 25 | |
| GGG CTC ACA GAA GCT GTA AAA AGC CTT GAC CTG TCC AAC AAC AGG ATC | 192 |
| Gly Leu Thr Glu Ala Val Lys Ser Leu Asp Leu Ser Asn Asn Arg Ile | |
| 30 35 40 | |
| ACC TAC ATT AGC AAC AGT GAC CTA CAG AGG TGT GTG AAC CTC CAG GCT | 240 |
| Thr Tyr Ile Ser Asn Ser Asp Leu Gln Arg Cys Val Asn Leu Gln Ala | |
| 45 50 55 | |
| CTG GTG CTG ACA TCC AAT GGA ATT AAC ACA ATA GAG GAA GAT TCT TTT | 288 |
| Leu Val Leu Thr Ser Asn Gly Ile Asn Thr Ile Glu Glu Asp Ser Phe | |
| 60 65 70 | |
| TCT TCC CTG GGC AGT CTT GAA CAT TTA GAC TTA TCC TAT AAT TAC TTA | 336 |
| Ser Ser Leu Gly Ser Leu Glu His Leu Asp Leu Ser Tyr Asn Tyr Leu | |
| 75 80 85 90 | |
| TCT AAT TTA TCG TCT TCC TGG TTC AAG CCC CTT TCT TCT TTA ACA TTC | 384 |
| Ser Asn Leu Ser Ser Ser Trp Phe Lys Pro Leu Ser Ser Leu Thr Phe | |
| 95 100 105 | |
| TTA AAC TTA CTG GGA AAT CCT TAC AAA ACC CTA GGG GAA ACA TCT CTT | 432 |
| Leu Asn Leu Leu Gly Asn Pro Tyr Lys Thr Leu Gly Glu Thr Ser Leu | |
| 110 115 120 | |
| TTT TCT CAT CTC ACA AAA TTG CAA ATC CTG AGA GTG GGA AAT ATG GAC | 480 |
| Phe Ser His Leu Thr Lys Leu Gln Ile Leu Arg Val Gly Asn Met Asp | |
| 125 130 135 | |

| | | |
|----|---|------|
| | ACC TTC ACT AAG ATT CAA AGA AAA GAT TTT GCT GGA CTT ACC TTC CTT | 528 |
| | Thr Phe Thr Lys Ile Gln Arg Lys Asp Phe Ala Gly Leu Thr Phe Leu | |
| | 140 145 150 | |
| 5 | GAG GAA CTT GAG ATT GAT GCT TCA GAT CTA CAG AGC TAT GAG CCA AAA | 576 |
| | Glu Glu Leu Glu Ile Asp Ala Ser Asp Leu Gln Ser Tyr Glu Pro Lys | |
| | 155 160 165 170 | |
| 10 | AGT TTG AAG TCA ATT CAG AAC GTA AGT CAT CTG ATC CTT CAT ATG AAG | 624 |
| | Ser Leu Lys Ser Ile Gln Asn Val Ser His Leu Ile Leu His Met Lys | |
| | 175 180 185 | |
| 15 | CAG CAT ATT TTA CTG CTG GAG ATT TTT GTA GAT GTT ACA AGT TCC GTG | 672 |
| | Gln His Ile Leu Leu Leu Glu Ile Phe Val Asp Val Thr Ser Ser Val | |
| | 190 195 200 | |
| 20 | GAA TGT TTG GAA CTG CGA GAT ACT GAT TTG GAC ACT TTC CAT TTT TCA | 720 |
| | Glu Cys Leu Glu Leu Arg Asp Thr Asp Leu Asp Thr Phe His Phe Ser | |
| | 205 210 215 | |
| 25 | GAA CTA TCC ACT GGT GAA ACA AAT TCA TTG ATT AAA AAG TTT ACA TTT | 768 |
| | Glu Leu Ser Thr Gly Glu Thr Asn Ser Leu Ile Lys Lys Phe Thr Phe | |
| | 220 225 230 | |
| 30 | AGA AAT GTG AAA ATC ACC GAT GAA AGT TTG TTT CAG GTT ATG AAA CTT | 816 |
| | Arg Asn Val Lys Ile Thr Asp Glu Ser Leu Phe Gln Val Met Lys Leu | |
| | 235 240 245 250 | |
| 35 | TTG AAT CAG ATT TCT GGA TTG TTA GAA TTA GAG TTT GAT GAC TGT ACC | 864 |
| | Leu Asn Gln Ile Ser Gly Leu Leu Glu Leu Glu Phe Asp Asp Cys Thr | |
| | 255 260 265 | |
| 40 | CTT AAT GGA GTT GGT AAT TTT AGA GCA TCT GAT AAT GAC AGA GTT ATA | 912 |
| | Leu Asn Gly Val Gly Asn Phe Arg Ala Ser Asp Asn Asp Arg Val Ile | |
| | 270 275 280 | |
| 45 | GAT CCA GGT AAA GTG GAA ACG TTA ACA ATC CGG AGG CTG CAT ATT CCA | 960 |
| | Asp Pro Gly Lys Val Glu Thr Leu Thr Ile Arg Arg Leu His Ile Pro | |
| | 285 290 295 | |
| 50 | AGG TTT TAC TTA TTT TAT GAT CTG AGC ACT TTA TAT TCA CTT ACA GAA | 1008 |
| | Arg Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Leu Tyr Ser Leu Thr Glu | |
| | 300 305 310 | |
| 55 | AGA GTT AAA AGA ATC ACA GTA GAA AAC AGT AAA GTT TTT CTG GTT CCT | 1056 |
| | Arg Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro | |
| | 315 320 325 330 | |
| 60 | TGT TTA CTT TCA CAA CAT TTA AAA TCA TTA GAA TAC TTG GAT CTC AGT | 1104 |
| | Cys Leu Leu Ser Gln His Leu Lys Ser Leu Glu Tyr Leu Asp Leu Ser | |
| | 335 340 345 | |
| 65 | GAA AAT TTG ATG GTT GAA GAA TAC TTG AAA AAT TCA GCC TGT GAG GAT | 1152 |
| | Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Glu Asp | |
| | 350 355 360 | |
| 70 | GCC TGG CCC TCT CTA CAA ACT TTA ATT TTA AGG CAA AAT CAT TTG GCA | 1200 |
| | Ala Trp Pro Ser Leu Gln Thr Leu Ile Leu Arg Gln Asn His Leu Ala | |
| | 365 370 375 | |
| 75 | TCA TTG GAA AAA ACC GGA GAG ACT TTG CTC ACT CTG AAA AAC TTG ACT | 1248 |

| | | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| | Ser | Leu | Glu | Lys | Thr | Gly | Glu | Thr | Leu | Leu | Thr | Leu | Lys | Asn | Leu | Thr | |
| | 380 | | | | | | 385 | | | | | 390 | | | | | |
| 5 | AAC | ATT | GAT | ATC | AGT | AAG | AAT | AGT | TTT | CAT | TCT | ATG | CCT | GAA | ACT | TGT | 1296 |
| | Asn | Ile | Asp | Ile | Ser | Lys | Asn | Ser | Phe | His | Ser | Met | Pro | Glu | Thr | Cys | |
| | 395 | | | | | 400 | | | | | 405 | | | | 410 | | |
| 10 | CAG | TGG | CCA | GAA | AAG | ATG | AAA | TAT | TTG | AAC | TTA | TCC | AGC | ACA | CGA | ATA | 1344 |
| | Gln | Trp | Pro | Glu | Lys | Met | Lys | Tyr | Leu | Asn | Leu | Ser | Ser | Thr | Arg | Ile | |
| | | | | | 415 | | | | | 420 | | | | | 425 | | |
| 15 | CAC | AGT | GTA | ACA | GGC | TGC | ATT | CCC | AAG | ACA | CTG | GAA | ATT | TTA | GAT | GTT | 1392 |
| | His | Ser | Val | Thr | Gly | Cys | Ile | Pro | Lys | Thr | Leu | Glu | Ile | Leu | Asp | Val | |
| | | | | 430 | | | | | 435 | | | | | 440 | | | |
| 20 | AGC | AAC | AAC | AAT | CTC | AAT | TTA | TTT | TCT | TTG | AAT | TTG | CCG | CAA | CTC | AAA | 1440 |
| | Ser | Asn | Asn | Asn | Leu | Asn | Leu | Phe | Ser | Leu | Asn | Leu | Pro | Gln | Leu | Lys | |
| | | | | 445 | | | | 450 | | | | | 455 | | | | |
| 25 | GAA | CTT | TAT | ATT | TCC | AGA | AAT | AAG | TTG | ATG | ACT | CTA | CCA | GAT | GCC | TCC | 1488 |
| | Glu | Leu | Tyr | Ile | Ser | Arg | Asn | Lys | Leu | Met | Thr | Leu | Pro | Asp | Ala | Ser | |
| | | 460 | | | | | 465 | | | | | 470 | | | | | |
| 30 | CTC | TTA | CCC | ATG | TTA | CTA | GTA | TTG | AAA | ATC | AGT | AGG | AAT | GCA | ATA | ACT | 1536 |
| | Leu | Leu | Pro | Met | Leu | Leu | Val | Leu | Lys | Ile | Ser | Arg | Asn | Ala | Ile | Thr | |
| | | | | | | 480 | | | | | 485 | | | | | 490 | |
| 35 | ACG | TTT | TCT | AAG | GAG | CAA | CTT | GAC | TCA | TTT | CAC | ACA | CTG | AAG | ACT | TTG | 1584 |
| | Thr | Phe | Ser | Lys | Glu | Gln | Leu | Asp | Ser | Phe | His | Thr | Leu | Lys | Thr | Leu | |
| | | | | | 495 | | | | | 500 | | | | | 505 | | |
| 40 | GAA | GCT | GGT | GGC | AAT | AAC | TTC | ATT | TGC | TCC | TGT | GAA | TTC | CTC | TCC | TTC | 1632 |
| | Glu | Ala | Gly | Gly | Asn | Asn | Phe | Ile | Cys | Ser | Cys | Glu | Phe | Leu | Ser | Phe | |
| | | | | 510 | | | | | 515 | | | | | 520 | | | |
| 45 | ACT | CAG | GAG | CAG | CAA | GCA | CTG | GCC | AAA | GTC | TTG | ATT | GAT | TGG | CCA | GCA | 1680 |
| | Thr | Gln | Glu | Gln | Gln | Ala | Leu | Ala | Lys | Val | Leu | Ile | Asp | Trp | Pro | Ala | |
| | | | | 525 | | | | 530 | | | | | 535 | | | | |
| 50 | AAT | TAC | CTG | TGT | GAC | TCT | CCA | TCC | CAT | GTG | CGT | GGC | CAG | CAG | GTT | CAG | 1728 |
| | Asn | Tyr | Leu | Cys | Asp | Ser | Pro | Ser | His | Val | Arg | Gly | Gln | Gln | Val | Gln | |
| | | 540 | | | | | 545 | | | | | 550 | | | | | |
| 55 | GAT | GTC | CGC | CTC | TCG | GTG | TCG | GAA | TGT | CAC | AGG | ACA | GCA | CTG | GTG | TCT | 1776 |
| | Asp | Val | Arg | Leu | Ser | Val | Ser | Glu | Cys | His | Arg | Thr | Ala | Leu | Val | Ser | |
| | | 555 | | | | 560 | | | | | 565 | | | | 570 | | |
| 60 | GGC | ATG | TGC | TGT | GCT | CTG | TTC | CTG | CTG | ATC | CTG | CTC | ACG | GGG | GTC | CTG | 1824 |
| | Gly | Met | Cys | Cys | Ala | Leu | Phe | Leu | Leu | Ile | Leu | Leu | Thr | Gly | Val | Leu | |
| | | | | | 575 | | | | | 580 | | | | | 585 | | |
| 65 | TGC | CAC | CGT | TTC | CAT | GGC | CTG | TGG | TAT | ATG | AAA | ATG | ATG | TGG | GCC | TGG | 1872 |
| | Cys | His | Arg | Phe | His | Gly | Leu | Trp | Tyr | Met | Lys | Met | Met | Trp | Ala | Trp | |
| | | | | 590 | | | | | 595 | | | | | 600 | | | |
| 70 | CTC | CAG | GCC | AAA | AGG | AAG | CCC | AGG | AAA | GCT | CCC | AGC | AGG | AAC | ATC | TGC | 1920 |
| | Leu | Gln | Ala | Lys | Arg | Lys | Pro | Arg | Lys | Ala | Pro | Ser | Arg | Asn | Ile | Cys | |
| | | | 605 | | | | | 610 | | | | | 615 | | | | |
| 75 | TAT | GAT | GCA | TTT | GTT | TCT | TAC | AGT | GAG | CGG | GAT | GCC | TAC | TGG | GTG | GAG | 1968 |
| | Tyr | Asp | Ala | Phe | Val | Ser | Tyr | Ser | Glu | Arg | Asp | Ala | Tyr | Trp | Val | Glu | |

| | 45 | 50 | 55 |
|----|-----------------|---|-------------------------------------|
| | Leu Val 60 | Leu Thr Ser Asn Gly 65 | Ile Asn Thr Ile Glu 70 |
| 5 | Ser 75 | Ser Leu Gly 80 | His Leu Asp 85 |
| | Ser Asn 95 | Leu Ser Trp Phe Lys 100 | Pro Leu Ser Ser Leu Thr Phe 105 |
| 10 | Leu Asn 110 | Leu Gly Asn Pro Tyr Lys 115 | Thr Leu Gly Glu Thr Ser Leu 120 |
| 15 | Phe Ser 125 | His Leu Thr Lys Leu Gln 130 | Ile Leu Arg Val Gly Asn Met Asp 135 |
| | Thr Phe 140 | Thr Lys Ile Gln Arg Lys Asp Phe Ala Gly 150 | Leu Thr Phe Leu 155 |
| 20 | Glu Glu 155 | Leu Glu Ile Asp Ala Ser Asp Leu Gln Ser Tyr Glu Pro Lys 160 | 165 170 |
| | Ser Leu Lys 175 | Ser Ile Gln Asn Val Ser His Leu Ile Leu His Met Lys 180 | 185 |
| 25 | Gln His 190 | Ile Leu Leu Leu Glu Ile Phe Val Asp Val Thr Ser Ser Val 200 | |
| 30 | Glu Cys 205 | Leu Glu Leu Arg Asp Thr Asp Leu Asp Thr Phe His Phe Ser 210 | 215 |
| | Glu Leu 220 | Ser Thr Gly Glu Thr Asn Ser Leu Ile Lys Lys Phe Thr Phe 225 | 230 |
| 35 | Arg Asn 235 | Val Lys Ile Thr Asp Glu Ser Leu Phe Gln Val Met Lys Leu 240 | 245 250 |
| | Leu Asn Gln 255 | Ile Ser Gly Leu Leu Glu Leu Glu Phe Asp Asp Cys Thr 260 | 265 |
| 40 | Leu Asn Gly 270 | Val Gly Asn Phe Arg Ala Ser Asp Asn Asp Arg Val Ile 275 | 280 |
| 45 | Asp Pro 285 | Gly Lys Val Glu Thr Leu Thr Ile Arg Arg Leu His Ile Pro 290 | 295 |
| | Arg Phe 300 | Tyr Leu Phe Tyr Asp Leu Ser Thr Leu Tyr Ser Leu Thr Glu 305 | 310 |
| 50 | Arg Val 315 | Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro 320 | 325 330 |
| | Cys Leu 335 | Leu Ser Gln His Leu Lys Ser Leu Glu Tyr Leu Asp Leu Ser 340 | 345 |
| 55 | Glu Asn 350 | Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Glu Asp 355 | 360 |
| 60 | Ala Trp 365 | Pro Ser Leu Gln Thr Leu Ile Leu Arg Gln Asn His Leu Ala 370 | 375 |

| | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | Ser | Leu | Glu | Lys | Thr | Gly | Glu | Thr | Leu | Leu | Thr | Leu | Lys | Asn | Leu | Thr |
| | 380 | | | | | | 385 | | | | | 390 | | | | |
| 5 | Asn | Ile | Asp | Ile | Ser | Lys | Asn | Ser | Phe | His | Ser | Met | Pro | Glu | Thr | Cys |
| | 395 | | | | | 400 | | | | | 405 | | | | | 410 |
| | Gln | Trp | Pro | Glu | Lys | Met | Lys | Tyr | Leu | Asn | Leu | Ser | Ser | Thr | Arg | Ile |
| | | | | | 415 | | | | | 420 | | | | | 425 | |
| 10 | His | Ser | Val | Thr | Gly | Cys | Ile | Pro | Lys | Thr | Leu | Glu | Ile | Leu | Asp | Val |
| | | | | 430 | | | | | 435 | | | | | | 440 | |
| | Ser | Asn | Asn | Asn | Leu | Asn | Leu | Phe | Ser | Leu | Asn | Leu | Pro | Gln | Leu | Lys |
| 15 | | | | 445 | | | | 450 | | | | | 455 | | | |
| | Glu | Leu | Tyr | Ile | Ser | Arg | Asn | Lys | Leu | Met | Thr | Leu | Pro | Asp | Ala | Ser |
| | 460 | | | | | | 465 | | | | | 470 | | | | |
| 20 | Leu | Leu | Pro | Met | Leu | Leu | Val | Leu | Lys | Ile | Ser | Arg | Asn | Ala | Ile | Thr |
| | 475 | | | | | 480 | | | | | 485 | | | | | 490 |
| | Thr | Phe | Ser | Lys | Glu | Gln | Leu | Asp | Ser | Phe | His | Thr | Leu | Lys | Thr | Leu |
| | | | | | 495 | | | | | 500 | | | | | 505 | |
| 25 | Glu | Ala | Gly | Gly | Asn | Asn | Phe | Ile | Cys | Ser | Cys | Glu | Phe | Leu | Ser | Phe |
| | | | | 510 | | | | | 515 | | | | | 520 | | |
| | Thr | Gln | Glu | Gln | Gln | Ala | Leu | Ala | Lys | Val | Leu | Ile | Asp | Trp | Pro | Ala |
| 30 | | | 525 | | | | | 530 | | | | | 535 | | | |
| | Asn | Tyr | Leu | Cys | Asp | Ser | Pro | Ser | His | Val | Arg | Gly | Gln | Gln | Val | Gln |
| | 540 | | | | | | 545 | | | | | 550 | | | | |
| 35 | Asp | Val | Arg | Leu | Ser | Val | Ser | Glu | Cys | His | Arg | Thr | Ala | Leu | Val | Ser |
| | 555 | | | | | 560 | | | | | 565 | | | | | 570 |
| | Gly | Met | Cys | Cys | Ala | Leu | Phe | Leu | Leu | Ile | Leu | Leu | Thr | Gly | Val | Leu |
| | | | | | 575 | | | | | 580 | | | | | 585 | |
| 40 | Cys | His | Arg | Phe | His | Gly | Leu | Trp | Tyr | Met | Lys | Met | Met | Trp | Ala | Trp |
| | | | | 590 | | | | | 595 | | | | | 600 | | |
| | Leu | Gln | Ala | Lys | Arg | Lys | Pro | Arg | Lys | Ala | Pro | Ser | Arg | Asn | Ile | Cys |
| 45 | | | 605 | | | | | 610 | | | | | 615 | | | |
| | Tyr | Asp | Ala | Phe | Val | Ser | Tyr | Ser | Glu | Arg | Asp | Ala | Tyr | Trp | Val | Glu |
| | 620 | | | | | | 625 | | | | | 630 | | | | |
| 50 | Asn | Leu | Met | Val | Gln | Glu | Leu | Glu | Asn | Phe | Asn | Pro | Pro | Phe | Lys | Leu |
| | 635 | | | | | 640 | | | | | 645 | | | | | 650 |
| | Cys | Leu | His | Lys | Arg | Asp | Phe | Ile | Pro | Gly | Lys | Trp | Ile | Ile | Asp | Asn |
| | | | | | 655 | | | | | 660 | | | | | 665 | |
| 55 | Ile | Ile | Asp | Ser | Ile | Glu | Lys | Ser | His | Lys | Thr | Val | Phe | Val | Leu | Ser |
| | | | | 670 | | | | | 675 | | | | | 680 | | |
| | Glu | Asn | Phe | Val | Lys | Ser | Glu | Trp | Cys | Lys | Tyr | Glu | Leu | Asp | Phe | Ser |
| 60 | | | 685 | | | | | 690 | | | | | 695 | | | |

His Phe Arg Leu Phe Glu Glu Asn Asn Asp Ala Ala Ile Leu Ile Leu
 700 705 710
 5 Leu Glu Pro Ile Glu Lys Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu
 715 720 725 730
 Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Met Asp Glu
 735 740 745
 10 Ala Gln Arg Glu Gly Phe Trp Val Asn Leu Arg Ala Ala Ile Lys Ser
 750 755 760

(2) INFORMATION FOR SEQ ID NO:5:

15

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 2715 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: cDNA

25

- (ix) FEATURE:
- (A) NAME/KEY: CDS
 - (B) LOCATION: 1..2712

30

- (ix) FEATURE:
- (A) NAME/KEY: mat_peptide
 - (B) LOCATION: 64..2712

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATG AGA CAG ACT TTG CCT TGT ATC TAC TTT TGG GGG GGC CTT TTG CCC 48
 Met Arg Gln Thr Leu Pro Cys Ile Tyr Phe Trp Gly Gly Leu Leu Pro
 -21 -20 -15 -10
 40 TTT GGG ATG CTG TGT GCA TCC TCC ACC ACC AAG TGC ACT GTT AGC CAT 96
 Phe Gly Met Leu Cys Ala Ser Ser Thr Thr Lys Cys Thr Val Ser His
 -5 1 5 10
 45 GAA GTT GCT GAC TGC AGC CAC CTG AAG TTG ACT CAG GTA CCC GAT GAT 144
 Glu Val Ala Asp Cys Ser His Leu Lys Leu Thr Gln Val Pro Asp Asp
 15 20 25
 50 CTA CCC ACA AAC ATA ACA GTG TTG AAC CTT ACC CAT AAT CAA CTC AGA 192
 Leu Pro Thr Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu Arg
 30 35 40
 AGA TTA CCA GCC GCC AAC TTC ACA AGG TAT AGC CAG CTA ACT AGC TTG 240
 Arg Leu Pro Ala Ala Asn Phe Thr Arg Tyr Ser Gln Leu Thr Ser Leu
 45 50 55
 55 GAT GTA GGA TTT AAC ACC ATC TCA AAA CTG GAG CCA GAA TTG TGC CAG 288
 Asp Val Gly Phe Asn Thr Ile Ser Lys Leu Glu Pro Glu Leu Cys Gln
 60 65 70 75
 60 AAA CTT CCC ATG TTA AAA GTT TTG AAC CTC CAG CAC AAT GAG CTA TCT 336
 Lys Leu Pro Met Leu Lys Val Leu Asn Leu Gln His Asn Glu Leu Ser

| | 80 | | | | | | | | 85 | | | | | | | | 90 | | | | | | | | |
|----|-------------------|-------------------|-------------------|-------------------|------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------|--|--|--|--|--|--|--|--|
| 5 | CAA Gln | CTT Leu | TCT Ser | GAT Asp 95 | AAA Lys | ACC Thr | TTT Phe | GCC Ala | TTC Phe 100 | TGC Cys | ACG Thr | AAT Asn | TTG Leu | ACT Thr 105 | GAA Glu | CTC Leu | 384 | | | | | | | | |
| 10 | CAT His | CTC Leu | ATG Met 110 | TCC Ser | AAC Asn | TCA Ser | ATC Ile | CAG Gln 115 | AAA Lys | ATT Ile | AAA Lys | AAT Asn | AAT Asn 120 | CCC Pro | TTT Phe | GTC Val | 432 | | | | | | | | |
| 15 | AAG Lys | CAG Gln 125 | AAG Lys | AAT Asn | TTA Leu | ATC Ile | ACA Thr 130 | TTA Leu | GAT Asp | CTG Leu | TCT Ser | CAT His 135 | AAT Asn | GGC Gly | TTG Leu | TCA Ser | 480 | | | | | | | | |
| 20 | TCT Ser 140 | ACA Thr | AAA Lys | TTA Leu | GGA Gly | ACT Thr 145 | CAG Gln | GTT Val | CAG Gln | CTG Leu | GAA Glu 150 | AAT Asn | CTC Leu | CAA Gln | GAG Glu | CTT Leu 155 | 528 | | | | | | | | |
| 25 | CTA Leu | TTA Leu | TCA Ser | AAC Asn 160 | AAT Asn | AAA Lys | ATT Ile | CAA Gln | GCG Ala 165 | CTA Leu | AAA Lys | AGT Ser | GAA Glu | GAA Glu 170 | CTG Leu | GAT Asp | 576 | | | | | | | | |
| 30 | ATC Ile | TTT Phe | GCC Ala 175 | AAT Asn | TCA Ser | TCT Ser | TTA Leu | AAA Lys 180 | AAA Lys | TTA Leu | GAG Glu | TTG Leu | TCA Ser 185 | TCG Ser | AAT Asn | CAA Gln | 624 | | | | | | | | |
| 35 | ATT Ile | AAA Lys 190 | GAG Glu | TTT Phe | TCT Ser | CCA Pro | GGG Gly 195 | TGT Cys | TTT Phe | CAC His | GCA Ala | ATT Ile | GGA Gly 200 | AGA Arg | TTA Leu | TTT Phe | 672 | | | | | | | | |
| 40 | GGC Gly 205 | CTC Leu | TTT Phe | CTG Leu | AAC Asn | AAT Asn | GTC Val 210 | CAG Gln | CTG Leu | GGT Gly | CCC Pro 215 | AGC Ser | CTT Leu | ACA Thr | GAG Glu | AAG Lys | 720 | | | | | | | | |
| 45 | CTA Leu 220 | TGT Cys | TTG Leu | GAA Glu | TTA Leu | GCA Ala 225 | AAC Asn | ACA Thr | AGC Ser | ATT Ile | CGG Arg 230 | AAT Asn | CTG Leu | TCT Ser | CTG Leu | AGT Ser 235 | 768 | | | | | | | | |
| 50 | AAC Asn | AGC Ser | CAG Gln | CTG Leu 240 | TCC Ser | ACC Thr | ACC Thr | AGC Ser | AAT Asn 245 | ACA Thr | ACT Thr | TTC Phe | TTG Leu | GGA Gly 250 | CTA Leu | AAG Lys | 816 | | | | | | | | |
| 55 | TGG Trp | ACA Thr | AAT Asn 255 | CTC Leu | ACT Thr | ATG Met | CTC Leu | GAT Asp 260 | CTT Leu | TCC Ser | TAC Tyr | AAC Asn | AAC Asn 265 | TTA Leu | AAT Asn | GTG Val | 864 | | | | | | | | |
| 60 | GTT Val | GGT Gly 270 | AAC Asn | GAT Asp | TCC Ser | TTT Phe | GCT Ala 275 | TGG Trp 280 | CTT Leu | CCA Pro | CAA Gln | CTA Leu | GAA Glu 285 | TAT Tyr | TTC Phe | TTC Phe | 912 | | | | | | | | |
| 65 | CTA Leu 285 | GAG Glu | TAT Tyr | AAT Asn | AAT Asn | ATA Ile | CAG Gln 290 | CAT His | TTG Leu | TTT Phe | TCT Ser | CAC His 295 | TCT Ser | TTG Leu | CAC His | GGG Gly | 960 | | | | | | | | |
| 70 | CTT Leu 300 | TTC Phe | AAT Asn | GTG Val | AGG Arg | TAC Tyr 305 | CTG Leu | AAT Asn | TTG Leu | AAA Lys 310 | CGG Arg | TCT Ser | TTT Phe | ACT Thr | AAA Lys | CAA Gln 315 | 1008 | | | | | | | | |
| 75 | AGT Ser | ATT Ile | TCC Ser | CTT Leu 320 | GCC Ala | TCA Ser | CTC Leu | CCC Pro | AAG Lys 325 | ATT Ile | GAT Asp | GAT Asp | TTT Phe | TCT Ser | TTT Phe 330 | CAG Gln | 1056 | | | | | | | | |

| | | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| 5 | TGG | CTA | AAA | TGT | TTG | GAG | CAC | CTT | AAC | ATG | GAA | GAT | AAT | GAT | ATT | CCA | 1104 |
| | Trp | Leu | Lys | Cys | Leu | Glu | His | Leu | Asn | Met | Glu | Asp | Asn | Asp | Ile | Pro | |
| | | | | 335 | | | | | 340 | | | | | 345 | | | |
| 10 | GGC | ATA | AAA | AGC | AAT | ATG | TTC | ACA | GGA | TTG | ATA | AAC | CTG | AAA | TAC | TTA | 1152 |
| | Gly | Ile | Lys | Ser | Asn | Met | Phe | Thr | Gly | Leu | Ile | Asn | Leu | Lys | Tyr | Leu | |
| | | | 350 | | | | | 355 | | | | | 360 | | | | |
| 15 | AGT | CTA | TCC | AAC | TCC | TTT | ACA | AGT | TTG | CGA | ACT | TTG | ACA | AAT | GAA | ACA | 1200 |
| | Ser | Leu | Ser | Asn | Ser | Phe | Thr | Ser | Leu | Arg | Thr | Leu | Thr | Asn | Glu | Thr | |
| | | 365 | | | | | 370 | | | | | 375 | | | | | |
| 20 | TTT | GTA | TCA | CTT | GCT | CAT | TCT | CCC | TTA | CAC | ATA | CTC | AAC | CTA | ACC | AAG | 1248 |
| | Phe | Val | Ser | Leu | Ala | His | Ser | Pro | Leu | His | Ile | Leu | Asn | Leu | Thr | Lys | |
| | 380 | | | | | 385 | | | | | 390 | | | | | 395 | |
| 25 | AAT | AAA | ATC | TCA | AAA | ATA | GAG | AGT | GAT | GCT | TTC | TCT | TGG | TTG | GGC | CAC | 1296 |
| | Asn | Lys | Ile | Ser | Lys | Ile | Glu | Ser | Asp | Ala | Phe | Ser | Trp | Leu | Gly | His | |
| | | | | 400 | | | | | 405 | | | | | | 410 | | |
| 30 | CTA | GAA | GTA | CTT | GAC | CTG | GGC | CTT | AAT | GAA | ATT | GGG | CAA | GAA | CTC | ACA | 1344 |
| | Leu | Glu | Val | Leu | Asp | Leu | Gly | Leu | Asn | Glu | Ile | Gly | Gln | Glu | Leu | Thr | |
| | | | | 415 | | | | 420 | | | | | | 425 | | | |
| 35 | GGC | CAG | GAA | TGG | AGA | GGT | CTA | GAA | AAT | ATT | TTC | GAA | ATC | TAT | CTT | TCC | 1392 |
| | Gly | Gln | Glu | Trp | Arg | Gly | Leu | Glu | Asn | Ile | Phe | Glu | Ile | Tyr | Leu | Ser | |
| | | | 430 | | | | | 435 | | | | | 440 | | | | |
| 40 | TAC | AAC | AAG | TAC | CTG | CAG | CTG | ACT | AGG | AAC | TCC | TTT | GCC | TTG | GTC | CCA | 1440 |
| | Tyr | Asn | Lys | Tyr | Leu | Gln | Leu | Thr | Arg | Asn | Ser | Phe | Ala | Leu | Val | Pro | |
| | | 445 | | | | | 450 | | | | 455 | | | | | | |
| 45 | AGC | CTT | CAA | CGA | CTG | ATG | CTC | CGA | AGG | GTG | GCC | CTT | AAA | AAT | GTG | GAT | 1488 |
| | Ser | Leu | Gln | Arg | Leu | Met | Leu | Arg | Arg | Val | Ala | Leu | Lys | Asn | Val | Asp | |
| | 460 | | | | | 465 | | | | 470 | | | | | | 475 | |
| 50 | AGC | TCT | CCT | TCA | CCA | TTC | CAG | CCT | CTT | CGT | AAC | TTG | ACC | ATT | CTG | GAT | 1536 |
| | Ser | Ser | Pro | Ser | Pro | Phe | Gln | Pro | Leu | Arg | Asn | Leu | Thr | Ile | Leu | Asp | |
| | | | | 480 | | | | | 485 | | | | | | 490 | | |
| 55 | CTA | AGC | AAC | AAC | AAC | ATA | GCC | AAC | ATA | AAT | GAT | GAC | ATG | TTG | GAG | GGT | 1584 |
| | Leu | Ser | Asn | Asn | Asn | Ile | Ala | Asn | Ile | Asn | Asp | Asp | Met | Leu | Glu | Gly | |
| | | | | 495 | | | | 500 | | | | | | 505 | | | |
| 60 | CTT | GAG | AAA | CTA | GAA | ATT | CTC | GAT | TTG | CAG | CAT | AAC | AAC | TTA | GCA | CGG | 1632 |
| | Leu | Glu | Lys | Leu | Glu | Ile | Leu | Asp | Leu | Gln | His | Asn | Asn | Leu | Ala | Arg | |
| | | | 510 | | | | | 515 | | | | | 520 | | | | |
| 65 | CTC | TGG | AAA | CAC | GCA | AAC | CCT | GGT | GGT | CCC | ATT | TAT | TTC | CTA | AAG | GGT | 1680 |
| | Leu | Trp | Lys | His | Ala | Asn | Pro | Gly | Gly | Pro | Ile | Tyr | Phe | Leu | Lys | Gly | |
| | | 525 | | | | | 530 | | | | | 535 | | | | | |
| 70 | CTG | TCT | CAC | CTC | CAC | ATC | CTT | AAC | TTG | GAG | TCC | AAC | GGC | TTT | GAC | GAG | 1728 |
| | Leu | Ser | His | Leu | His | Ile | Leu | Asn | Leu | Glu | Ser | Asn | Gly | Phe | Asp | Glu | |
| | 540 | | | | | 545 | | | | | 550 | | | | | 555 | |
| 75 | ATC | CCA | GTT | GAG | GTC | TTC | AAG | GAT | TTA | TTT | GAA | CTA | AAG | ATC | ATC | GAT | 1776 |
| | Ile | Pro | Val | Glu | Val | Phe | Lys | Asp | Leu | Phe | Glu | Leu | Lys | Ile | Ile | Asp | |
| | | | | | 560 | | | | | 565 | | | | | 570 | | |

| | | |
|----|---|------|
| | TTA GGA TTG AAT AAT TTA AAC ACA CTT CCA GCA TCT GTC TTT AAT AAT | 1824 |
| | Leu Gly Leu Asn Asn Leu Asn Thr Leu Pro Ala Ser Val Phe Asn Asn | |
| | 575 580 585 | |
| 5 | CAG GTG TCT CTA AAG TCA TTG AAC CTT CAG AAG AAT CTC ATA ACA TCC | 1872 |
| | Gln Val Ser Leu Lys Ser Leu Asn Leu Gln Lys Asn Leu Ile Thr Ser | |
| | 590 595 600 | |
| 10 | GTT GAG AAG AAG GTT TTC GGG CCA GCT TTC AGG AAC CTG ACT GAG TTA | 1920 |
| | Val Glu Lys Lys Val Phe Gly Pro Ala Phe Arg Asn Leu Thr Glu Leu | |
| | 605 610 615 | |
| 15 | GAT ATG CGC TTT AAT CCC TTT GAT TGC ACG TGT GAA AGT ATT GCC TGG | 1968 |
| | Asp Met Arg Phe Asn Pro Phe Asp Cys Thr Cys Glu Ser Ile Ala Trp | |
| | 620 625 630 635 | |
| 20 | TTT GTT AAT TGG ATT AAC GAG ACC CAT ACC AAC ATC CCT GAG CTG TCA | 2016 |
| | Phe Val Asn Trp Ile Asn Glu Thr His Thr Asn Ile Pro Glu Leu Ser | |
| | 640 645 650 | |
| | AGC CAC TAC CTT TGC AAC ACT CCA CCT CAC TAT CAT GGG TTC CCA GTG | 2064 |
| | Ser His Tyr Leu Cys Asn Thr Pro Pro His Tyr His Gly Phe Pro Val | |
| | 655 660 665 | |
| 25 | AGA CTT TTT GAT ACA TCA TCT TGC AAA GAC AGT GCC CCC TTT GAA CTC | 2112 |
| | Arg Leu Phe Asp Thr Ser Ser Cys Lys Asp Ser Ala Pro Phe Glu Leu | |
| | 670 675 680 | |
| 30 | TTT TTC ATG ATC AAT ACC AGT ATC CTG TTG ATT TTT ATC TTT ATT GTA | 2160 |
| | Phe Phe Met Ile Asn Thr Ser Ile Leu Leu Ile Phe Ile Phe Ile Val | |
| | 685 690 695 | |
| 35 | CTT CTC ATC CAC TTT GAG GGC TGG AGG ATA TCT TTT TAT TGG AAT GTT | 2208 |
| | Leu Leu Ile His Phe Glu Gly Trp Arg Ile Ser Phe Tyr Trp Asn Val | |
| | 700 705 710 715 | |
| 40 | TCA GTA CAT CGA GTT CTT GGT TTC AAA GAA ATA GAC AGA CAG ACA GAA | 2256 |
| | Ser Val His Arg Val Leu Gly Phe Lys Glu Ile Asp Arg Gln Thr Glu | |
| | 720 725 730 | |
| | CAG TTT GAA TAT GCA GCA TAT ATA ATT CAT GCC TAT AAA GAT AAG GAT | 2304 |
| | Gln Phe Glu Tyr Ala Ala Tyr Ile Ile His Ala Tyr Lys Asp Lys Asp | |
| | 735 740 745 | |
| 45 | TGG GTC TGG GAA CAT TTC TCT TCA ATG GAA AAG GAA GAC CAA TCT CTC | 2352 |
| | Trp Val Trp Glu His Phe Ser Ser Met Glu Lys Glu Asp Gln Ser Leu | |
| | 750 755 760 | |
| 50 | AAA TTT TGT CTG GAA GAA AGG GAC TTT GAG GCG GGT GTT TTT GAA CTA | 2400 |
| | Lys Phe Cys Leu Glu Glu Arg Asp Phe Glu Ala Gly Val Phe Glu Leu | |
| | 765 770 775 | |
| 55 | GAA GCA ATT GTT AAC AGC ATC AAA AGA AGC AGA AAA ATT ATT TTT GTT | 2448 |
| | Glu Ala Ile Val Asn Ser Ile Lys Arg Ser Arg Lys Ile Ile Phe Val | |
| | 780 785 790 795 | |
| 60 | ATA ACA CAC CAT CTA TTA AAA GAC CCA TTA TGC AAA AGA TTC AAG GTA | 2496 |
| | Ile Thr His His Leu Leu Lys Asp Pro Leu Cys Lys Arg Phe Lys Val | |
| | 800 805 810 | |
| | CAT CAT GCA GTT CAA CAA GCT ATT GAA CAA AAT CTG GAT TCC ATT ATA | 2544 |

His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile Ile
 815 820 825

5 TTG GTT TTC CTT GAG GAG ATT CCA GAT TAT AAA CTG AAC CAT GCA CTC 2592
 Leu Val Phe Leu Glu Glu Ile Pro Asp Tyr Lys Leu Asn His Ala Leu
 830 835 840

10 TGT TTG CGA AGA GGA ATG TTT AAA TCT CAC TGC ATC TTG AAC TGG CCA 2640
 Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp Pro
 845 850 855

15 GTT CAG AAA GAA CGG ATA GGT GCC TTT CGT CAT AAA TTG CAA GTA GCA 2688
 Val Gln Lys Glu Arg Ile Gly Ala Phe Arg His Lys Leu Gln Val Ala
 860 865 870 875

20 CTT GGA TCC AAA AAC TCT GTA CAT TAA 2715
 Leu Gly Ser Lys Asn Ser Val His
 880

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 904 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Arg Gln Thr Leu Pro Cys Ile Tyr Phe Trp Gly Gly Leu Leu Pro
 -21 -20 -15 -10

35 Phe Gly Met Leu Cys Ala Ser Ser Thr Thr Lys Cys Thr Val Ser His
 -5 1 5 10

40 Glu Val Ala Asp Cys Ser His Leu Lys Leu Thr Gln Val Pro Asp Asp
 15 20 25

45 Leu Pro Thr Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu Arg
 30 35 40

50 Arg Leu Pro Ala Ala Asn Phe Thr Arg Tyr Ser Gln Leu Thr Ser Leu
 45 50 55

55 Asp Val Gly Phe Asn Thr Ile Ser Lys Leu Glu Pro Glu Leu Cys Gln
 60 65 70 75

60 Lys Leu Pro Met Leu Lys Val Leu Asn Leu Gln His Asn Glu Leu Ser
 80 85 90

65 Gln Leu Ser Asp Lys Thr Phe Ala Phe Cys Thr Asn Leu Thr Glu Leu
 95 100 105

70 His Leu Met Ser Asn Ser Ile Gln Lys Ile Lys Asn Asn Pro Phe Val
 110 115 120

75 Lys Gln Lys Asn Leu Ile Thr Leu Asp Leu Ser His Asn Gly Leu Ser
 125 130 135

Ser Thr Lys Leu Gly Thr Gln Val Gln Leu Glu Asn Leu Gln Glu Leu
 140 145 150 155
 5 Leu Leu Ser Asn Asn Lys Ile Gln Ala Leu Lys Ser Glu Glu Leu Asp
 160 165 170
 Ile Phe Ala Asn Ser Ser Leu Lys Lys Leu Glu Leu Ser Ser Asn Gln
 175 180 185
 10 Ile Lys Glu Phe Ser Pro Gly Cys Phe His Ala Ile Gly Arg Leu Phe
 190 195 200
 Gly Leu Phe Leu Asn Asn Val Gln Leu Gly Pro Ser Leu Thr Glu Lys
 205 210 215
 15 Leu Cys Leu Glu Leu Ala Asn Thr Ser Ile Arg Asn Leu Ser Leu Ser
 220 225 230 235
 20 Asn Ser Gln Leu Ser Thr Thr Ser Asn Thr Thr Phe Leu Gly Leu Lys
 240 245 250
 Trp Thr Asn Leu Thr Met Leu Asp Leu Ser Tyr Asn Asn Leu Asn Val
 255 260 265
 25 Val Gly Asn Asp Ser Phe Ala Trp Leu Pro Gln Leu Glu Tyr Phe Phe
 270 275 280
 Leu Glu Tyr Asn Asn Ile Gln His Leu Phe Ser His Ser Leu His Gly
 285 290 295
 30 Leu Phe Asn Val Arg Tyr Leu Asn Leu Lys Arg Ser Phe Thr Lys Gln
 300 305 310 315
 35 Ser Ile Ser Leu Ala Ser Leu Pro Lys Ile Asp Asp Phe Ser Phe Gln
 320 325 330
 Trp Leu Lys Cys Leu Glu His Leu Asn Met Glu Asp Asn Asp Ile Pro
 335 340 345
 40 Gly Ile Lys Ser Asn Met Phe Thr Gly Leu Ile Asn Leu Lys Tyr Leu
 350 355 360
 Ser Leu Ser Asn Ser Phe Thr Ser Leu Arg Thr Leu Thr Asn Glu Thr
 365 370 375
 45 Phe Val Ser Leu Ala His Ser Pro Leu His Ile Leu Asn Leu Thr Lys
 380 385 390 395
 50 Asn Lys Ile Ser Lys Ile Glu Ser Asp Ala Phe Ser Trp Leu Gly His
 400 405 410
 Leu Glu Val Leu Asp Leu Gly Leu Asn Glu Ile Gly Gln Glu Leu Thr
 415 420 425
 55 Gly Gln Glu Trp Arg Gly Leu Glu Asn Ile Phe Glu Ile Tyr Leu Ser
 430 435 440
 Tyr Asn Lys Tyr Leu Gln Leu Thr Arg Asn Ser Phe Ala Leu Val Pro
 445 450 455
 60 Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val Asp

| | | | | | | | |
|----|-----------------|-----------------|-----------------|-----------------|-----|--|-----|
| | 460 | | 465 | | 470 | | 475 |
| | Ser Ser Pro Ser | Pro Phe Gln Pro | Leu Arg Asn Leu | Thr Ile Leu Asp | | | |
| | | 480 | 485 | 490 | | | |
| 5 | Leu Ser Asn Asn | Asn Ile Ala Asn | Ile Asn Asp Asp | Met Leu Glu Gly | | | |
| | | 495 | 500 | 505 | | | |
| 10 | Leu Glu Lys Leu | Glu Ile Leu Asp | Leu Gln His Asn | Asn Leu Ala Arg | | | |
| | | 510 | 515 | 520 | | | |
| | Leu Trp Lys His | Ala Asn Pro Gly | Gly Pro Ile Tyr | Phe Leu Lys Gly | | | |
| | | 525 | 530 | 535 | | | |
| 15 | Leu Ser His Leu | His Ile Leu Asn | Leu Glu Ser Asn | Gly Phe Asp Glu | | | |
| | | 540 | 545 | 550 | | | 555 |
| | Ile Pro Val Glu | Val Phe Lys Asp | Leu Phe Glu Leu | Lys Ile Ile Asp | | | |
| | | 560 | 565 | 570 | | | |
| 20 | Leu Gly Leu Asn | Asn Leu Asn Thr | Leu Pro Ala Ser | Val Phe Asn Asn | | | |
| | | 575 | 580 | 585 | | | |
| 25 | Gln Val Ser Leu | Lys Ser Leu Asn | Leu Gln Lys Asn | Leu Ile Thr Ser | | | |
| | | 590 | 595 | 600 | | | |
| | Val Glu Lys Lys | Val Phe Gly Pro | Ala Phe Arg Asn | Leu Thr Glu Leu | | | |
| | | 605 | 610 | 615 | | | |
| 30 | Asp Met Arg Phe | Asn Pro Phe Asp | Cys Thr Cys Glu | Ser Ile Ala Trp | | | |
| | | 620 | 625 | 630 | | | 635 |
| | Phe Val Asn Trp | Ile Asn Glu Thr | His Thr Asn Ile | Pro Glu Leu Ser | | | |
| | | 640 | 645 | 650 | | | |
| 35 | Ser His Tyr Leu | Cys Asn Thr Pro | Pro His Tyr His | Gly Phe Pro Val | | | |
| | | 655 | 660 | 665 | | | |
| 40 | Arg Leu Phe Asp | Thr Ser Ser Cys | Lys Asp Ser Ala | Pro Phe Glu Leu | | | |
| | | 670 | 675 | 680 | | | |
| | Phe Phe Met Ile | Asn Thr Ser Ile | Leu Leu Ile Phe | Ile Phe Ile Val | | | |
| | | 685 | 690 | 695 | | | |
| 45 | Leu Leu Ile His | Phe Glu Gly Trp | Arg Ile Ser Phe | Tyr Trp Asn Val | | | |
| | | 700 | 705 | 710 | | | 715 |
| | Ser Val His Arg | Val Leu Gly Phe | Lys Glu Ile Asp | Arg Gln Thr Glu | | | |
| | | 720 | 725 | 730 | | | |
| 50 | Gln Phe Glu Tyr | Ala Ala Tyr Ile | Ile His Ala Tyr | Lys Asp Lys Asp | | | |
| | | 735 | 740 | 745 | | | |
| 55 | Trp Val Trp Glu | His Phe Ser Ser | Met Glu Lys Glu | Asp Gln Ser Leu | | | |
| | | 750 | 755 | 760 | | | |
| | Lys Phe Cys Leu | Glu Glu Arg Asp | Phe Glu Ala Gly | Val Phe Glu Leu | | | |
| | | 765 | 770 | 775 | | | |
| 60 | Glu Ala Ile Val | Asn Ser Ile Lys | Arg Ser Arg Lys | Ile Ile Phe Val | | | |
| | | 780 | 785 | 790 | | | 795 |

Ile Thr His His Leu Leu Lys Asp Pro Leu Cys Lys Arg Phe Lys Val
800 805 810

5 His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile Ile
815 820 825

Leu Val Phe Leu Glu Glu Ile Pro Asp Tyr Lys Leu Asn His Ala Leu
830 835 840

10 Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp Pro
845 850 855

15 Val Gln Lys Glu Arg Ile Gly Ala Phe Arg His Lys Leu Gln Val Ala
860 865 870 875

Leu Gly Ser Lys Asn Ser Val His
880

20 (2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2400 base pairs
(B) TYPE: nucleic acid
25 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30 (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..2397

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ATG GAG CTG AAT TTC TAC AAA ATC CCC GAC AAC CTC CCC TTC TCA ACC 48
Met Glu Leu Asn Phe Tyr Lys Ile Pro Asp Asn Leu Pro Phe Ser Thr
40 1 5 10 15

AAG AAC CTG GAC CTG AGC TTT AAT CCC CTG AGG CAT TTA GGC AGC TAT 96
Lys Asn Leu Asp Leu Ser Phe Asn Pro Leu Arg His Leu Gly Ser Tyr
20 25 30

45 AGC TTC TTC AGT TTC CCA GAA CTG CAG GTG CTG GAT TTA TCC AGG TGT 144
Ser Phe Phe Ser Phe Pro Glu Leu Gln Val Leu Asp Leu Ser Arg Cys
35 40 45

50 GAA ATC CAG ACA ATT GAA GAT GGG GCA TAT CAG AGC CTA AGC CAC CTC 192
Glu Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu
50 55 60

55 TCT ACC TTA ATA TTG ACA GGA AAC CCC ATC CAG AGT TTA GCC CTG GGA 240
Ser Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly
65 70 75 80

GCC TTT TCT GGA CTA TCA AGT TTA CAG AAG CTG GTG GCT GTG GAG ACA 288
Ala Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr
60 85 90 95

| | | |
|----|---|------|
| | AAT CTA GCA TCT CTA GAG AAC TTC CCC ATT GGA CAT CTC AAA ACT TTG | 336 |
| | Asn Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu | |
| | 100 105 110 | |
| 5 | AAA GAA CTT AAT GTG GCT CAC AAT CTT ATC CAA TCT TTC AAA TTA CCT | 384 |
| | Lys Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro | |
| | 115 120 125 | |
| 10 | GAG TAT TTT TCT AAT CTG ACC AAT CTA GAG CAC TTG GAC CTT TCC AGC | 432 |
| | Glu Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser | |
| | 130 135 140 | |
| 15 | AAC AAG ATT CAA AGT ATT TAT TGC ACA GAC TTG CGG GTT CTA CAT CAA | 480 |
| | Asn Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln | |
| | 145 150 155 160 | |
| 20 | ATG CCC CTA CTC AAT CTC TCT TTA GAC CTG TCC CTG AAC CCT ATG AAC | 528 |
| | Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn | |
| | 165 170 175 | |
| 25 | TTT ATC CAA CCA GGT GCA TTT AAA GAA ATT AGG CTT CAT AAG CTG ACT | 576 |
| | Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr | |
| | 180 185 190 | |
| 30 | TTA AGA AAT AAT TTT GAT AGT TTA AAT GTA ATG AAA ACT TGT ATT CAA | 624 |
| | Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln | |
| | 195 200 205 | |
| 35 | GGT CTG GCT GGT TTA GAA GTC CAT CGT TTG GTT CTG GGA GAA TTT AGA | 672 |
| | Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg | |
| | 210 215 220 | |
| 40 | AAT GAA GGA AAC TTG GAA AAG TTT GAC AAA TCT GCT CTA GAG GGC CTG | 720 |
| | Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu | |
| | 225 230 235 240 | |
| 45 | TGC AAT TTG ACC ATT GAA GAA TTC CGA TTA GCA TAC TTA GAC TAC TAC | 768 |
| | Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr | |
| | 245 250 255 | |
| 50 | CTC GAT GAT ATT ATT GAC TTA TTT AAT TGT TTG ACA AAT GTT TCT TCA | 816 |
| | Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser | |
| | 260 265 270 | |
| 55 | TTT TCC CTG GTG AGT GTG ACT ATT GAA AGG GTA AAA GAC TTT TCT TAT | 864 |
| | Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr | |
| | 275 280 285 | |
| 60 | AAT TTC GGA TGG CAA CAT TTA GAA TTA GTT AAC TGT AAA TTT GGA CAG | 912 |
| | Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln | |
| | 290 295 300 | |
| 65 | TTT CCC ACA TTG AAA CTC AAA TCT CTC AAA AGG CTT ACT TTC ACT TCC | 960 |
| | Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser | |
| | 305 310 315 320 | |
| 70 | AAC AAA GGT GGG AAT GCT TTT TCA GAA GTT GAT CTA CCA AGC CTT GAG | 1008 |
| | Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu | |
| | 325 330 335 | |
| 75 | TTT CTA GAT CTC AGT AGA AAT GGC TTG AGT TTC AAA GGT TGC TGT TCT | 1056 |

| | | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| | Phe | Leu | Asp | Leu | Ser | Arg | Asn | Gly | Leu | Ser | Phe | Lys | Gly | Cys | Cys | Ser | |
| | | | | 340 | | | | | 345 | | | | | 350 | | | |
| 5 | CAA | AGT | GAT | TTT | GGG | ACA | ACC | AGC | CTA | AAG | TAT | TTA | GAT | CTG | AGC | TTC | 1104 |
| | Gln | Ser | Asp | Phe | Gly | Thr | Thr | Ser | Leu | Lys | Tyr | Leu | Asp | Leu | Ser | Phe | |
| | | | 355 | | | | | 360 | | | | | 365 | | | | |
| 10 | AAT | GGT | GTT | ATT | ACC | ATG | AGT | TCA | AAC | TTC | TTG | GGC | TTA | GAA | CAA | CTA | 1152 |
| | Asn | Gly | Val | Ile | Thr | Met | Ser | Ser | Asn | Phe | Leu | Gly | Leu | Glu | Gln | Leu | |
| | | 370 | | | | | 375 | | | | | 380 | | | | | |
| 15 | GAA | CAT | CTG | GAT | TTC | CAG | CAT | TCC | AAT | TTG | AAA | CAA | ATG | AGT | GAG | TTT | 1200 |
| | Glu | His | Leu | Asp | Phe | Gln | His | Ser | Asn | Leu | Lys | Gln | Met | Ser | Glu | Phe | |
| | 385 | | | | | 390 | | | | | 395 | | | | | 400 | |
| | TCA | GTA | TTC | CTA | TCA | CTC | AGA | AAC | CTC | ATT | TAC | CTT | GAC | ATT | TCT | CAT | 1248 |
| | Ser | Val | Phe | Leu | Ser | Leu | Arg | Asn | Leu | Ile | Tyr | Leu | Asp | Ile | Ser | His | |
| | | | | | 405 | | | | | 410 | | | | | 415 | | |
| 20 | ACT | CAC | ACC | AGA | GTT | GCT | TTC | AAT | GGC | ATC | TTC | AAT | GGC | TTG | TCC | AGT | 1296 |
| | Thr | His | Thr | Arg | Val | Ala | Phe | Asn | Gly | Ile | Phe | Asn | Gly | Leu | Ser | Ser | |
| | | | | 420 | | | | | 425 | | | | | 430 | | | |
| 25 | CTC | GAA | GTC | TTG | AAA | ATG | GCT | GGC | AAT | TCT | TTC | CAG | GAA | AAC | TTC | CTT | 1344 |
| | Leu | Glu | Val | Leu | Lys | Met | Ala | Gly | Asn | Ser | Phe | Gln | Glu | Asn | Phe | Leu | |
| | | | 435 | | | | | 440 | | | | | 445 | | | | |
| 30 | CCA | GAT | ATC | TTC | ACA | GAG | CTG | AGA | AAC | TTG | ACC | TTC | CTG | GAC | CTC | TCT | 1392 |
| | Pro | Asp | Ile | Phe | Thr | Glu | Leu | Arg | Asn | Leu | Thr | Phe | Leu | Asp | Leu | Ser | |
| | | 450 | | | | | 455 | | | | | 460 | | | | | |
| 35 | CAG | TGT | CAA | CTG | GAG | CAG | TTG | TCT | CCA | ACA | GCA | TTT | AAC | TCA | CTC | TCC | 1440 |
| | Gln | Cys | Gln | Leu | Glu | Gln | Leu | Ser | Pro | Thr | Ala | Phe | Asn | Ser | Leu | Ser | |
| | 465 | | | | | 470 | | | | | 475 | | | | | 480 | |
| | AGT | CTT | CAG | GTA | CTA | AAT | ATG | AGC | CAC | AAC | AAC | TTC | TTT | TCA | TTG | GAT | 1488 |
| | Ser | Leu | Gln | Val | Leu | Asn | Met | Ser | His | Asn | Asn | Phe | Phe | Ser | Leu | Asp | |
| | | | | | 485 | | | | 490 | | | | | | 495 | | |
| 40 | ACG | TTT | CCT | TAT | AAG | TGT | CTG | AAC | TCC | CTC | CAG | GTT | CTT | GAT | TAC | AGT | 1536 |
| | Thr | Phe | Pro | Tyr | Lys | Cys | Leu | Asn | Ser | Leu | Gln | Val | Leu | Asp | Tyr | Ser | |
| | | | | 500 | | | | | 505 | | | | | 510 | | | |
| 45 | CTC | AAT | CAC | ATA | ATG | ACT | TCC | AAA | AAA | CAG | GAA | CTA | CAG | CAT | TTT | CCA | 1584 |
| | Leu | Asn | His | Ile | Met | Thr | Ser | Lys | Lys | Gln | Glu | Leu | Gln | His | Phe | Pro | |
| | | | 515 | | | | | 520 | | | | | 525 | | | | |
| 50 | AGT | AGT | CTA | GCT | TTC | TTA | AAT | CTT | ACT | CAG | AAT | GAC | TTT | GCT | TGT | ACT | 1632 |
| | Ser | Ser | Leu | Ala | Phe | Leu | Asn | Leu | Thr | Gln | Asn | Asp | Phe | Ala | Cys | Thr | |
| | | 530 | | | | | 535 | | | | | 540 | | | | | |
| 55 | TGT | GAA | CAC | CAG | AGT | TTC | CTG | CAA | TGG | ATC | AAG | GAC | CAG | AGG | CAG | CTC | 1680 |
| | Cys | Glu | His | Gln | Ser | Phe | Leu | Gln | Trp | Ile | Lys | Asp | Gln | Arg | Gln | Leu | |
| | 545 | | | | | 550 | | | | | 555 | | | | | 560 | |
| | TTG | GTG | GAA | GTT | GAA | CGA | ATG | GAA | TGT | GCA | ACA | CCT | TCA | GAT | AAG | CAG | 1728 |
| | Leu | Val | Glu | Val | Glu | Arg | Met | Glu | Cys | Ala | Thr | Pro | Ser | Asp | Lys | Gln | |
| | | | | | 565 | | | | 570 | | | | | | 575 | | |
| 60 | GGC | ATG | CCT | GTG | CTG | AGT | TTG | AAT | ATC | ACC | TGT | CAG | ATG | AAT | AAG | ACC | 1776 |
| | Gly | Met | Pro | Val | Leu | Ser | Leu | Asn | Ile | Thr | Cys | Gln | Met | Asn | Lys | Thr | |

| | 580 | | | | | | | 585 | | | | | | | 590 | | | | | | | |
|----|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------|--|--|--|--|--|
| 5 | ATC Ile | ATT Ile | GGT Gly 595 | GTG Val | TCG Ser | GTC Val | CTC Leu | AGT Ser 600 | GTG Val | CTT Leu | GTA Val | GTA Val | TCT Ser 605 | GTT Val | GTA Val | GCA Ala | 1824 | | | | | |
| 10 | GTT Val | CTG Leu 610 | GTC Val | TAT Tyr | AAG Lys | TTC Phe | TAT Tyr 615 | TTT Phe | CAC His | CTG Leu | ATG Met | CTT Leu 620 | CTT Leu | GCT Ala | GGC Gly | TGC Cys | 1872 | | | | | |
| 15 | ATA Ile 625 | AAG Lys | TAT Tyr | GGT Gly | AGA Arg | GGT Gly 630 | GAA Glu | AAC Asn | ATC Ile | TAT Tyr | GAT Asp 635 | GCC Ala | TTT Phe | GTT Val | ATC Ile 640 | TAC Tyr | 1920 | | | | | |
| 20 | TCA Ser | AGC Ser | CAG Gln | GAT Asp | GAG Glu 645 | GAC Asp | TGG Trp | GTA Val | AGG Arg 650 | AAT Asn | GAG Glu | CTA Leu | GTA Val | AAG Lys 655 | AAT Asn | TTA Leu | 1968 | | | | | |
| 25 | GAA Glu | GAA Glu | GGG Gly | GTG Val 660 | CCT Pro | CCA Pro | TTT Phe | CAG Gln | CTC Leu 665 | TGC Cys | CTT Leu | CAC His | TAC Tyr | AGA Arg 670 | GAC Asp | TTT Phe | 2016 | | | | | |
| 30 | ATT Ile | CCC Pro | GGT Gly 675 | GTG Val | GCC Ala | ATT Ile | GCT Ala | GCC Ala 680 | AAC Asn | ATC Ile | ATC Ile | CAT His | GAA Glu 685 | GGT Gly | TTC Phe | CAT His | 2064 | | | | | |
| 35 | AAA Lys | AGC Ser 690 | CGA Arg | AAG Lys | GTG Val | ATT Ile | GTT Val 695 | GTG Val | GTG Val | TCC Ser | CAG Gln | CAC His 700 | TTC Phe | ATC Ile | CAG Gln | AGC Ser | 2112 | | | | | |
| 40 | CGC Arg 705 | TGG Trp | TGT Cys | ATC Ile | TTT Phe | GAA Glu 710 | TAT Tyr | GAG Glu | ATT Ile | GCT Ala 715 | CAG Gln | ACC Thr | TGG Trp | CAG Gln | TTT Phe | CTG Leu 720 | 2160 | | | | | |
| 45 | AGC Ser | AGT Ser | CGT Arg | GCT Ala 725 | GGT Gly | ATC Ile | ATC Ile | TTC Phe | ATT Ile | GTC Val 730 | CTG Leu | CAG Gln | AAG Lys | GTG Val 735 | GAG Glu | AAG Lys | 2208 | | | | | |
| 50 | ACC Thr | CTG Leu | CTC Leu | AGG Arg 740 | CAG Gln | CAG Gln | GTG Val | GAG Glu | CTG Leu 745 | TAC Tyr | CGC Arg | CTT Leu | CTC Leu | AGC Ser 750 | AGG Arg | AAC Asn | 2256 | | | | | |
| 55 | ACT Thr | TAC Tyr | CTG Leu 755 | GAG Glu | TGG Trp | GAG Glu | GAC Asp | AGT Ser 760 | GTC Val | CTG Leu | GGG Gly | CGG Arg | CAC His 765 | ATC Ile | TTC Phe | TGG Trp | 2304 | | | | | |
| | AGA Arg | CGA Arg 770 | CTC Leu | AGA Arg | AAA Lys | GCC Ala | CTG Leu 775 | CTG Leu | GAT Asp | GGT Gly | AAA Lys 780 | TCA Ser | TGG Trp | AAT Asn | CCA Pro | GAA Glu | 2352 | | | | | |
| | GGA Gly 785 | ACA Thr | GTG Val | GGT Gly | ACA Thr | GGA Gly 790 | TGC Cys | AAT Asn | TGG Trp | CAG Gln | GAA Glu 795 | GCA Ala | ACA Thr | TCT Ser | ATC Ile | | 2397 | | | | | |
| | TGA | | | | | | | | | | | | | | | | 2400 | | | | | |

(2) INFORMATION FOR SEQ ID NO:8:

60

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 799 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Glu Leu Asn Phe Tyr Lys Ile Pro Asp Asn Leu Pro Phe Ser Thr
 1 5 10 15
 Lys Asn Leu Asp Leu Ser Phe Asn Pro Leu Arg His Leu Gly Ser Tyr
 20 25 30
 Ser Phe Phe Ser Phe Pro Glu Leu Gln Val Leu Asp Leu Ser Arg Cys
 35 40 45
 Glu Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu
 50 55 60
 Ser Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly
 65 70 75 80
 Ala Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr
 85 90 95
 Asn Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu
 100 105 110
 Lys Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro
 115 120 125
 Glu Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser
 130 135 140
 Asn Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln
 145 150 155 160
 Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn
 165 170 175
 Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr
 180 185 190
 Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln
 195 200 205
 Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg
 210 215 220
 Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu
 225 230 235 240
 Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr
 245 250 255
 Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser
 260 265 270
 Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr
 275 280 285

Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln
 290 295 300
 5 Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser
 305 310 315 320
 Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu
 325 330 335
 10 Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser
 340 345 350
 Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe
 355 360 365
 15 Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu
 370 375 380
 Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe
 385 390 395 400
 Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His
 405 410 415
 25 Thr His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser
 420 425 430
 Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu
 435 440 445
 30 Pro Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser
 450 455 460
 Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser
 465 470 475 480
 Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp
 485 490 495
 40 Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser
 500 505 510
 Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro
 515 520 525
 45 Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr
 530 535 540
 Cys Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu
 545 550 555 560
 Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln
 565 570 575
 55 Gly Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr
 580 585 590
 Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala
 595 600 605
 60 Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys

610 615 620
 Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr
 625 630 635 640
 5 Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu
 645 650 655
 Glu Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe
 10 660 665 670
 Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His
 675 680 685
 15 Lys Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser
 690 695 700
 Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu
 20 705 710 715 720
 Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys
 725 730 735
 Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn
 25 740 745 750
 Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp
 755 760 765
 30 Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu
 770 775 780
 Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile
 35 785 790 795

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1275 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 1..1095

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TGT TGG GAT GTT TTT GAG GGA CTT TCT CAT CTT CAA GTT CTG TAT TTG 48
 55 Cys Trp Asp Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu
 1 5 10 15
 AAT CAT AAC TAT CTT AAT TCC CTT CCA CCA GGA GTA TTT AGC CAT CTG 96
 60 Asn His Asn Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu
 20 25 30

| | | |
|----|---|-----|
| | ACT GCA TTA AGG GGA CTA AGC CTC AAC TCC AAC AGG CTG ACA GTT CTT | 144 |
| | Thr Ala Leu Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu | |
| | 35 40 45 | |
| 5 | TCT CAC AAT GAT TTA CCT GCT AAT TTA GAG ATC CTG GAC ATA TCC AGG | 192 |
| | Ser His Asn Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg | |
| | 50 55 60 | |
| 10 | AAC CAG CTC CTA GCT CCT AAT CCT GAT GTA TTT GTA TCA CTT AGT GTC | 240 |
| | Asn Gln Leu Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val | |
| | 65 70 75 80 | |
| 15 | TTG GAT ATA ACT CAT AAC AAG TTC ATT TGT GAA TGT GAA CTT AGC ACT | 288 |
| | Leu Asp Ile Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr | |
| | 85 90 95 | |
| 20 | TTT ATC AAT TGG CTT AAT CAC ACC AAT GTC ACT ATA GCT GGG CCT CCT | 336 |
| | Phe Ile Asn Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro | |
| | 100 105 110 | |
| 25 | GCA GAC ATA TAT TGT GTG TAC CCT GAC TCG TTC TCT GGG GTT TCC CTC | 384 |
| | Ala Asp Ile Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu | |
| | 115 120 125 | |
| 30 | TTC TCT CTT TCC ACG GAA GGT TGT GAT GAA GAG GAA GTC TTA AAG TCC | 432 |
| | Phe Ser Leu Ser Thr Glu Gly Cys Asp Glu Glu Val Leu Lys Ser | |
| | 130 135 140 | |
| 35 | CTA AAG TTC TCC CTT TTC ATT GTA TGC ACT GTC ACT CTG ACT CTG TTC | 480 |
| | Leu Lys Phe Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe | |
| | 145 150 155 160 | |
| 40 | CTC ATG ACC ATC CTC ACA GTC ACA AAG TTC CGG GGC TTC TGT TTT ATC | 528 |
| | Leu Met Thr Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile | |
| | 165 170 175 | |
| 45 | TGT TAT AAG ACA GCC CAG AGA CTG GTG TTC AAG GAC CAT CCC CAG GGC | 576 |
| | Cys Tyr Lys Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly | |
| | 180 185 190 | |
| 50 | ACA GAA CCT GAT ATG TAC AAA TAT GAT GCC TAT TTG TGC TTC AGC AGC | 624 |
| | Thr Glu Pro Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser | |
| | 195 200 205 | |
| 55 | AAA GAC TTC ACA TGG GTG CAG AAT GCT TTG CTC AAA CAC CTG GAC ACT | 672 |
| | Lys Asp Phe Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr | |
| | 210 215 220 | |
| 60 | CAA TAC AGT GAC CAA AAC AGA TTC AAC CTG TGC TTT GAA GAA AGA GAC | 720 |
| | Gln Tyr Ser Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp | |
| | 225 230 235 240 | |
| 65 | TTT GTC CCA GGA GAA AAC CGC ATT GCC AAT ATC CAG GAT GCC ATC TGG | 768 |
| | Phe Val Pro Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp | |
| | 245 250 255 | |
| 70 | AAC AGT AGA AAG ATC GTT TGT CTT GTG AGC AGA CAC TTC CTT AGA GAT | 816 |
| | Asn Ser Arg Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp | |
| | 260 265 270 | |
| 75 | GGC TGG TGC CTT GAA GCC TTC AGT TAT GCC CAG GGC AGG TGC TTA TCT | 864 |

Gly Trp Cys Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser
 275 280 285

5 GAC CTT AAC AGT GCT CTC ATC ATG GTG GTG GTT GGG TCC TTG TCC CAG 912
 Asp Leu Asn Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln
 290 295 300

10 TAC CAG TTG ATG AAA CAT CAA TCC ATC AGA GGC TTT GTA CAG AAA CAG 960
 Tyr Gln Leu Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln
 305 310 315 320

15 CAG TAT TTG AGG TGG CCT GAG GAT CTC CAG GAT GTT GGC TGG TTT CTT 1008
 Gln Tyr Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu
 325 330 335

CAT AAA CTC TCT CAA CAG ATA CTA AAG AAA GAA AAG GAA AAG AAG AAA 1056
 His Lys Leu Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys
 340 345 350

20 GAC AAT AAC ATT CCG TTG CAA ACT GTA GCA ACC ATC TCC TAATCAAAGG 1105
 Asp Asn Asn Ile Pro Leu Gln Thr Val Ala Thr Ile Ser
 355 360 365

25 AGCAATTTCC AACTTATCTC AAGCCACAAA TAACTCTTCA CTTTGTATTT GCACCAAGTT 1165
 ATCATTTTGG GGTCTCTCTT GGAGGTTTTT TTTTCTTTT TGCTACTATG AAAACAACAT 1225
 AAATCTCTCA ATTTTCGTAT CAAAAAAAAA AAAAAAAAAA TGGCGGCCGC 1275

30 (2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 365 amino acids
 35 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Cys Trp Asp Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu
 1 5 10 15

45 Asn His Asn Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu
 20 25 30

Thr Ala Leu Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu
 35 40 45

50 Ser His Asn Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg
 50 55 60

55 Asn Gln Leu Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val
 65 70 75 80

Leu Asp Ile Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr
 85 90 95

60 Phe Ile Asn Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro
 100 105 110

Ala Asp Ile Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu
 115 120 125

5 Phe Ser Leu Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser
 130 135 140

Leu Lys Phe Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe
 145 150 155 160

10 Leu Met Thr Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile
 165 170 175

Cys Tyr Lys Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly
 180 185 190

15 Thr Glu Pro Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser
 195 200 205

20 Lys Asp Phe Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr
 210 215 220

Gln Tyr Ser Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp
 225 230 235 240

25 Phe Val Pro Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp
 245 250 255

Asn Ser Arg Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp
 260 265 270

30 Gly Trp Cys Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser
 275 280 285

35 Asp Leu Asn Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln
 290 295 300

Tyr Gln Leu Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln
 305 310 315 320

40 Gln Tyr Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu
 325 330 335

His Lys Leu Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys
 340 345 350

45 Asp Asn Asn Ile Pro Leu Gln Thr Val Ala Thr Ile Ser
 355 360 365

50 (2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3138 base pairs

(B) TYPE: nucleic acid

55 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

60

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 1..3135

(ix) FEATURE:

5 (A) NAME/KEY: mat_peptide
(B) LOCATION: 67..3135

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

| | | |
|----|---|-----|
| 10 | ATG TGG ACA CTG AAG AGA CTA ATT CTT ATC CTT TTT AAC ATA ATC CTA | 48 |
| | Met Trp Thr Leu Lys Arg Leu Ile Leu Ile Leu Phe Asn Ile Ile Leu | |
| | -22 -20 -15 -10 | |
| 15 | ATT TCC AAA CTC CTT GGG GCT AGA TGG TTT CCT AAA ACT CTG CCC TGT | 96 |
| | Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys Thr Leu Pro Cys | |
| | -5 1 5 10 | |
| 20 | GAT GTC ACT CTG GAT GTT CCA AAG AAC CAT GTG ATC GTG GAC TGC ACA | 144 |
| | Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile Val Asp Cys Thr | |
| | 15 20 25 | |
| 25 | GAC AAG CAT TTG ACA GAA ATT CCT GGA GGT ATT CCC ACG AAC ACC ACG | 192 |
| | Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro Thr Asn Thr Thr | |
| | 30 35 40 | |
| 30 | AAC CTC ACC CTC ACC ATT AAC CAC ATA CCA GAC ATC TCC CCA GCG TCC | 240 |
| | Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile Ser Pro Ala Ser | |
| | 45 50 55 | |
| 35 | TTT CAC AGA CTG GAC CAT CTG GTA GAG ATC GAT TTC AGA TGC AAC TGT | 288 |
| | Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe Arg Cys Asn Cys | |
| | 60 65 70 | |
| 40 | GTA CCT ATT CCA CTG GGG TCA AAA AAC AAC ATG TGC ATC AAG AGG CTG | 336 |
| | Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys Ile Lys Arg Leu | |
| | 75 80 85 90 | |
| 45 | CAG ATT AAA CCC AGA AGC TTT AGT GGA CTC ACT TAT TTA AAA TCC CTT | 384 |
| | Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr Leu Lys Ser Leu | |
| | 95 100 105 | |
| 50 | TAC CTG GAT GGA AAC CAG CTA CTA GAG ATA CCG CAG GGC CTC CCG CCT | 432 |
| | Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln Gly Leu Pro Pro | |
| | 110 115 120 | |
| 55 | AGC TTA CAG CTT CTC AGC CTT GAG GCC AAC AAC ATC TTT TCC ATC AGA | 480 |
| | Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile Phe Ser Ile Arg | |
| | 125 130 135 | |
| 60 | AAA GAG AAT CTA ACA GAA CTG GCC AAC ATA GAA ATA CTC TAC CTG GGC | 528 |
| | Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile Leu Tyr Leu Gly | |
| | 140 145 150 | |
| 65 | CAA AAC TGT TAT TAT CGA AAT CCT TGT TAT GTT TCA TAT TCA ATA GAG | 576 |
| | Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser Tyr Ser Ile Glu | |
| | 155 160 165 170 | |
| 70 | AAA GAT GCC TTC CTA AAC TTG ACA AAG TTA AAA GTG CTC TCC CTG AAA | 624 |
| | Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val Leu Ser Leu Lys | |
| | 175 180 185 | |

| | | | | | | | | | | | | | | | | | |
|----|-------------------|------------|-------------------|-------------------|------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------|
| 5 | GAT Asp | AAC Asn | AAT Asn | GTC Val 190 | ACA Thr | GCC Ala | GTC Val | CCT Pro | ACT Thr 195 | GTT Val | TTG Leu | CCA Pro | TCT Ser | ACT Thr 200 | TTA Leu | ACA Thr | 672 |
| | GAA Glu | CTA Leu | TAT Tyr 205 | CTC Leu | TAC Tyr | AAC Asn | AAC Asn | ATG Met 210 | ATT Ile | GCA Ala | AAA Lys | ATC Ile | CAA Gln 215 | GAA Glu | GAT Asp | GAT Asp | 720 |
| 10 | TTT Phe 220 | AAT Asn | AAC Asn | CTC Leu | AAC Asn | CAA Gln | TTA Leu 225 | CAA Gln | ATT Ile | CTT Leu | GAC Asp | CTA Leu 230 | AGT Ser | GGA Gly | AAT Asn | TGC Cys | 768 |
| 15 | CCT Pro 235 | CGT Arg | TGT Cys | TAT Tyr | AAT Asn | GCC Ala 240 | CCA Pro | TTT Phe | CCT Pro | TGT Cys | GCG Ala 245 | CCG Pro | TGT Cys | AAA Lys | AAT Asn | AAT Asn 250 | 816 |
| 20 | TCT Ser | CCC Pro | CTA Leu | CAG Gln 255 | ATC Ile | CCT Pro | GTA Val | AAT Asn | GCT Ala | TTT Phe 260 | GAT Asp | GCG Ala | CTG Leu | ACA Thr 265 | GAA Glu | TTA Leu | 864 |
| 25 | AAA Lys | GTT Val | TTA Leu | CGT Arg 270 | CTA Leu | CAC His | AGT Ser | AAC Asn | TCT Ser 275 | CTT Leu | CAG Gln | CAT His | GTG Val 280 | CCC Pro | CCA Pro | AGA Arg | 912 |
| | TGG Trp | TTT Phe | AAG Lys 285 | AAC Asn | ATC Ile | AAC Asn | AAA Lys | CTC Leu 290 | CAG Gln | GAA Glu | CTG Leu | GAT Asp | CTG Leu 295 | TCC Ser | CAA Gln | AAC Asn | 960 |
| 30 | TTC Phe 300 | TTG Leu | GCC Ala | AAA Lys | GAA Glu | ATT Ile | GGG Gly 305 | GAT Asp | GCT Ala | AAA Lys | TTT Phe | CTG Leu 310 | CAT His | TTT Phe | CTC Leu | CCC Pro | 1008 |
| 35 | AGC Ser 315 | CTC Leu | ATC Ile | CAA Gln | TTG Leu | GAT Asp 320 | CTG Leu | TCT Ser | TTC Phe | AAT Asn | TTT Phe 325 | GAA Glu | CTT Leu | CAG Gln | GTC Val | TAT Tyr 330 | 1056 |
| 40 | CGT Arg | GCA Ala | TCT Ser | ATG Met 335 | AAT Asn | CTA Leu | TCA Ser | CAA Gln | GCA Ala | TTT Phe 340 | TCT Ser | TCA Ser | CTG Leu | AAA Lys | AGC Ser 345 | CTG Leu | 1104 |
| 45 | AAA Lys | ATT Ile | CTG Leu | CGG Arg 350 | ATC Ile | AGA Arg | GGA Gly | TAT Tyr | GTC Val 355 | TTT Phe | AAA Lys | GAG Glu | TTG Leu | AAA Lys 360 | AGC Ser | TTT Phe | 1152 |
| | AAC Asn | CTC Leu | TCG Ser 365 | CCA Pro | TTA Leu | CAT His | AAT Asn | CTT Leu 370 | CAA Gln | AAT Asn | CTT Leu | GAA Glu | GTT Val 375 | CTT Leu | GAT Asp | CTT Leu | 1200 |
| 50 | GGC Gly 380 | ACT Thr | AAC Asn | TTT Phe | ATA Ile | AAA Lys | ATT Ile 385 | GCT Ala | AAC Asn | CTC Leu | AGC Ser | ATG Met 390 | TTT Phe | AAA Lys | CAA Gln | TTT Phe | 1248 |
| 55 | AAA Lys 395 | AGA Arg | CTG Leu | AAA Lys | GTC Val | ATA Ile 400 | GAT Asp | CTT Leu | TCA Ser | GTG Val | AAT Asn 405 | AAA Lys | ATA Ile | TCA Ser | CCT Pro | TCA Ser 410 | 1296 |
| 60 | GGA Gly | GAT Asp | TCA Ser | AGT Ser 415 | GAA Glu | GTT Val | GGC Gly | TTC Phe | TGC Cys | TCA Ser 420 | AAT Asn | GCC Ala | AGA Arg | ACT Thr 425 | TCT Ser | GTA Val | 1344 |

| | | | |
|----|--|---|------|
| | | GAA AGT TAT GAA CCC CAG GTC CTG GAA CAA TTA CAT TAT TTC AGA TAT | 1392 |
| | | Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His Tyr Phe Arg Tyr | |
| | | 430 435 440 | |
| 5 | | GAT AAG TAT GCA AGG AGT TGC AGA TTC AAA AAC AAA GAG GCT TCT TTC | 1440 |
| | | Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys Glu Ala Ser Phe | |
| | | 445 450 455 | |
| 10 | | ATG TCT GTT AAT GAA AGC TGC TAC AAG TAT GGG CAG ACC TTG GAT CTA | 1488 |
| | | Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln Thr Leu Asp Leu | |
| | | 460 465 470 | |
| 15 | | AGT AAA AAT AGT ATA TTT TTT GTC AAG TCC TCT GAT TTT CAG CAT CTT | 1536 |
| | | Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp Phe Gln His Leu | |
| | | 475 480 485 490 | |
| 20 | | TCT TTC CTC AAA TGC CTG AAT CTG TCA GGA AAT CTC ATT AGC CAA ACT | 1584 |
| | | Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu Ile Ser Gln Thr | |
| | | 495 500 505 | |
| 25 | | CTT AAT GGC AGT GAA TTC CAA CCT TTA GCA GAG CTG AGA TAT TTG GAC | 1632 |
| | | Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu Arg Tyr Leu Asp | |
| | | 510 515 520 | |
| 30 | | TTC TCC AAC AAC CGG CTT GAT TTA CTC CAT TCA ACA GCA TTT GAA GAG | 1680 |
| | | Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr Ala Phe Glu Glu | |
| | | 525 530 535 | |
| 35 | | CTT CAC AAA CTG GAA GTT CTG GAT ATA AGC AGT AAT AGC CAT TAT TTT | 1728 |
| | | Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn Ser His Tyr Phe | |
| | | 540 545 550 | |
| 40 | | CAA TCA GAA GGA ATT ACT CAT ATG CTA AAC TTT ACC AAG AAC CTA AAG | 1776 |
| | | Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr Lys Asn Leu Lys | |
| | | 555 560 565 570 | |
| 45 | | GTT CTG CAG AAA CTG ATG ATG AAC GAC AAT GAC ATC TCT TCC TCC ACC | 1824 |
| | | Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile Ser Ser Ser Thr | |
| | | 575 580 585 | |
| 50 | | AGC AGG ACC ATG GAG AGT GAG TCT CTT AGA ACT CTG GAA TTC AGA GGA | 1872 |
| | | Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu Glu Phe Arg Gly | |
| | | 590 595 600 | |
| 55 | | AAT CAC TTA GAT GTT TTA TGG AGA GAA GGT GAT AAC AGA TAC TTA CAA | 1920 |
| | | Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn Arg Tyr Leu Gln | |
| | | 605 610 615 | |
| 60 | | TTA TTC AAG AAT CTG CTA AAA TTA GAG GAA TTA GAC ATC TCT AAA AAT | 1968 |
| | | Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp Ile Ser Lys Asn | |
| | | 620 625 630 | |
| 65 | | TCC CTA AGT TTC TTG CCT TCT GGA GTT TTT GAT GGT ATG CCT CCA AAT | 2016 |
| | | Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly Met Pro Pro Asn | |
| | | 635 640 645 650 | |
| 70 | | CTA AAG AAT CTC TCT TTG GCC AAA AAT GGG CTC AAA TCT TTC AGT TGG | 2064 |
| | | Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys Ser Phe Ser Trp | |
| | | 655 660 665 | |
| 75 | | AAG AAA CTC CAG TGT CTA AAG AAC CTG GAA ACT TTG GAC CTC AGC CAC | 2112 |

| | | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| | Lys | Lys | Leu | Gln | Cys | Leu | Lys | Asn | Leu | Glu | Thr | Leu | Asp | Leu | Ser | His | |
| | | | | 670 | | | | | 675 | | | | | 680 | | | |
| 5 | AAC | CAA | CTG | ACC | ACT | GTC | CCT | GAG | AGA | TTA | TCC | AAC | TGT | TCC | AGA | AGC | 2160 |
| | Asn | Gln | Leu | Thr | Thr | Val | Pro | Glu | Arg | Leu | Ser | Asn | Cys | Ser | Arg | Ser | |
| | | | 685 | | | | | 690 | | | | | 695 | | | | |
| 10 | CTC | AAG | AAT | CTG | ATT | CTT | AAG | AAT | AAT | CAA | ATC | AGG | AGT | CTG | ACG | AAG | 2208 |
| | Leu | Lys | Asn | Leu | Ile | Leu | Lys | Asn | Asn | Gln | Ile | Arg | Ser | Leu | Thr | Lys | |
| | | 700 | | | | | 705 | | | | | 710 | | | | | |
| 15 | TAT | TTT | CTA | CAA | GAT | GCC | TTC | CAG | TTG | CGA | TAT | CTG | GAT | CTC | AGC | TCA | 2256 |
| | Tyr | Phe | Leu | Gln | Asp | Ala | Phe | Gln | Leu | Arg | Tyr | Leu | Asp | Leu | Ser | Ser | |
| | 715 | | | | | 720 | | | | | 725 | | | | | 730 | |
| 20 | AAT | AAA | ATC | CAG | ATG | ATC | CAA | AAG | ACC | AGC | TTC | CCA | GAA | AAT | GTC | CTC | 2304 |
| | Asn | Lys | Ile | Gln | Met | Ile | Gln | Lys | Thr | Ser | Phe | Pro | Glu | Asn | Val | Leu | |
| | | | | 735 | | | | | | 740 | | | | | 745 | | |
| 25 | AAC | AAT | CTG | AAG | ATG | TTG | CTT | TTG | CAT | CAT | AAT | CGG | TTT | CTG | TGC | ACC | 2352 |
| | Asn | Asn | Leu | Lys | Met | Leu | Leu | Leu | His | His | Asn | Arg | Phe | Leu | Cys | Thr | |
| | | | | 750 | | | | | 755 | | | | | 760 | | | |
| 30 | TGT | GAT | GCT | GTG | TGG | TTT | GTC | TGG | TGG | GTT | AAC | CAT | ACG | GAG | GTG | ACT | 2400 |
| | Cys | Asp | Ala | Val | Trp | Phe | Val | Trp | Trp | Val | Asn | His | Thr | Glu | Val | Thr | |
| | | | 765 | | | | | 770 | | | | | 775 | | | | |
| 35 | ATT | CCT | TAC | CTG | GCC | ACA | GAT | GTG | ACT | TGT | GTG | GGG | CCA | GGA | GCA | CAC | 2448 |
| | Ile | Pro | Tyr | Leu | Ala | Thr | Asp | Val | Thr | Cys | Val | Gly | Pro | Gly | Ala | His | |
| | | 780 | | | | | 785 | | | | | 790 | | | | | |
| 40 | AAG | GGC | CAA | AGT | GTG | ATC | TCC | CTG | GAT | CTG | TAC | ACC | TGT | GAG | TTA | GAT | 2496 |
| | Lys | Gly | Gln | Ser | Val | Ile | Ser | Leu | Asp | Leu | Tyr | Thr | Cys | Glu | Leu | Asp | |
| | 795 | | | | | 800 | | | | | 805 | | | | | 810 | |
| 45 | CTG | ACT | AAC | CTG | ATT | CTG | TTC | TCA | CTT | TCC | ATA | TCT | GTA | TCT | CTC | TTT | 2544 |
| | Leu | Thr | Asn | Leu | Ile | Leu | Phe | Ser | Leu | Ser | Ile | Ser | Val | Ser | Leu | Phe | |
| | | | | 815 | | | | | | 820 | | | | | 825 | | |
| 50 | CTC | ATG | GTG | ATG | ATG | ACA | GCA | AGT | CAC | CTC | TAT | TTC | TGG | GAT | GTG | TGG | 2592 |
| | Leu | Met | Val | Met | Met | Thr | Ala | Ser | His | Leu | Tyr | Phe | Trp | Asp | Val | Trp | |
| | | | | 830 | | | | | 835 | | | | | 840 | | | |
| 55 | TAT | ATT | TAC | CAT | TTC | TGT | AAG | GCC | AAG | ATA | AAG | GGG | TAT | CAG | CGT | CTA | 2640 |
| | Tyr | Ile | Tyr | His | Phe | Cys | Lys | Ala | Lys | Ile | Lys | Gly | Tyr | Gln | Arg | Leu | |
| | | | 845 | | | | | 850 | | | | | 855 | | | | |
| 60 | ATA | TCA | CCA | GAC | TGT | TGC | TAT | GAT | GCT | TTT | ATT | GTG | TAT | GAC | ACT | AAA | 2688 |
| | Ile | Ser | Pro | Asp | Cys | Cys | Tyr | Asp | Ala | Phe | Ile | Val | Tyr | Asp | Thr | Lys | |
| | | 860 | | | | | 865 | | | | | 870 | | | | | |
| 65 | GAC | CCA | GCT | GTG | ACC | GAG | TGG | GTT | TTG | GCT | GAG | CTG | GTG | GCC | AAA | CTG | 2736 |
| | Asp | Pro | Ala | Val | Thr | Glu | Trp | Val | Leu | Ala | Glu | Leu | Val | Ala | Lys | Leu | |
| | 875 | | | | | 880 | | | | | 885 | | | | | 890 | |
| 70 | GAA | GAC | CCA | AGA | GAG | AAA | CAT | TTT | AAT | TTA | TGT | CTC | GAG | GAA | AGG | GAC | 2784 |
| | Glu | Asp | Pro | Arg | Glu | Lys | His | Phe | Asn | Leu | Cys | Leu | Glu | Glu | Arg | Asp | |
| | | | | 895 | | | | | | 900 | | | | | 905 | | |
| 75 | TGG | TTA | CCA | GGG | CAG | CCA | GTT | CTG | GAA | AAC | CTT | TCC | CAG | AGC | ATA | CAG | 2832 |
| | Trp | Leu | Pro | Gly | Gln | Pro | Val | Leu | Glu | Asn | Leu | Ser | Gln | Ser | Ile | Gln | |

| | 910 | 915 | 920 | |
|-----------------------------------|---|------|-----|--|
| 5 | CTT AGC AAA AAG ACA GTG TTT GTG ATG ACA GAC AAG TAT GCA AAG ACT Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys Tyr Ala Lys Thr 925 930 935 | 2880 | | |
| 10 | GAA AAT TTT AAG ATA GCA TTT TAC TTG TCC CAT CAG AGG CTC ATG GAT Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln Arg Leu Met Asp 940 945 950 | 2928 | | |
| 15 | GAA AAA GTT GAT GTG ATT ATC TTG ATA TTT CTT GAG AAG CCC TTT CAG Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu Lys Pro Phe Gln 955 960 965 970 | 2976 | | |
| 20 | AAG TCC AAG TTC CTC CAG CTC CGG AAA AGG CTC TGT GGG AGT TCT GTC Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys Gly Ser Ser Val 975 980 985 | 3024 | | |
| 25 | CTT GAG TGG CCA ACA AAC CCG CAA GCT CAC CCA TAC TTC TGG CAG TGT Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro Tyr Phe Trp Gln Cys 990 995 1000 | 3072 | | |
| 30 | CTA AAG AAC GCC CTG GCC ACA GAC AAT CAT GTG GCC TAT AGT CAG GTG Leu Lys Asn Ala Leu Ala Thr Asp Asn His Val Ala Tyr Ser Gln Val 1005 1010 1015 | 3120 | | |
| 35 | TTC AAG GAA ACG GTC TAG Phe Lys Glu Thr Val 1020 | 3138 | | |
| (2) INFORMATION FOR SEQ ID NO:12: | | | | |
| 40 | (i) SEQUENCE CHARACTERISTICS: | | | |
| 45 | (A) LENGTH: 1045 amino acids | | | |
| | (B) TYPE: amino acid | | | |
| | (D) TOPOLOGY: linear | | | |
| 50 | (ii) MOLECULE TYPE: protein | | | |
| 55 | (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: | | | |
| 60 | Met Trp Thr Leu Lys Arg Leu Ile Leu Ile Leu Phe Asn Ile Ile Leu -22 -20 -15 -10 | | | |
| 65 | Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys Thr Leu Pro Cys -5 1 5 10 | | | |
| 70 | Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile Val Asp Cys Thr 15 20 25 | | | |
| 75 | Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro Thr Asn Thr Thr 30 35 40 | | | |
| 80 | Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile Ser Pro Ala Ser 45 50 55 | | | |
| 85 | Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe Arg Cys Asn Cys 60 65 70 | | | |
| 90 | Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys Ile Lys Arg Leu | | | |

| | 75 | | 80 | | 85 | | 90 | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | Gln | Ile | Lys | Pro | Arg | Ser | Phe | Ser | Gly | Leu | Thr | Tyr | Leu | Lys | Ser | Leu |
| | | | | | 95 | | | | | 100 | | | | | 105 | |
| 5 | Tyr | Leu | Asp | Gly | Asn | Gln | Leu | Leu | Glu | Ile | Pro | Gln | Gly | Leu | Pro | Pro |
| | | | | 110 | | | | | 115 | | | | | 120 | | |
| 10 | Ser | Leu | Gln | Leu | Leu | Ser | Leu | Glu | Ala | Asn | Asn | Ile | Phe | Ser | Ile | Arg |
| | | | 125 | | | | | 130 | | | | | 135 | | | |
| | Lys | Glu | Asn | Leu | Thr | Glu | Leu | Ala | Asn | Ile | Glu | Ile | Leu | Tyr | Leu | Gly |
| | | 140 | | | | | 145 | | | | | 150 | | | | |
| 15 | Gln | Asn | Cys | Tyr | Tyr | Arg | Asn | Pro | Cys | Tyr | Val | Ser | Tyr | Ser | Ile | Glu |
| | 155 | | | | | 160 | | | | | 165 | | | | | 170 |
| | Lys | Asp | Ala | Phe | Leu | Asn | Leu | Thr | Lys | Leu | Lys | Val | Leu | Ser | Leu | Lys |
| | | | | | 175 | | | | | 180 | | | | | 185 | |
| 20 | Asp | Asn | Asn | Val | Thr | Ala | Val | Pro | Thr | Val | Leu | Pro | Ser | Thr | Leu | Thr |
| | | | | 190 | | | | | 195 | | | | | 200 | | |
| | Glu | Leu | Tyr | Leu | Tyr | Asn | Asn | Met | Ile | Ala | Lys | Ile | Gln | Glu | Asp | Asp |
| 25 | | | 205 | | | | | 210 | | | | | 215 | | | |
| | Phe | Asn | Asn | Leu | Asn | Gln | Leu | Gln | Ile | Leu | Asp | Leu | Ser | Gly | Asn | Cys |
| | | 220 | | | | | 225 | | | | | 230 | | | | |
| 30 | Pro | Arg | Cys | Tyr | Asn | Ala | Pro | Phe | Pro | Cys | Ala | Pro | Cys | Lys | Asn | Asn |
| | 235 | | | | | 240 | | | | | 245 | | | | | 250 |
| | Ser | Pro | Leu | Gln | Ile | Pro | Val | Asn | Ala | Phe | Asp | Ala | Leu | Thr | Glu | Leu |
| | | | | 255 | | | | | | 260 | | | | | 265 | |
| 35 | Lys | Val | Leu | Arg | Leu | His | Ser | Asn | Ser | Leu | Gln | His | Val | Pro | Pro | Arg |
| | | | | 270 | | | | | 275 | | | | | 280 | | |
| | Trp | Phe | Lys | Asn | Ile | Asn | Lys | Leu | Gln | Glu | Leu | Asp | Leu | Ser | Gln | Asn |
| 40 | | | 285 | | | | | 290 | | | | | 295 | | | |
| | Phe | Leu | Ala | Lys | Glu | Ile | Gly | Asp | Ala | Lys | Phe | Leu | His | Phe | Leu | Pro |
| | | 300 | | | | | 305 | | | | | 310 | | | | |
| 45 | Ser | Leu | Ile | Gln | Leu | Asp | Leu | Ser | Phe | Asn | Phe | Glu | Leu | Gln | Val | Tyr |
| | 315 | | | | | 320 | | | | | 325 | | | | | 330 |
| | Arg | Ala | Ser | Met | Asn | Leu | Ser | Gln | Ala | Phe | Ser | Ser | Leu | Lys | Ser | Leu |
| | | | | 335 | | | | | | 340 | | | | | 345 | |
| 50 | Lys | Ile | Leu | Arg | Ile | Arg | Gly | Tyr | Val | Phe | Lys | Glu | Leu | Lys | Ser | Phe |
| | | | | 350 | | | | | 355 | | | | | 360 | | |
| | Asn | Leu | Ser | Pro | Leu | His | Asn | Leu | Gln | Asn | Leu | Glu | Val | Leu | Asp | Leu |
| 55 | | | 365 | | | | | 370 | | | | | 375 | | | |
| | Gly | Thr | Asn | Phe | Ile | Lys | Ile | Ala | Asn | Leu | Ser | Met | Phe | Lys | Gln | Phe |
| | | 380 | | | | | 385 | | | | | 390 | | | | |
| 60 | Lys | Arg | Leu | Lys | Val | Ile | Asp | Leu | Ser | Val | Asn | Lys | Ile | Ser | Pro | Ser |
| | 395 | | | | | 400 | | | | | 405 | | | | | 410 |

| | | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| | Gly | Asp | Ser | Ser | Glu | Val | Gly | Phe | Cys | Ser | Asn | Ala | Arg | Thr | Ser | Val | |
| | | | | | 415 | | | | | 420 | | | | | 425 | | |
| 5 | Glu | Ser | Tyr | Glu | Pro | Gln | Val | Leu | Glu | Gln | Leu | His | Tyr | Phe | Arg | Tyr | |
| | | | | 430 | | | | | 435 | | | | | 440 | | | |
| | Asp | Lys | Tyr | Ala | Arg | Ser | Cys | Arg | Phe | Lys | Asn | Lys | Glu | Ala | Ser | Phe | |
| | | | 445 | | | | | 450 | | | | | 455 | | | | |
| 10 | Met | Ser | Val | Asn | Glu | Ser | Cys | Tyr | Lys | Tyr | Gly | Gln | Thr | Leu | Asp | Leu | |
| | 460 | | | | | | 465 | | | | | 470 | | | | | |
| | Ser | Lys | Asn | Ser | Ile | Phe | Phe | Val | Lys | Ser | Ser | Asp | Phe | Gln | His | Leu | |
| 15 | 475 | | | | 480 | | | | | 485 | | | | | | 490 | |
| | Ser | Phe | Leu | Lys | Cys | Leu | Asn | Leu | Ser | Gly | Asn | Leu | Ile | Ser | Gln | Thr | |
| | | | | 495 | | | | | | 500 | | | | | 505 | | |
| 20 | Leu | Asn | Gly | Ser | Glu | Phe | Gln | Pro | Leu | Ala | Glu | Leu | Arg | Tyr | Leu | Asp | |
| | | | | 510 | | | | | 515 | | | | | 520 | | | |
| | Phe | Ser | Asn | Asn | Arg | Leu | Asp | Leu | Leu | His | Ser | Thr | Ala | Phe | Glu | Glu | |
| | | | 525 | | | | | 530 | | | | | 535 | | | | |
| 25 | Leu | His | Lys | Leu | Glu | Val | Leu | Asp | Ile | Ser | Ser | Asn | Ser | His | Tyr | Phe | |
| | 540 | | | | | | 545 | | | | | 550 | | | | | |
| | Gln | Ser | Glu | Gly | Ile | Thr | His | Met | Leu | Asn | Phe | Thr | Lys | Asn | Leu | Lys | |
| 30 | 555 | | | | 560 | | | | | | 565 | | | | | 570 | |
| | Val | Leu | Gln | Lys | Leu | Met | Met | Asn | Asp | Asn | Asp | Ile | Ser | Ser | Ser | Thr | |
| | | | | 575 | | | | | 580 | | | | | | 585 | | |
| 35 | Ser | Arg | Thr | Met | Glu | Ser | Glu | Ser | Leu | Arg | Thr | Leu | Glu | Phe | Arg | Gly | |
| | | | | 590 | | | | | 595 | | | | | 600 | | | |
| | Asn | His | Leu | Asp | Val | Leu | Trp | Arg | Glu | Gly | Asp | Asn | Arg | Tyr | Leu | Gln | |
| | | | 605 | | | | | 610 | | | | | 615 | | | | |
| 40 | Leu | Phe | Lys | Asn | Leu | Leu | Lys | Leu | Glu | Glu | Leu | Asp | Ile | Ser | Lys | Asn | |
| | 620 | | | | | | 625 | | | | | 630 | | | | | |
| | Ser | Leu | Ser | Phe | Leu | Pro | Ser | Gly | Val | Phe | Asp | Gly | Met | Pro | Pro | Asn | |
| 45 | 635 | | | | 640 | | | | | 645 | | | | | | 650 | |
| | Leu | Lys | Asn | Leu | Ser | Leu | Ala | Lys | Asn | Gly | Leu | Lys | Ser | Phe | Ser | Trp | |
| | | | | 655 | | | | | | 660 | | | | | 665 | | |
| 50 | Lys | Lys | Leu | Gln | Cys | Leu | Lys | Asn | Leu | Glu | Thr | Leu | Asp | Leu | Ser | His | |
| | | | 670 | | | | | | 675 | | | | | 680 | | | |
| | Asn | Gln | Leu | Thr | Thr | Val | Pro | Glu | Arg | Leu | Ser | Asn | Cys | Ser | Arg | Ser | |
| | | | 685 | | | | | 690 | | | | | 695 | | | | |
| 55 | Leu | Lys | Asn | Leu | Ile | Leu | Lys | Asn | Asn | Gln | Ile | Arg | Ser | Leu | Thr | Lys | |
| | 700 | | | | | | 705 | | | | | 710 | | | | | |
| | Tyr | Phe | Leu | Gln | Asp | Ala | Phe | Gln | Leu | Arg | Tyr | Leu | Asp | Leu | Ser | Ser | |
| 60 | 715 | | | | 720 | | | | | | 725 | | | | | 730 | |

| | | | | | | | | | | | | | | | | | |
|----|-----|------|------|-----|-----|-----|-----|------|-----|-----|-----|-----|------|------|-----|-----|--|
| | Asn | Lys | Ile | Gln | Met | Ile | Gln | Lys | Thr | Ser | Phe | Pro | Glu | Asn | Val | Leu | |
| | | | | | 735 | | | | | 740 | | | | | 745 | | |
| 5 | Asn | Asn | Leu | Lys | Met | Leu | Leu | Leu | His | His | Asn | Arg | Phe | Leu | Cys | Thr | |
| | | | | 750 | | | | | 755 | | | | | 760 | | | |
| | Cys | Asp | Ala | Val | Trp | Phe | Val | Trp | Trp | Val | Asn | His | Thr | Glu | Val | Thr | |
| | | | 765 | | | | | 770 | | | | | 775 | | | | |
| 10 | Ile | Pro | Tyr | Leu | Ala | Thr | Asp | Val | Thr | Cys | Val | Gly | Pro | Gly | Ala | His | |
| | | 780 | | | | | 785 | | | | | 790 | | | | | |
| | Lys | Gly | Gln | Ser | Val | Ile | Ser | Leu | Asp | Leu | Tyr | Thr | Cys | Glu | Leu | Asp | |
| 15 | | 795 | | | | 800 | | | | | 805 | | | | | 810 | |
| | Leu | Thr | Asn | Leu | Ile | Leu | Phe | Ser | Leu | Ser | Ile | Ser | Val | Ser | Leu | Phe | |
| | | | | 815 | | | | | | 820 | | | | | 825 | | |
| 20 | Leu | Met | Val | Met | Met | Thr | Ala | Ser | His | Leu | Tyr | Phe | Trp | Asp | Val | Trp | |
| | | | 830 | | | | | | 835 | | | | | 840 | | | |
| | Tyr | Ile | Tyr | His | Phe | Cys | Lys | Ala | Lys | Ile | Lys | Gly | Tyr | Gln | Arg | Leu | |
| | | 845 | | | | | | 850 | | | | | 855 | | | | |
| 25 | Ile | Ser | Pro | Asp | Cys | Cys | Tyr | Asp | Ala | Phe | Ile | Val | Tyr | Asp | Thr | Lys | |
| | | 860 | | | | | 865 | | | | | 870 | | | | | |
| | Asp | Pro | Ala | Val | Thr | Glu | Trp | Val | Leu | Ala | Glu | Leu | Val | Ala | Lys | Leu | |
| 30 | | 875 | | | | 880 | | | | | 885 | | | | | 890 | |
| | Glu | Asp | Pro | Arg | Glu | Lys | His | Phe | Asn | Leu | Cys | Leu | Glu | Glu | Arg | Asp | |
| | | | | 895 | | | | | 900 | | | | | | 905 | | |
| 35 | Trp | Leu | Pro | Gly | Gln | Pro | Val | Leu | Glu | Asn | Leu | Ser | Gln | Ser | Ile | Gln | |
| | | | 910 | | | | | | 915 | | | | | 920 | | | |
| | Leu | Ser | Lys | Lys | Thr | Val | Phe | Val | Met | Thr | Asp | Lys | Tyr | Ala | Lys | Thr | |
| | | | 925 | | | | | 930 | | | | | 935 | | | | |
| 40 | Glu | Asn | Phe | Lys | Ile | Ala | Phe | Tyr | Leu | Ser | His | Gln | Arg | Leu | Met | Asp | |
| | | 940 | | | | | 945 | | | | | 950 | | | | | |
| | Glu | Lys | Val | Asp | Val | Ile | Ile | Leu | Ile | Phe | Leu | Glu | Lys | Pro | Phe | Gln | |
| 45 | | 955 | | | | 960 | | | | | 965 | | | | | 970 | |
| | Lys | Ser | Lys | Phe | Leu | Gln | Leu | Arg | Lys | Arg | Leu | Cys | Gly | Ser | Ser | Val | |
| | | | | 975 | | | | | 980 | | | | | | 985 | | |
| 50 | Leu | Glu | Trp | Pro | Thr | Asn | Pro | Gln | Ala | His | Pro | Tyr | Phe | Trp | Gln | Cys | |
| | | | 990 | | | | | | 995 | | | | | 1000 | | | |
| | Leu | Lys | Asn | Ala | Leu | Ala | Thr | Asp | Asn | His | Val | Ala | Tyr | Ser | Gln | Val | |
| | | | 1005 | | | | | 1010 | | | | | 1015 | | | | |
| 55 | Phe | Lys | Glu | Thr | Val | | | | | | | | | | | | |
| | | 1020 | | | | | | | | | | | | | | | |

(2) INFORMATION FOR SEQ ID NO:13:

- 60 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 180 base pairs

(B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

10 (A) NAME/KEY: CDS
 (B) LOCATION: 1..177

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

| | | |
|----|---|-----|
| 15 | CTT GGA AAA CCT CTT CAG AAG TCT AAG TTT CTT CAG CTC AGG AAG AGA | 48 |
| | Leu Gly Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg | |
| | 1 5 10 15 | |
| 20 | CTC TGC AGG AGC TCT GTC CTT GAG TGG CCT GCA AAT CCA CAG GCT CAC | 96 |
| | Leu Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His | |
| | 20 25 30 | |
| 25 | CCA TAC TTC TGG CAG TGC CTG AAA AAT GCC CTG ACC ACA GAC AAT CAT | 144 |
| | Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn His | |
| | 35 40 45 | |
| | GTG GCT TAT AGT CAA ATG TTC AAG GAA ACA GTC TAG | 180 |
| | Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val | |
| | 50 55 | |

30

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 59 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

| | |
|----|---|
| 45 | Leu Gly Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg |
| | 1 5 10 15 |
| | Leu Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His |
| | 20 25 30 |
| 50 | Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn His |
| | 35 40 45 |
| | Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val |
| | 50 55 |

55 (2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

60 (A) LENGTH: 990 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 2..988

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

| | | |
|----|---|-----|
| | G AAT TCC AGA CTT ATA AAC TTG AAA AAT CTC TAT TTG GCC TGG AAC | 46 |
| | Asn Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr Leu Ala Trp Asn | |
| | 1 5 10 15 | |
| 15 | TGC TAT TTT AAC AAA GTT TGC GAG AAA ACT AAC ATA GAA GAT GGA GTA | 94 |
| | Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile Glu Asp Gly Val | |
| | 20 25 30 | |
| 20 | TTT GAA ACG CTG ACA AAT TTG GAG TTG CTA TCA CTA TCT TTC AAT TCT | 142 |
| | Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu Ser Phe Asn Ser | |
| | 35 40 45 | |
| 25 | CTT TCA CAT GTG CCA CCC AAA CTG CCA AGC TCC CTA CGC AAA CTT TTT | 190 |
| | Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe | |
| | 50 55 60 | |
| 30 | CTG AGC AAC ACC CAG ATC AAA TAC ATT AGT GAA GAA GAT TTC AAG GGA | 238 |
| | Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu Asp Phe Lys Gly | |
| | 65 70 75 | |
| 35 | TTG ATA AAT TTA ACA TTA CTA GAT TTA AGC GGG AAC TGT CCG AGG TGC | 286 |
| | Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys | |
| | 80 85 90 95 | |
| 40 | TTC AAT GCC CCA TTT CCA TGC GTG CCT TGT GAT GGT GGT GCT TCA ATT | 334 |
| | Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly Gly Ala Ser Ile | |
| | 100 105 110 | |
| 45 | AAT ATA GAT CGT TTT GCT TTT CAA AAC TTG ACC CAA CTT CGA TAC CTA | 382 |
| | Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln Leu Arg Tyr Leu | |
| | 115 120 125 | |
| 50 | AAC CTC TCT AGC ACT TCC CTC AGG AAG ATT AAT GCT GCC TGG TTT AAA | 430 |
| | Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala Ala Trp Phe Lys | |
| | 130 135 140 | |
| 55 | AAT ATG CCT CAT CTG AAG GTG CTG GAT CTT GAA TTC AAC TAT TTA GTG | 478 |
| | Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe Asn Tyr Leu Val | |
| | 145 150 155 | |
| 60 | GGA GAA ATA GCC TCT GGG GCA TTT TTA ACG ATG CTG CCC CGC TTA GAA | 526 |
| | Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu Pro Arg Leu Glu | |
| | 160 165 170 175 | |
| 65 | ATA CTT GAC TTG TCT TTT AAC TAT ATA AAG GGG AGT TAT CCA CAG CAT | 574 |
| | Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser Tyr Pro Gln His | |
| | 180 185 190 | |
| 70 | ATT AAT ATT TCC AGA AAC TTC TCT AAA CTT TTG TCT CTA CGG GCA TTG | 622 |
| | Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser Leu Arg Ala Leu | |

| | 195 | 200 | 205 | |
|----|---|-----|-----|--|
| 5 | CAT TTA AGA GGT TAT GTG TTC CAG GAA CTC AGA GAA GAT GAT TTC CAG His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu Asp Asp Phe Gln 210 215 220 | 670 | | |
| 10 | CCC CTG ATG CAG CTT CCA AAC TTA TCG ACT ATC AAC TTG GGT ATT AAT Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn Leu Gly Ile Asn 225 230 235 | 718 | | |
| 15 | TTT ATT AAG CAA ATC GAT TTC AAA CTT TTC CAA AAT TTC TCC AAT CTG Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn Phe Ser Asn Leu 240 245 250 255 | 766 | | |
| 20 | GAA ATT ATT TAC TTG TCA GAA AAC AGA ATA TCA CCG TTG GTA AAA GAT Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro Leu Val Lys Asp 260 265 270 | 814 | | |
| 25 | ACC CGG CAG AGT TAT GCA AAT AGT TCC TCT TTT CAA CGT CAT ATC CGG Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln Arg His Ile Arg 275 280 285 | 862 | | |
| 30 | AAA CGA CGC TCA ACA GAT TTT GAG TTT GAC CCA CAT TCG AAC TTT TAT Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His Ser Asn Phe Tyr 290 295 300 | 910 | | |
| 35 | CAT TTC ACC CGT CCT TTA ATA AAG CCA CAA TGT GCT GCT TAT GGA AAA His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala Ala Tyr Gly Lys 305 310 315 | 958 | | |
| 40 | GCC TTA GAT TTA AGC CTC AAC AGT ATT TTC TT Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe 320 325 | 990 | | |

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 329 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

| | |
|--|--|
| Asn Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr Leu Ala Trp Asn Cys 1 5 10 15 | |
| Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile Glu Asp Gly Val Phe 20 25 30 | |
| Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu Ser Phe Asn Ser Leu 35 40 45 | |
| Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu 50 55 60 | |
| Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu Asp Phe Lys Gly Leu 65 70 75 80 | |

Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Phe
 85 90 95
 5 Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly Gly Ala Ser Ile Asn
 100 105 110
 Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln Leu Arg Tyr Leu Asn
 115 120 125
 10 Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala Ala Trp Phe Lys Asn
 130 135 140
 Met Pro His Leu Lys Val Leu Asp Leu Glu Phe Asn Tyr Leu Val Gly
 145 150 155 160
 15 Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu Pro Arg Leu Glu Ile
 165 170 175
 20 Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser Tyr Pro Gln His Ile
 180 185 190
 Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser Leu Arg Ala Leu His
 195 200 205
 25 Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu Asp Asp Phe Gln Pro
 210 215 220
 Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn Leu Gly Ile Asn Phe
 225 230 235 240
 30 Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn Phe Ser Asn Leu Glu
 245 250 255
 35 Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro Leu Val Lys Asp Thr
 260 265 270
 Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln Arg His Ile Arg Lys
 275 280 285
 40 Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His Ser Asn Phe Tyr His
 290 295 300
 Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala Ala Tyr Gly Lys Ala
 305 310 315 320
 45 Leu Asp Leu Ser Leu Asn Ser Ile Phe
 325

(2) INFORMATION FOR SEQ ID NO:17:

50

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1557 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: cDNA

60

- (ix) FEATURE:
- (A) NAME/KEY: CDS

(B) LOCATION: 1..513

(ix) FEATURE:

5 (A) NAME/KEY: misc_feature
(B) LOCATION: 278
(D) OTHER INFORMATION: /note= "nucleotide 278 designated
G, may be G or C"

(ix) FEATURE:

10 (A) NAME/KEY: misc_feature
(B) LOCATION: 445
(D) OTHER INFORMATION: /note= "nucleotide 445 designated
A, may be A or T"

(ix) FEATURE:

15 (A) NAME/KEY: misc_feature
(B) LOCATION: 572
(D) OTHER INFORMATION: /note= "nucleotides 572, 593, 600,
20 607, 617, 622, 625, 631, 640, 646, 653, 719, 775, and 861 are
designated C; each may be A, C, G, or T"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

| | | |
|----|---|-----|
| 25 | CAG TCT CTT TCC ACA TCC CAA ACT TTC TAT GAT GCT TAC ATT TCT TAT | 48 |
| | Gln Ser Leu Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr | |
| | 1 5 10 15 | |
| 30 | GAC ACC AAA GAT GCC TCT GTT ACT GAC TGG GTG ATA AAT GAG CTG CGC | 96 |
| | Asp Thr Lys Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg | |
| | 20 25 30 | |
| 35 | TAC CAC CTT GAA GAG AGC CGA GAC AAA AAC GTT CTC CTT TGT CTA GAG | 144 |
| | Tyr His Leu Glu Glu Ser Arg Asp Lys Asn Val Leu Leu Cys Leu Glu | |
| | 35 40 45 | |
| 40 | GAG AGG GAT TGG GAC CCG GGA TTG GCC ATC ATC GAC AAC CTC ATG CAG | 192 |
| | Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile Ile Asp Asn Leu Met Gln | |
| | 50 55 60 | |
| 45 | AGC ATC AAC CAA AGC AAG AAA ACA GTA TTT GTT TTA ACC AAA AAA TAT | 240 |
| | Ser Ile Asn Gln Ser Lys Lys Thr Val Phe Val Leu Thr Lys Lys Tyr | |
| | 65 70 75 80 | |
| 50 | GCA AAA AGC TGG AAC TTT AAA ACA GCT TTT TAC TTG GGC TTG CAG AGG | 288 |
| | Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe Tyr Leu Gly Leu Gln Arg | |
| | 85 90 95 | |
| 55 | CTA ATG GGT GAG AAC ATG GAT GTG ATT ATA TTT ATC CTG CTG GAG CCA | 336 |
| | Leu Met Gly Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro | |
| | 100 105 110 | |
| 60 | GTG TTA CAG CAT TCT CCG TAT TTG AGG CTA CGG CAG CGG ATC TGT AAG | 384 |
| | Val Leu Gln His Ser Pro Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys | |
| | 115 120 125 | |
| 60 | AGC TCC ATC CTC CAG TGG CCT GAC AAC CCG AAG GCA GAA AGG TTG TTT | 432 |
| | Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro Lys Ala Glu Arg Leu Phe | |
| | 130 135 140 | |
| 60 | TGG CAA ACT CTG AGA AAT GTG GTC TTG ACT GAA AAT GAT TCA CGG TAT | 480 |

Trp Gln Thr Leu Arg Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr
 145 150 155 160

5 AAC AAT ATG TAT GTC GAT TCC ATT AAG CAA TAC TAACTGACGT TAAGTCATGA 533
 Asn Asn Met Tyr Val Asp Ser Ile Lys Gln Tyr
 165 170

10 TTTCGCGCCA TAATAAAGAT GCAAAGGAAT GACATTTCCG TATTAGTTAT CTATTGCTAC 593
 GGTAACCAAA TTAATCCCAA AAACCTTACG TCGGTTTCAA AACAACCACA TTCTGCTGGC 653
 CCCACAGTTT TTGAGGGTCA GGAGTCCAGG CCCAGCATAA CTGGGTCTTC TGCTTCAGGG 713
 TGTCTCCAGA GGCTGCAATG TAGGTGTTCA CCAGAGACAT AGGCATCACT GGGGTACAC 773
 15 TCCATGTGGT TGTTTTCTGG ATTCAATTCC TCCTGGGCTA TTGGCCAAAG GCTATACTCA 833
 TGTAAGCCAT GCGAGCCTAT CCCACAACGG CAGCTTGCTT CATCAGAGCT AGCAAAAAAG 893
 20 AGAGGTGCT AGCAAGATGA AGTCACAATC TTTTGTAATC GAATCAAAAA AGTGATATCT 953
 CATCACTTTG GCCATATTCT ATTTGTTAGA AGTAAACCAC AGGTCCCACC AGCTCCATGG 1013
 GAGTGACCAC CTCAGTCCAG GGAAAACAGC TGAAGACCAA GATGGTGAGC TCTGATTGCT 1073
 25 TCAGTTGGTC ATCAACTATT TTCCCTTGAC TGCTGTCCCTG GGATGGCCCG CTATCTTGAT 1133
 GGATAGATTG TGAATATCAG GAGGCCAGGG ATCACTGTGG ACCATCTTAG CAGTTGACCT 1193
 30 AACACATCTT CTTTTCAATA TCTAAGAACT TTTGCCACTG TGAATAATGG TCCTAATATT 1253
 AAGCTGTTGT TTATATTTAT CATATATCTA TGGCTACATG GTTATATTAT GCTGTGGTTG 1313
 CGTTCGGTTT TATTTACAGT TGCTTTTACA AATATTTGCT GTAACATTTG ACTTCTAAGG 1373
 35 TTTAGATGCC ATTTAAGAAC TGAGATGGAT AGCTTTTAAA GCATCTTTTA CTTCTTACCA 1433
 TTTTTTAAAA GTATGCAGCT AAATTCGAAG CTTTGGTCT ATATTGTTAA TTGCCATTGC 1493
 40 TGTAATCTT AAAATGAATG AATAAAAAATG TTTCAATTTA AAAAAAAAAA AAAAAAAAAA 1553
 AAAA 1557

45 (2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 171 amino acids

(B) TYPE: amino acid

50 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

55 Gln Ser Leu Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr
 1 5 10 15

60 Asp Thr Lys Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg
 20 25 30

Tyr His Leu Glu Glu Ser Arg Asp Lys Asn Val Leu Leu Cys Leu Glu
 35 40 45
 5 Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile Ile Asp Asn Leu Met Gln
 50 55 60
 Ser Ile Asn Gln Ser Lys Lys Thr Val Phe Val Leu Thr Lys Lys Tyr
 65 70 75 80
 10 Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe Tyr Leu Gly Leu Gln Arg
 85 90 95
 Leu Met Gly Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro
 100 105 110
 15 Val Leu Gln His Ser Pro Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys
 115 120 125
 20 Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro Lys Ala Glu Arg Leu Phe
 130 135 140
 Trp Gln Thr Leu Arg Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr
 145 150 155 160
 25 Asn Asn Met Tyr Val Asp Ser Ile Lys Gln Tyr
 165 170

(2) INFORMATION FOR SEQ ID NO:19:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 629 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 35 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 40 (A) NAME/KEY: CDS
 (B) LOCATION: 1..486
 (ix) FEATURE:
 45 (A) NAME/KEY: misc_feature
 (B) LOCATION: 144
 (D) OTHER INFORMATION: /note= "nucleotides 144 and 225
 designated C; may be C or T"

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

AAT GAA TTG ATC CCC AAT CTA GAG AAG GAA GAT GGT TCT ATC TTG ATT 48
 Asn Glu Leu Ile Pro Asn Leu Glu Lys Glu Asp Gly Ser Ile Leu Ile
 1 5 10 15
 55 TGC CTT TAT GAA AGC TAC TTT GAC CCT GGC AAA AGC ATT AGT GAA AAT 96
 Cys Leu Tyr Glu Ser Tyr Phe Asp Pro Gly Lys Ser Ile Ser Glu Asn
 20 25 30
 60 ATT GTA AGC TTC ATT GAG AAA AGC TAT AAG TCC ATC TTT GTT TTG TCC 144
 Ile Val Ser Phe Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser

| | | | | |
|----|--|-----|-----|-----|
| | 35 | 40 | 45 | |
| 5 | CCC AAC TTT GTC CAG AAT GAG TGG TGC CAT TAT GAA TTC TAC TTT GCC Pro Asn Phe Val Gln Asn Glu Trp Cys His Tyr Glu Phe Tyr Phe Ala | 192 | | |
| | 50 | 55 | 60 | |
| 10 | CAC CAC AAT CTC TTC CAT GAA AAT TCT GAT CAC ATA ATT CTT ATC TTA His His Asn Leu Phe His Glu Asn Ser Asp His Ile Ile Leu Ile Leu | 240 | | |
| | 65 | 70 | 75 | 80 |
| | CTG GAA CCC ATT CCA TTC TAT TGC ATT CCC ACC AGG TAT CAT AAA CTG Leu Glu Pro Ile Pro Phe Tyr Cys Ile Pro Thr Arg Tyr His Lys Leu | 288 | | |
| | 85 | 90 | 95 | |
| 15 | GAA GCT CTC CTG GAA AAA AAA GCA TAC TTG GAA TGG CCC AAG GAT AGG Glu Ala Leu Leu Glu Lys Lys Ala Tyr Leu Glu Trp Pro Lys Asp Arg | 336 | | |
| | 100 | 105 | 110 | |
| 20 | CGT AAA TGT GGG CTT TTC TGG GCA AAC CTT CGA GCT GCT GTT AAT GTT Arg Lys Cys Gly Leu Phe Trp Ala Asn Leu Arg Ala Ala Val Asn Val | 384 | | |
| | 115 | 120 | 125 | |
| 25 | AAT GTA TTA GCC ACC AGA GAA ATG TAT GAA CTG CAG ACA TTC ACA GAG Asn Val Leu Ala Thr Arg Glu Met Tyr Glu Leu Gln Thr Phe Thr Glu | 432 | | |
| | 130 | 135 | 140 | |
| 30 | TTA AAT GAA GAG TCT CGA GGT TCT ACA ATC TCT CTG ATG AGA ACA GAC Leu Asn Glu Glu Ser Arg Gly Ser Thr Ile Ser Leu Met Arg Thr Asp | 480 | | |
| | 145 | 150 | 155 | 160 |
| | TGT CTA TAAATCCCA CAGTCCTTGG GAAGTTGGGG ACCACATACA CTGTTGGGAT Cys Leu | 536 | | |
| 35 | GTACATTGAT ACAACCTTTA TGATGGCAAT TTGACAATAT TTATTAAAAAT AAAAAATGGT | 596 | | |
| | TATTCCTTC AAAAAAAAAA AAAAAAAAAA AAA | 629 | | |
| 40 | (2) INFORMATION FOR SEQ ID NO:20: | | | |
| | (i) SEQUENCE CHARACTERISTICS: | | | |
| | (A) LENGTH: 162 amino acids | | | |
| | (B) TYPE: amino acid | | | |
| 45 | (D) TOPOLOGY: linear | | | |
| | (ii) MOLECULE TYPE: protein | | | |
| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: | | | |
| 50 | Asn Glu Leu Ile Pro Asn Leu Glu Lys Glu Asp Gly Ser Ile Leu Ile | | | |
| | 1 | 5 | 10 | 15 |
| 55 | Cys Leu Tyr Glu Ser Tyr Phe Asp Pro Gly Lys Ser Ile Ser Glu Asn | | | |
| | 20 | 25 | 30 | |
| | Ile Val Ser Phe Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser | | | |
| | 35 | 40 | 45 | |
| 60 | Pro Asn Phe Val Gln Asn Glu Trp Cys His Tyr Glu Phe Tyr Phe Ala | | | |
| | 50 | 55 | 60 | |

His His Asn Leu Phe His Glu Asn Ser Asp His Ile Ile Leu Ile Leu
 65 70 75 80
 5 Leu Glu Pro Ile Pro Phe Tyr Cys Ile Pro Thr Arg Tyr His Lys Leu
 85 90 95
 Glu Ala Leu Leu Glu Lys Lys Ala Tyr Leu Glu Trp Pro Lys Asp Arg
 100 105 110
 10 Arg Lys Cys Gly Leu Phe Trp Ala Asn Leu Arg Ala Ala Val Asn Val
 115 120 125
 Asn Val Leu Ala Thr Arg Glu Met Tyr Glu Leu Gln Thr Phe Thr Glu
 130 135 140
 15 Leu Asn Glu Glu Ser Arg Gly Ser Thr Ile Ser Leu Met Arg Thr Asp
 145 150 155 160
 20 Cys Leu

(2) INFORMATION FOR SEQ ID NO:21:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 427 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
 35 (A) NAME/KEY: CDS
 (B) LOCATION: 1..426

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

40 AAG AAC TCC AAA GAA AAC CTC CAG TTT CAT GCT TTT ATT TCA TAT AGT 48
 Lys Asn Ser Lys Glu Asn Leu Gln Phe His Ala Phe Ile Ser Tyr Ser
 1 5 10 15
 45 GAA CAT GAT TCT GCC TGG GTG AAA AGT GAA TTG GTA CCT TAC CTA GAA 96
 Glu His Asp Ser Ala Trp Val Lys Ser Glu Leu Val Pro Tyr Leu Glu
 20 25 30
 AAA GAA GAT ATA CAG ATT TGT CTT CAT GAG AGA AAC TTT GTC CCT GGC 144
 50 Lys Glu Asp Ile Gln Ile Cys Leu His Glu Arg Asn Phe Val Pro Gly
 35 40 45
 AAG AGC ATT GTG GAA AAT ATC ATC AAC TGC ATT GAG AAG AGT TAC AAG 192
 55 Lys Ser Ile Val Glu Asn Ile Ile Asn Cys Ile Glu Lys Ser Tyr Lys
 50 55 60
 TCC ATC TTT GTT TTG TCT CCC AAC TTT GTC CAG AGT GAG TGG TGC CAT 240
 Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Ser Glu Trp Cys His
 65 70 75 80
 60 TAC GAA CTC TAT TTT GCC CAT CAC AAT CTC TTT CAT GAA GGA TCT AAT 288

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 1..627

10

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(B) LOCATION: 54
(D) OTHER INFORMATION: /note= "nucleotides 54, 103, and
15 345 are designated A; each may be A or G"

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(B) LOCATION: 313
(D) OTHER INFORMATION: /note= "nucleotide 313 designated
20 G, may be G or T"

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(B) LOCATION: 316
(D) OTHER INFORMATION: /note= "nucleotides 316, 380, 407,
25 and 408 designated C; each may be A, C, G, or T"

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

| | | |
|----|---|-----|
| | GCT TCC ACC TGT GCC TGG CCT GGC TTC CCT GGC GGG GGC GGC AAA GTG | 48 |
| | Ala Ser Thr Cys Ala Trp Pro Gly Phe Pro Gly Gly Gly Lys Val | |
| | 1 5 10 15 | |
| 35 | GGC GAA ATG AGG ATG CCC TGC CCT ACG ATG CCT TCG TGG TCT TCG ACA | 96 |
| | Gly Glu Met Arg Met Pro Cys Pro Thr Met Pro Ser Trp Ser Ser Thr | |
| | 20 25 30 | |
| 40 | AAA CGC AGA GCG CAG TGG CAG ACT GGG TGT ACA ACG AGC TTC GGG GGC | 144 |
| | Lys Arg Arg Ala Gln Trp Gln Thr Gly Cys Thr Thr Ser Phe Gly Gly | |
| | 35 40 45 | |
| 45 | AGC TGG AGG AGT GCC GTG GGC GCT GGG CAC TCC GCC TGT GCC TGG AGG | 192 |
| | Ser Trp Arg Ser Ala Val Gly Ala Gly His Ser Ala Cys Ala Trp Arg | |
| | 50 55 60 | |
| | AAC GCG ACT GGC TGC CTG GCA AAA CCC TCT TTG AGA ACC TGT GGG CCT | 240 |
| | Asn Ala Thr Gly Cys Leu Ala Lys Pro Ser Leu Arg Thr Cys Gly Pro | |
| 50 | 65 70 75 80 | |
| | CGG TCT ATG GCA GCC GCA AGA CGC TGT TTG TGC TGG CCC ACA CGG ACC | 288 |
| | Arg Ser Met Ala Ala Ala Arg Arg Cys Leu Cys Trp Pro Thr Arg Thr | |
| | 85 90 95 | |
| 55 | GGG TCA GTG GTC TCT TGC GCG CCA GTT CTC CTG CTG GCC CAG CAG CGC | 336 |
| | Gly Ser Val Val Ser Cys Ala Pro Val Leu Leu Leu Ala Gln Gln Arg | |
| | 100 105 110 | |
| 60 | CTG CTG GAA GAC CGC AAG GAC GTC GTG GTG CTG GTG ATC CTA ACG CCT | 384 |
| | Leu Leu Glu Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Thr Pro | |

| | | | | |
|----|--|-----|-----|-----|
| | 115 | 120 | 125 | |
| 5 | GAC GGC CAA GCC TCC CGA CTA CCC GAT GCG CTG ACC AGC GCC TCT GCC Asp Gly Gln Ala Ser Arg Leu Pro Asp Ala Leu Thr Ser Ala Ser Ala | 432 | | |
| | 130 | 135 | 140 | |
| 10 | GCC AGA GTG TCC TCC TCT GGC CCC ACC AGC CCA GTG GTC GCG CAG CTT Ala Arg Val Ser Ser Ser Gly Pro Thr Ser Pro Val Val Ala Gln Leu | 480 | | |
| | 145 | 150 | 155 | 160 |
| | CTG AGG CCA GCA TGC ATG GCC CTG ACC AGG GAC AAC CAC CAC TTC TAT Leu Arg Pro Ala Cys Met Ala Leu Thr Arg Asp Asn His His Phe Tyr | 528 | | |
| | 165 | 170 | 175 | |
| 15 | AAC CGG AAC TTC TGC CAG GGA ACC CAC GGC CGA ATA GCC GTG AGC CGG Asn Arg Asn Phe Cys Gln Gly Thr His Gly Arg Ile Ala Val Ser Arg | 576 | | |
| | 180 | 185 | 190 | |
| 20 | AAT CCT GCA CGG TGC CAC CTC CAC ACA CAC CTA ACA TAT GCC TGC CTG Asn Pro Ala Arg Cys His Leu His Thr His Leu Thr Tyr Ala Cys Leu | 624 | | |
| | 195 | 200 | 205 | |
| 25 | ATC TGACCAACAC ATGCTCGCCA CCCTCACCAC ACACC Ile | 662 | | |

(2) INFORMATION FOR SEQ ID NO:24:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 209 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

| | |
|----|--|
| 40 | Ala Ser Thr Cys Ala Trp Pro Gly Phe Pro Gly Gly Gly Gly Lys Val 1 5 10 15 |
| | Gly Glu Met Arg Met Pro Cys Pro Thr Met Pro Ser Trp Ser Ser Thr 20 25 30 |
| 45 | Lys Arg Arg Ala Gln Trp Gln Thr Gly Cys Thr Thr Ser Phe Gly Gly 35 40 45 |
| | Ser Trp Arg Ser Ala Val Gly Ala Gly His Ser Ala Cys Ala Trp Arg 50 55 60 |
| 50 | Asn Ala Thr Gly Cys Leu Ala Lys Pro Ser Leu Arg Thr Cys Gly Pro 65 70 75 80 |
| 55 | Arg Ser Met Ala Ala Ala Arg Arg Cys Leu Cys Trp Pro Thr Arg Thr 85 90 95 |
| | Gly Ser Val Val Ser Cys Ala Pro Val Leu Leu Leu Ala Gln Gln Arg 100 105 110 |
| 60 | Leu Leu Glu Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Thr Pro 115 120 125 |

Asp Gly Gln Ala Ser Arg Leu Pro Asp Ala Leu Thr Ser Ala Ser Ala
130 135 140

5 Ala Arg Val Ser Ser Ser Gly Pro Thr Ser Pro Val Val Ala Gln Leu
145 150 155 160

Leu Arg Pro Ala Cys Met Ala Leu Thr Arg Asp Asn His His Phe Tyr
165 170 175

10 Asn Arg Asn Phe Cys Gln Gly Thr His Gly Arg Ile Ala Val Ser Arg
180 185 190

15 Asn Pro Ala Arg Cys His Leu His Thr His Leu Thr Tyr Ala Cys Leu
195 200 205

Ile

20 (2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4865 base pairs
(B) TYPE: nucleic acid
25 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30 (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 107..2617

35 (ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 173..2617

40 (ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 81
(D) OTHER INFORMATION: /note= "nucleotides 81, 3144, 3205,
and 3563 designated A, each may be A, C, G, or T"

45 (ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 84
(D) OTHER INFORMATION: /note= "nucleotide 84 designated C,
may be C or G"

50 (ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 739
(D) OTHER INFORMATION: /note= "nucleotide 739 designated

55 C, may be C or T"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3132
(D) OTHER INFORMATION: /note= "nucleotides 3132, 3532,
60 3538, and 3553 designated G, each may be G or T"

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 3638
 (D) OTHER INFORMATION: /note= "nucleotide 3638 designated
 A, may be A or T"

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 3677
 (D) OTHER INFORMATION: /note= "nucleotides 3677, 3685, and
 3736 designated C, each may be A or C"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

| | | | | | | |
|-------------|-------------|-------------|-------------|-------------|-------------|-----|
| AAAATACTCC | CTTGCCTCAA | AAACTGCTCG | GTCAAACGGT | GATAGCAAAC | CACGCATTCA | 60 |
| CAGGGCCACT | GCTGCTCACA | AAACCAGTGA | GGATGATGCC | AGGATG | ATG TCT GCC | 115 |
| | | | | Met Ser Ala | | |
| | | | | -22 | -20 | |
| TCG CGC CTG | GCT GGG ACT | CTG ATC CCA | GCC ATG GCC | TTC CTC TCC | TGC | 163 |
| Ser Arg Leu | Ala Gly Thr | Leu Ile Pro | Ala Met Ala | Phe Leu Ser | Cys | |
| | -15 | | -10 | | -5 | |
| GTG AGA CCA | GAA AGC TGG | GAG CCC TGC | GTG GAG GTT | CCT AAT ATT | ACT | 211 |
| Val Arg Pro | Glu Ser Trp | Glu Pro Cys | Val Glu Val | Pro Asn Ile | Thr | |
| | 1 | 5 | | 10 | | |
| TAT CAA TGC | ATG GAG CTG | AAT TTC TAC | AAA ATC CCC | GAC AAC CTC | CCC | 259 |
| Tyr Gln Cys | Met Glu Leu | Asn Phe Tyr | Lys Ile Pro | Asp Asn Leu | Pro | |
| | 15 | 20 | 25 | | | |
| TTC TCA ACC | AAG AAC CTG | GAC CTG AGC | TTT AAT CCC | CTG AGG CAT | TTA | 307 |
| Phe Ser Thr | Lys Asn Leu | Asp Leu Ser | Phe Asn Pro | Leu Arg His | Leu | |
| | 30 | 35 | 40 | | 45 | |
| GGC AGC TAT | AGC TTC TTC | AGT TTC CCA | GAA CTG CAG | GTG CTG GAT | TTA | 355 |
| Gly Ser Tyr | Ser Phe Phe | Ser Phe Pro | Glu Leu Gln | Val Leu Asp | Leu | |
| | 50 | 55 | | 60 | | |
| TCC AGG TGT | GAA ATC CAG | ACA ATT GAA | GAT GGG GCA | TAT CAG AGC | CTA | 403 |
| Ser Arg Cys | Glu Ile Gln | Thr Ile Glu | Asp Gly Ala | Tyr Gln Ser | Leu | |
| | 65 | 70 | | 75 | | |
| AGC CAC CTC | TCT ACC TTA | ATA TTG ACA | GGA AAC CCC | ATC CAG AGT | TTA | 451 |
| Ser His Leu | Ser Thr Leu | Ile Leu Thr | Gly Asn Pro | Ile Gln Ser | Leu | |
| | 80 | 85 | | 90 | | |
| GCC CTG GGA | GCC TTT TCT | GGA CTA TCA | AGT TTA CAG | AAG CTG GTG | GCT | 499 |
| Ala Leu Gly | Ala Phe Ser | Gly Leu Ser | Ser Leu Gln | Lys Leu Val | Ala | |
| | 95 | 100 | | 105 | | |
| GTG GAG ACA | AAT CTA GCA | TCT CTA GAG | AAC TTC CCC | ATT GGA CAT | CTC | 547 |
| Val Glu Thr | Asn Leu Ala | Ser Leu Glu | Asn Phe Pro | Ile Gly His | Leu | |
| | 110 | 115 | 120 | | 125 | |
| AAA ACT TTG | AAA GAA CTT | AAT GTG GCT | CAC AAT CTT | ATC CAA TCT | TTC | 595 |
| Lys Thr Leu | Lys Glu Leu | Asn Val Ala | His Asn Leu | Ile Gln Ser | Phe | |
| | 130 | 135 | | 140 | | |

| | | | | | | | | | | | | | | | | | |
|----|-------------------|------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------|
| 5 | AAA Lys | TTA Leu | CCT Pro | GAG Glu 145 | TAT Tyr | TTT Phe | TCT Ser | AAT Asn | CTG Leu 150 | ACC Thr | AAT Asn | CTA Leu | GAG Glu | CAC His 155 | TTG Leu | GAC Asp | 643 |
| | CTT Leu | TCC Ser | AGC Ser 160 | AAC Asn | AAG Lys | ATT Ile | CAA Gln | AGT Ser 165 | ATT Ile | TAT Tyr | TGC Cys | ACA Thr | GAC Asp 170 | TTG Leu | CGG Arg | GTT Val | 691 |
| 10 | CTA Leu 175 | CAT His | CAA Gln | ATG Met | CCC Pro | CTA Leu | CTC Leu 180 | AAT Asn | CTC Leu | TCT Ser | TTA Leu | GAC Asp 185 | CTG Leu | TCC Ser | CTG Leu | AAC Asn | 739 |
| 15 | CCT Pro 190 | ATG Met | AAC Asn | TTT Phe | ATC Ile | CAA Gln 195 | CCA Pro | GGT Gly | GCA Ala | TTT Phe 200 | AAA Lys | GAA Glu | ATT Ile | AGG Arg | CTT Leu | CAT His 205 | 787 |
| 20 | AAG Lys | CTG Leu | ACT Thr | TTA Leu 210 | AGA Arg | AAT Asn | AAT Asn | TTT Phe | GAT Asp | AGT Ser 215 | TTA Leu | AAT Asn | GTA Val | ATG Met | AAA Lys 220 | ACT Thr | 835 |
| 25 | TGT Cys | ATT Ile | CAA Gln | GGT Gly 225 | CTG Leu | GCT Ala | GGT Gly | TTA Leu | GAA Glu 230 | GTC Val | CAT His | CGT Arg | TTG Leu 235 | GTT Val | CTG Leu | GGA Gly | 883 |
| | GAA Glu | TTT Phe | AGA Arg 240 | AAT Asn | GAA Glu | GGA Gly | AAC Asn | TTG Leu 245 | GAA Glu | AAG Lys | TTT Phe | GAC Asp | AAA Lys 250 | TCT Ser | GCT Ala | CTA Leu | 931 |
| 30 | GAG Glu 255 | GGC Gly | CTG Leu | TGC Cys | AAT Asn | TTG Leu | ACC Thr 260 | ATT Ile | GAA Glu | GAA Glu | TTC Phe | CGA Arg 265 | TTA Leu | GCA Ala | TAC Tyr | TTA Leu | 979 |
| 35 | GAC Asp 270 | TAC Tyr | TAC Tyr | CTC Leu | GAT Asp | GAT Asp 275 | ATT Ile | ATT Ile | GAC Asp | TTA Leu | TTT Phe 280 | AAT Asn | TGT Cys | TTG Leu | ACA Thr | AAT Asn 285 | 1027 |
| 40 | GTT Val | TCT Ser | TCA Ser | TTT Phe | TCC Ser 290 | CTG Leu | GTG Val | AGT Ser | GTG Val | ACT Thr 295 | ATT Ile | GAA Glu | AGG Arg | GTA Val | AAA Lys 300 | GAC Asp | 1075 |
| 45 | TTT Phe | TCT Ser | TAT Tyr | AAT Asn 305 | TTC Phe | GGA Gly | TGG Trp | CAA Gln | CAT His 310 | TTA Leu | GAA Glu | TTA Leu | GTT Val | AAC Asn 315 | TGT Cys | AAA Lys | 1123 |
| | TTT Phe | GGA Gly | CAG Gln 320 | TTT Phe | CCC Pro | ACA Thr | TTG Leu | AAA Lys 325 | CTC Leu | AAA Lys | TCT Ser | CTC Leu | AAA Lys 330 | AGG Arg | CTT Leu | ACT Thr | 1171 |
| 50 | TTC Phe 335 | ACT Thr | TCC Ser | AAC Asn | AAA Lys | GGT Gly | GGG Gly 340 | AAT Asn | GCT Ala | TTT Phe | TCA Ser | GAA Glu 345 | GTT Val | GAT Asp | CTA Leu | CCA Pro | 1219 |
| 55 | AGC Ser 350 | CTT Leu | GAG Glu | TTT Phe | CTA Leu | GAT Asp 355 | CTC Leu | AGT Ser | AGA Arg | AAT Asn | GGC Gly 360 | TTG Leu | AGT Ser | TTC Phe | AAA Lys | GGT Gly 365 | 1267 |
| 60 | TGC Cys | TGT Cys | TCT Ser | CAA Gln 370 | AGT Ser | GAT Asp | TTT Phe | GGG Gly | ACA Thr | ACC Thr 375 | AGC Ser | CTA Leu | AAG Lys | TAT Tyr | TTA Leu 380 | GAT Asp | 1315 |

| | | |
|----|---|------|
| | CTG AGC TTC AAT GGT GTT ATT ACC ATG AGT TCA AAC TTC TTG GGC TTA | 1363 |
| | Leu Ser Phe Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu | |
| | 385 390 395 | |
| 5 | GAA CAA CTA GAA CAT CTG GAT TTC CAG CAT TCC AAT TTG AAA CAA ATG | 1411 |
| | Glu Gln Leu Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met | |
| | 400 405 410 | |
| 10 | AGT GAG TTT TCA GTA TTC CTA TCA CTC AGA AAC CTC ATT TAC CTT GAC | 1459 |
| | Ser Glu Phe Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp | |
| | 415 420 425 | |
| 15 | ATT TCT CAT ACT CAC ACC AGA GTT GCT TTC AAT GGC ATC TTC AAT GGC | 1507 |
| | Ile Ser His Thr His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly | |
| | 430 435 440 445 | |
| 20 | TTG TCC AGT CTC GAA GTC TTG AAA ATG GCT GGC AAT TCT TTC CAG GAA | 1555 |
| | Leu Ser Ser Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu | |
| | 450 455 460 | |
| | AAC TTC CTT CCA GAT ATC TTC ACA GAG CTG AGA AAC TTG ACC TTC CTG | 1603 |
| | Asn Phe Leu Pro Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu | |
| | 465 470 475 | |
| 25 | GAC CTC TCT CAG TGT CAA CTG GAG CAG TTG TCT CCA ACA GCA TTT AAC | 1651 |
| | Asp Leu Ser Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn | |
| | 480 485 490 | |
| 30 | TCA CTC TCC AGT CTT CAG GTA CTA AAT ATG AGC CAC AAC AAC TTC TTT | 1699 |
| | Ser Leu Ser Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe | |
| | 495 500 505 | |
| 35 | TCA TTG GAT ACG TTT CCT TAT AAG TGT CTG AAC TCC CTC CAG GTT CTT | 1747 |
| | Ser Leu Asp Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu | |
| | 510 515 520 525 | |
| 40 | GAT TAC AGT CTC AAT CAC ATA ATG ACT TCC AAA AAA CAG GAA CTA CAG | 1795 |
| | Asp Tyr Ser Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln | |
| | 530 535 540 | |
| | CAT TTT CCA AGT AGT CTA GCT TTC TTA AAT CTT ACT CAG AAT GAC TTT | 1843 |
| | His Phe Pro Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe | |
| | 545 550 555 | |
| 45 | GCT TGT ACT TGT GAA CAC CAG AGT TTC CTG CAA TGG ATC AAG GAC CAG | 1891 |
| | Ala Cys Thr Cys Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln | |
| | 560 565 570 | |
| 50 | AGG CAG CTC TTG GTG GAA GTT GAA CGA ATG GAA TGT GCA ACA CCT TCA | 1939 |
| | Arg Gln Leu Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser | |
| | 575 580 585 | |
| 55 | GAT AAG CAG GGC ATG CCT GTG CTG AGT TTG AAT ATC ACC TGT CAG ATG | 1987 |
| | Asp Lys Gln Gly Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met | |
| | 590 595 600 605 | |
| 60 | AAT AAG ACC ATC ATT GGT GTG TCG GTC CTC AGT GTG CTT GTA GTA TCT | 2035 |
| | Asn Lys Thr Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser | |
| | 610 615 620 | |
| | GTT GTA GCA GTT CTG GTC TAT AAG TTC TAT TTT CAC CTG ATG CTT CTT | 2083 |

[illegible]

| | | | | | | | |
|----|-------------|------------|-------------|-------------|------------|-------------|------|
| | TATGTTATAG | CCATCATAAA | ACCATTTTGG | TAGTTTTGAC | TGAACTGGGT | GTTCACTTTT | 3027 |
| | TCCTTTTTGA | TTGAATACAA | TTTAAATTCT | ACTTGATGAC | TGCAGTCGTC | AAGGGGCTCC | 3087 |
| 5 | TGATGCAAGA | TGCCCCCTCC | ATTTTAAGTC | TGTCTCCTTA | CAGAGGTAA | AGTCTAATGG | 3147 |
| | CTAATTCCTA | AGGAAACCTG | ATTAACACAT | GCTCACAACC | ATCCTGGTCA | TTCTCGAACA | 3207 |
| 10 | TGTTCTATTT | TTTAACTAAT | CACCCCTGAT | ATATTTTTAT | TTTTATATAT | CCAGTTTTC | 3267 |
| | TTTTTTTACG | TCTTGCCTAT | AAGCTAATAT | CATAAATAAG | GTTGTTTAAG | ACGTGCTTCA | 3327 |
| | AATATCCATA | TTAACCCTA | TTTTTCAAGG | AAGTATGGAA | AAGTACACTC | TGTCACCTTG | 3387 |
| 15 | TCACTCGATG | TCATTCCAAA | GTTATTGCCT | ACTAAGTAAT | GACTGTCATG | AAAGCAGCAT | 3447 |
| | TGAAATAAAT | TGTTTAAAGG | GGGCACTCTT | TTAAACGGGA | AGAAAATTTT | CGCTTCCTGG | 3507 |
| 20 | TCATTATCATG | GACAATTTGG | GCTAGAGGCA | GGAAGGAAGT | GGGATGACCT | CAGGAAGTCA | 3567 |
| | CCTTTTCTTG | ATTCCAGAAA | CATATGGGCT | GATAAACCCG | GGGTGACCTC | ATGAAATGAG | 3627 |
| | TTGCAGCAGA | AGTTTATTTT | TTTCAGAAC | AGTGATGTTT | GATGGACCTC | TGAATCTCTT | 3687 |
| 25 | TAGGGAGACA | CAGATGGCTG | GGATCCCTCC | CCTGTACCCT | TCTCACTGCC | AGGAGAACTA | 3747 |
| | CGTGTGAAGG | TATTCAAGGC | AGGGAGTATA | CATTGCTGTT | TCCTGTTGGG | CAATGCTCCT | 3807 |
| 30 | TGACCACATT | TTGGGAAGAG | TGGATGTTAT | CATTGAGAAA | ACAATGTGTC | TGGAATTAAT | 3867 |
| | GGGGTTCTTA | TAAAGAAGGT | TCCCAGAAAA | GAATGTTTCAT | TCCAGCTTCT | TCAGGAAACA | 3927 |
| | GGAACATTCA | AGGAAAAGGA | CAATCAGGAT | GTCATCAGGG | AAATGAAAAT | AAAAACCACA | 3987 |
| 35 | ATGAGATATC | ACCTTATACC | AGGTAGATGG | CTACTATAAA | AAAATGAAGT | GTCATCAAGG | 4047 |
| | ATATAGAGAA | ATTGGAACCC | TTCTTCACTG | CTGGAGGGAA | TGGAAAATGG | TGTAGCCGTT | 4107 |
| 40 | ATGAAAAACA | GTACGGAGGT | TTCTCAAAAA | TTAAAAATAG | AACTGCTATA | TGATCCAGCA | 4167 |
| | ATCTCACTTC | TGTATATATA | CCCCAAATAA | TTGAAATCAG | AATTTCAAGA | AAATATTTAC | 4227 |
| | ACTCCCATGT | TCATTGTGGC | ACTCTTCACA | ATCACTGTTT | CCAAAGTTAT | GGAAACAACC | 4287 |
| 45 | CAAATTTCCA | TTGGAAAATA | AATGGACAAA | GGAAATGTGC | ATATAACGTA | CAATGGGGAT | 4347 |
| | ATTATTCAGC | CTAAAAAAG | GGGGATCCTT | GTTATTTATG | ACAACATGAA | TAAACCCGGA | 4407 |
| 50 | GGCCATTATG | CTATGTAAAA | TGAGCAAGTA | ACAGAAAGAC | AAATACTGCC | TGATTTTCATT | 4467 |
| | TATATGAGGT | TCTAAAATAG | TCAAACATCAT | AGAAGCAGAG | AATAGAACAG | TGGTTCCTAG | 4527 |
| | GGAAAAGGAG | GAAGGGAGAA | ATGAGGAAAT | AGGGAGTTGT | CTAATTGGTA | TAAAATTATA | 4587 |
| 55 | GTATGCAAGA | TGAATTAGCT | CTAAAGATCA | GCTGTATAGC | AGAGTTCGTA | TAATGAACAA | 4647 |
| | TACTGTATTA | TGCACTTAAC | ATTTTGTAA | GAGGGTACCT | CTCATGTTAA | GTGTTCTTAC | 4707 |
| 60 | CATATACATA | TACACAAGGA | AGCTTTTGG | GGTGATGGAT | ATATTTATTA | CCTTGATTGT | 4767 |
| | GGTGATGGTT | TGACAGGTAT | GTGACTATGT | CTAAACATCAT | CAAATTGTAT | ACATTAAATA | 4827 |

TATGCAGTTT TATAATATCA AAAAAAAAAA AAAAAAAAAA

4865

5 (2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 837 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

15 Met Ser Ala Ser Arg Leu Ala Gly Thr Leu Ile Pro Ala Met Ala Phe
 -22 -20 -15 -10

20 Leu Ser Cys Val Arg Pro Glu Ser Trp Glu Pro Cys Val Glu Val Pro
 -5 1 5 10

Asn Ile Thr Tyr Gln Cys Met Glu Leu Asn Phe Tyr Lys Ile Pro Asp
 15 20 25

25 Asn Leu Pro Phe Ser Thr Lys Asn Leu Asp Leu Ser Phe Asn Pro Leu
 30 35 40

Arg His Leu Gly Ser Tyr Ser Phe Phe Ser Phe Pro Glu Leu Gln Val
 45 50 55

30 Leu Asp Leu Ser Arg Cys Glu Ile Gln Thr Ile Glu Asp Gly Ala Tyr
 60 65 70

Gln Ser Leu Ser His Leu Ser Thr Leu Ile Leu Thr Gly Asn Pro Ile
 35 75 80 85 90

Gln Ser Leu Ala Leu Gly Ala Phe Ser Gly Leu Ser Ser Leu Gln Lys
 95 100 105

40 Leu Val Ala Val Glu Thr Asn Leu Ala Ser Leu Glu Asn Phe Pro Ile
 110 115 120

Gly His Leu Lys Thr Leu Lys Glu Leu Asn Val Ala His Asn Leu Ile
 125 130 135

45 Gln Ser Phe Lys Leu Pro Glu Tyr Phe Ser Asn Leu Thr Asn Leu Glu
 140 145 150

50 His Leu Asp Leu Ser Ser Asn Lys Ile Gln Ser Ile Tyr Cys Thr Asp
 155 160 165 170

Leu Arg Val Leu His Gln Met Pro Leu Leu Asn Leu Ser Leu Asp Leu
 175 180 185

55 Ser Leu Asn Pro Met Asn Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile
 190 195 200

Arg Leu His Lys Leu Thr Leu Arg Asn Asn Phe Asp Ser Leu Asn Val
 205 210 215

60 Met Lys Thr Cys Ile Gln Gly Leu Ala Gly Leu Glu Val His Arg Leu

| | | | | | | | | | | | | | | | | |
|----|------------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| | | 220 | | | | 225 | | | | 230 | | | | | | |
| 5 | Val 235 | Leu | Gly | Glu | Phe | Arg 240 | Asn | Glu | Gly | Asn | Leu 245 | Glu | Lys | Phe | Asp | Lys 250 |
| | Ser | Ala | Leu | Glu | Gly 255 | Leu | Cys | Asn | Leu | Thr 260 | Ile | Glu | Glu | Phe | Arg 265 | Leu |
| 10 | Ala | Tyr | Leu | Asp 270 | Tyr | Tyr | Leu | Asp | Asp 275 | Ile | Ile | Asp | Leu | Phe 280 | Asn | Cys |
| | Leu | Thr | Asn 285 | Val | Ser | Ser | Phe | Ser 290 | Leu | Val | Ser | Val | Thr 295 | Ile | Glu | Arg |
| 15 | Val 300 | Lys | Asp | Phe | Ser | Tyr | Asn 305 | Phe | Gly | Trp | Gln 310 | His | Leu | Glu | Leu | Val |
| 20 | Asn 315 | Cys | Lys | Phe | Gly | Gln 320 | Phe | Pro | Thr | Leu | Lys 325 | Leu | Lys | Ser | Leu | Lys 330 |
| | Arg | Leu | Thr | Phe | Thr 335 | Ser | Asn | Lys | Gly | Gly 340 | Asn | Ala | Phe | Ser | Glu 345 | Val |
| 25 | Asp | Leu | Pro | Ser 350 | Leu | Glu | Phe | Leu | Asp 355 | Leu | Ser | Arg | Asn | Gly 360 | Leu | Ser |
| | Phe | Lys | Gly 365 | Cys | Cys | Ser | Gln | Ser 370 | Asp | Phe | Gly | Thr | Thr 375 | Ser | Leu | Lys |
| 30 | Tyr 380 | Leu | Asp | Leu | Ser | Phe | Asn 385 | Gly | Val | Ile | Thr | Met 390 | Ser | Ser | Asn | Phe |
| 35 | Leu 395 | Gly | Leu | Glu | Gln 400 | Leu | Glu | His | Leu | Asp | Phe 405 | Gln | His | Ser | Asn | Leu 410 |
| | Lys | Gln | Met | Ser | Glu 415 | Phe | Ser | Val | Phe | Leu 420 | Ser | Leu | Arg | Asn | Leu 425 | Ile |
| 40 | Tyr | Leu | Asp | Ile 430 | Ser | His | Thr | His | Thr 435 | Arg | Val | Ala | Phe | Asn 440 | Gly | Ile |
| | Phe | Asn | Gly 445 | Leu | Ser | Ser | Leu | Glu 450 | Val | Leu | Lys | Met | Ala 455 | Gly | Asn | Ser |
| 45 | Phe 460 | Gln | Glu | Asn | Phe | Leu | Pro 465 | Asp | Ile | Phe | Thr | Glu 470 | Leu | Arg | Asn | Leu |
| 50 | Thr 475 | Phe | Leu | Asp | Leu 480 | Ser | Gln | Cys | Gln | Leu | Glu 485 | Gln | Leu | Ser | Pro | Thr 490 |
| | Ala | Phe | Asn | Ser | Leu 495 | Ser | Ser | Leu | Gln | Val 500 | Leu | Asn | Met | Ser | His 505 | Asn |
| 55 | Asn | Phe | Phe | Ser 510 | Leu | Asp | Thr | Phe | Pro 515 | Tyr | Lys | Cys | Leu | Asn 520 | Ser | Leu |
| | Gln | Val | Leu 525 | Asp | Tyr | Ser | Leu | Asn 530 | His | Ile | Met | Thr | Ser 535 | Lys | Lys | Gln |
| 60 | Glu 540 | Leu | Gln | His | Phe | Pro | Ser 545 | Ser | Leu | Ala | Phe | Leu 550 | Asn | Leu | Thr | Gln |

Asn Asp Phe Ala Cys Thr Cys Glu His Gln Ser Phe Leu Gln Trp Ile
 555 560 565 570
 5 Lys Asp Gln Arg Gln Leu Leu Val Glu Val Glu Arg Met Glu Cys Ala
 575 580 585
 Thr Pro Ser Asp Lys Gln Gly Met Pro Val Leu Ser Leu Asn Ile Thr
 590 595 600
 10 Cys Gln Met Asn Lys Thr Ile Ile Gly Val Ser Val Leu Ser Val Leu
 605 610 615
 Val Val Ser Val Val Ala Val Leu Val Tyr Lys Phe Tyr Phe His Leu
 15 620 625 630
 Met Leu Leu Ala Gly Cys Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr
 635 640 645 650
 20 Asp Ala Phe Val Ile Tyr Ser Ser Gln Asp Glu Asp Trp Val Arg Asn
 655 660 665
 Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Pro Phe Gln Leu Cys
 25 670 675 680
 Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala Asn Ile
 685 690 695
 30 Ile His Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val Val Ser
 700 705 710
 Gln His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala
 715 720 725 730
 35 Gln Thr Trp Gln Phe Leu Ser Ser Arg Ala Gly Ile Ile Phe Ile Val
 735 740 745
 Leu Gln Lys Val Glu Lys Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr
 40 750 755 760
 Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu
 765 770 775
 45 Gly Arg His Ile Phe Trp Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly
 780 785 790
 Lys Ser Trp Asn Pro Glu Gly Thr Val Gly Thr Gly Cys Asn Trp Gln
 795 800 805 810
 50 Glu Ala Thr Ser Ile
 815

(2) INFORMATION FOR SEQ ID NO:27:

55 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 300 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 60 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..300

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 186
 (D) OTHER INFORMATION: /note= "nucleotides 186, 196, 217, 276, and 300 designated C, each may be A, C, G, or T"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

| | | |
|----|---|-----|
| 15 | TCC TAT TCT ATG GAA AAA GAT GCT TTC CTA TTT ATG AGA AAT TTG AAG | 48 |
| | Ser Tyr Ser Met Glu Lys Asp Ala Phe Leu Phe Met Arg Asn Leu Lys | |
| | 1 5 10 15 | |
| 20 | GTT CTC TCA CTA AAA GAT AAC AAT GTC ACA GCT GTC CCC ACC ACT TTG | 96 |
| | Val Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu | |
| | 20 25 30 | |
| 25 | CCA CCT AAT TTA CTA GAG CTC TAT CTT TAT AAC AAT ATC ATT AAG AAA | 144 |
| | Pro Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys | |
| | 35 40 45 | |
| 30 | ATC CAA GAA AAT GAT TTC AAT AAC CTC AAT GAG TTG CAA GTC CTT GAC | 192 |
| | Ile Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp | |
| | 50 55 60 | |
| 35 | CTA CGT GGA AAT TGC CCT CGA TGT CAT AAT GTC CCA TAT CCG TGT ACA | 240 |
| | Leu Arg Gly Asn Cys Pro Arg Cys His Asn Val Pro Tyr Pro Cys Thr | |
| | 65 70 75 80 | |
| 40 | CCG TGT GAA AAT AAT TCC CCC TTA CAG ATC CAT GAC AAT GCT TTC AAT | 288 |
| | Pro Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn | |
| | 85 90 95 | |
| 45 | TCA TCG ACA GAC | 300 |
| | Ser Ser Thr Asp | |
| | 100 | |

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 100 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

| | |
|----|---|
| 55 | Ser Tyr Ser Met Glu Lys Asp Ala Phe Leu Phe Met Arg Asn Leu Lys |
| | 1 5 10 15 |
| 60 | Val Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu |
| | 20 25 30 |

Pro Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys
 35 40 45

5 Ile Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp
 50 55 60

Leu Arg Gly Asn Cys Pro Arg Cys His Asn Val Pro Tyr Pro Cys Thr
 65 70 75 80

10 Pro Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn.
 85 90 95

Ser Ser Thr Asp
 100

15

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1756 base pairs
 20 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
 25

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..1182
 30

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 1643
 (D) OTHER INFORMATION: /note= "nucleotide 1643 designated
 35 A, may be A or G"

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 1664
 40 (D) OTHER INFORMATION: /note= "nucleotide 1664 designated
 C, may be A, C, G, or T"

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 45 (B) LOCATION: 1680
 (D) OTHER INFORMATION: /note= "nucleotides 1680 and 1735
 designated G, may be G or T"

(ix) FEATURE:
 50 (A) NAME/KEY: misc_feature
 (B) LOCATION: 1719
 (D) OTHER INFORMATION: /note= "nucleotide 1719 designated
 C, may be C or T"

(ix) FEATURE:
 55 (A) NAME/KEY: misc_feature
 (B) LOCATION: 1727
 (D) OTHER INFORMATION: /note= "nucleotide 1727 designated
 A, may be A, G, or T"
 60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

| | | | | | | | | | | | | | | | | | |
|----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| 5 | TCT Ser | CCA Pro | GAA Glu | ATT Ile | CCC Pro | TGG Trp | AAT Asn | TCC Ser | TTG Leu | CCT Pro | CCT Pro | GAG Glu | GTT Val | TTT Phe | GAG Glu | GGT Gly | 48 |
| | 1 | | | | 5 | | | | 10 | | | | | 15 | | | |
| 10 | ATG Met | CCG Pro | CCA Pro | AAT Asn | CTA Leu | AAG Lys | AAT Asn | CTC Leu | TCC Ser | TTG Leu | GCC Ala | AAA Lys | AAT Asn | GGG Gly | CTC Leu | AAA Lys | 96 |
| | | | | 20 | | | | 25 | | | | | 30 | | | | |
| 15 | TCT Ser | TTC Phe | TTT Phe | TGG Trp | GAC Asp | AGA Arg | CTC Leu | CAG Gln | TTA Leu | CTG Leu | AAG Lys | CAT His | TTG Leu | GAA Glu | ATT Ile | TTG Leu | 144 |
| | | | 35 | | | | 40 | | | | | 45 | | | | | |
| 20 | GAC Asp | CTC Leu | AGC Ser | CAT His | AAC Asn | CAG Gln | CTG Leu | ACA Thr | AAA Lys | GTA Val | CCT Pro | GAG Glu | AGA Arg | TTG Leu | GCC Ala | AAC Asn | 192 |
| | | 50 | | | | 55 | | | | 60 | | | | | | | |
| 25 | TGT Cys | TCC Ser | AAA Lys | AGT Ser | CTC Leu | ACA Thr | ACA Thr | CTG Leu | ATT Ile | CTT Leu | AAG Lys | CAT His | AAT Asn | CAA Gln | ATC Ile | AGG Arg | 240 |
| | 65 | | | | 70 | | | | | 75 | | | | | | 80 | |
| 30 | CAA Gln | TTG Leu | ACA Thr | AAA Lys | TAT Tyr | TTT Phe | CTA Leu | GAA Glu | GAT Asp | GCT Ala | TTG Leu | CAA Gln | TTG Leu | CGC Arg | TAT Tyr | CTA Leu | 288 |
| | | | | 85 | | | | 90 | | | | 95 | | | | | |
| 35 | GAC Asp | ATC Ile | AGT Ser | TCA Ser | AAT Asn | AAA Lys | ATC Ile | CAG Gln | GTC Val | ATT Ile | CAG Gln | AAG Lys | ACT Thr | AGC Ser | TTC Phe | CCA Pro | 336 |
| | | | | 100 | | | | 105 | | | | 110 | | | | | |
| 40 | GAA Glu | AAT Asn | GTC Val | CTC Leu | AAC Asn | AAT Asn | CTG Leu | GAG Glu | ATG Met | TTG Leu | GTT Val | TTA Leu | CAT His | CAC His | AAT Asn | CGC Arg | 384 |
| | | | 115 | | | | 120 | | | | | 125 | | | | | |
| 45 | TTT Phe | CTT Leu | TGC Cys | AAC Asn | TGT Cys | GAT Asp | GCT Ala | GTG Val | TGG Trp | TTT Phe | GTC Val | TGG Trp | TGG Trp | GTT Val | AAC Asn | CAT His | 432 |
| | 130 | | | | | 135 | | | | | 140 | | | | | | |
| 50 | ACA Thr | GAT Asp | GTT Val | ACT Thr | ATT Ile | CCA Pro | TAC Tyr | CTG Leu | GCC Ala | ACT Thr | GAT Asp | GTG Val | ACT Thr | TGT Cys | GTA Val | GGT Gly | 480 |
| | 145 | | | | | 150 | | | | 155 | | | | | | 160 | |
| 55 | CCA Pro | GGA Gly | GCA Ala | CAC His | AAA Lys | GGT Gly | CAA Gln | AGT Ser | GTC Val | ATA Ile | TCC Ser | CTT Leu | GAT Asp | CTG Leu | TAT Tyr | ACG Thr | 528 |
| | | | | 165 | | | | 170 | | | | | | 175 | | | |
| 60 | TGT Cys | GAG Glu | TTA Leu | GAT Asp | CTC Leu | ACA Thr | AAC Asn | CTG Leu | ATT Ile | CTG Leu | TTC Phe | TCA Ser | GTT Val | TCC Ser | ATA Ile | TCA Ser | 576 |
| | | | 180 | | | | | 185 | | | | | 190 | | | | |
| 65 | TCA Ser | GTC Val | CTC Leu | TTT Phe | CTT Leu | ATG Met | GTA Val | GTT Val | ATG Met | ACA Thr | ACA Thr | AGT Ser | CAC His | CTC Leu | TTT Phe | TTC Phe | 624 |
| | | | 195 | | | | 200 | | | | | 205 | | | | | |
| 70 | TGG Trp | GAT Asp | ATG Met | TGG Trp | TAC Tyr | ATT Ile | TAT Tyr | TAT Tyr | TTT Phe | TGG Trp | AAA Lys | GCA Ala | AAG Lys | ATA Ile | AAG Lys | GGG Gly | 672 |
| | 210 | | | | | 215 | | | | | 220 | | | | | | |
| 75 | TAT Tyr | CCA Pro | GCA Ala | TCT Ser | GCA Ala | ATC Ile | CCA Pro | TGG Trp | AGT Ser | CCT Pro | TGT Cys | TAT Tyr | GAT Asp | GCT Ala | TTT Phe | ATT Ile | 720 |
| | 225 | | | | | 230 | | | | 235 | | | | | | 240 | |

| | | |
|----|--|------|
| 5 | GTG TAT GAC ACT AAA AAC TCA GCT GTG ACA GAA TGG GTT TTG CAG GAG | 768 |
| | Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu 245 250 255 | |
| 10 | CTG GTG GCA AAA TTG GAA GAT CCA AGA GAA AAA CAC TTC AAT TTG TGT | 816 |
| | Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys 260 265 270 | |
| 15 | CTA GAA GAA AGA GAC TGG CTA CCA GGA CAG CCA GTT CTA GAA AAC CTT | 864 |
| | Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu 275 280 285 | |
| 20 | TCC CAG AGC ATA CAG CTC AGC AAA AAG ACA GTG TTT GTG ATG ACA CAG | 912 |
| | Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln 290 295 300 | |
| 25 | AAA TAT GCT AAG ACT GAG AGT TTT AAG ATG GCA TTT TAT TTG TCT CAT | 960 |
| | Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His 305 310 315 320 | |
| 30 | CAG AGG CTC CTG GAT GAA AAA GTG GAT GTG ATT ATC TTG ATA TTC TTG | 1008 |
| | Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu 325 330 335 | |
| 35 | GAA AGA CCT CTT CAG AAG TCT AAG TTT CTT CAG CTC AGG AAG AGA CTC | 1056 |
| | Glu Arg Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu 340 345 350 | |
| 40 | TGC AGG AGC TCT GTC CTT GAG TGG CCT GCA AAT CCA CAG GCT CAC CCA | 1104 |
| | Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His Pro 355 360 365 | |
| 45 | TAC TTC TGG CAG TGC CTG AAA AAT GCC CTG ACC ACA GAC AAT CAT GTG | 1152 |
| | Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn His Val 370 375 380 | |
| 50 | GCT TAT AGT CAA ATG TTC AAG GAA ACA GTC TAGCTCTCTG AAGAATGTCA | 1202 |
| | Ala Tyr Ser Gln Met Phe Lys Glu Thr Val 385 390 | |
| 55 | CCACCTAGGA CATGCCTTGG TACCTGAAGT TTTTCATAAAG GTTTCATATA ATGAAGGTCT | 1262 |
| | GAATTTTTC TAACAGTTGT CATGGCTCAG ATTGGTGGGA AATCATCAAT ATATGGCTAA | 1322 |
| 60 | GAAATTAAGA AGGGGAGACT GATAGAAGAT AATTTCTTTC TTCATGTGCC ATGCTCAGTT | 1382 |
| | AAATATTTTC CCTAGCTCAA ATCTGAAAAA CTGTGCCCTAG GAGACAACAC AAGGCTTTGA | 1442 |
| 65 | TTTATCTGCA TACAATTGAT AAGAGCCACA CATCTGCCCT GAAGAAGTAC TAGTAGTTTT | 1502 |
| | AGTAGTAGGG TAAAAATTAC ACAAGCTTTC TCTCTCTCTG ATACTGAACT GTACCAGACT | 1562 |
| 70 | TCAATGAAAT AAAAGCCCAG AGAACTTCTC AGTAAATGGT TTCATTATCA TGTAGTATCC | 1622 |
| | ACCATGCAAT ATGCCACAAA ACCGCTACTG GTACAGGACA GCTGGTAGCT GCTTCAAGGC | 1682 |
| 75 | CTCTTATCAT TTTCTTGGGG CCCATGGAGG GGTCTCTCTG GAAAAAGGGA AGGTTTTTTT | 1742 |
| | TGGCCATCCA TGAA | 1756 |

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 394 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Ser Pro Glu Ile Pro Trp Asn Ser Leu Pro Pro Glu Val Phe Glu Gly
 1 5 10 15
 Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys
 20 25 30
 Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile Leu
 35 40 45
 Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala Asn
 50 55 60
 Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile Arg
 65 70 75 80
 Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr Leu
 85 90 95
 Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe Pro
 100 105 110
 Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn Arg
 115 120 125
 Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His
 130 135 140
 Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly
 145 150 155 160
 Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr
 165 170 175
 Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile Ser
 180 185 190
 Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe Phe
 195 200 205
 Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys Gly
 210 215 220
 Tyr Pro Ala Ser Ala Ile Pro Trp Ser Pro Cys Tyr Asp Ala Phe Ile
 225 230 235 240
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu
 245 250 255
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys

[illegible]

(2) INFORMATION FOR SEO ID NO:31:

30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 999 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: CDS
40 (B) LOCATION: 2..847

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 4
45 (D) OTHER INFORMATION: /note= "nucleotides 4 and 23
designated C, each may be A, C, G, or T"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
50 (B) LOCATION: 650
(D) OTHER INFORMATION: /note= "nucleotide 650 designated
G, may be A or G"

(ix) FEATURE:
55 (A) NAME/KEY: misc_feature
(B) LOCATION: 715
(D) OTHER INFORMATION: /note= "nucleotides 715, 825, and
845 designated C, each may be C or T"

60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

| | | |
|----|---|-----|
| | C TCC GAT GCC AAG ATT CGG CAC CAG GCA TAT TCA GAG GTC ATG ATG | 46 |
| | Ser Asp Ala Lys Ile Arg His Gln Ala Tyr Ser Glu Val Met Met | |
| 5 | 1 5 10 15 | |
| | GTT GGA TGG TCA GAT TCA TAC ACC TGT GAA TAC CCT TTA AAC CTA AGG | 94 |
| | Val Gly Trp Ser Asp Ser Tyr Thr Cys Glu Tyr Pro Leu Asn Leu Arg | |
| | 20 25 30 | |
| 10 | GGA ACT AGG TTA AAA GAC GTT CAT CTC CAC GAA TTA TCT TGC AAC ACA | 142 |
| | Gly Thr Arg Leu Lys Asp Val His Leu His Glu Leu Ser Cys Asn Thr | |
| | 35 40 45 | |
| 15 | GCT CTG TTG ATT GTC ACC ATT GTG GTT ATT ATG CTA GTT CTG GGG TTG | 190 |
| | Ala Leu Leu Ile Val Thr Ile Val Val Ile Met Leu Val Leu Gly Leu | |
| | 50 55 60 | |
| 20 | GCT GTG GCC TTC TGC TGT CTC CAC TTT GAT CTG CCC TGG TAT CTC AGG | 238 |
| | Ala Val Ala Phe Cys Cys Leu His Phe Asp Leu Pro Trp Tyr Leu Arg | |
| | 65 70 75 | |
| | ATG CTA GGT CAA TGC ACA CAA ACA TGG CAC AGG GTT AGG AAA ACA ACC | 286 |
| | Met Leu Gly Gln Cys Thr Gln Thr Trp His Arg Val Arg Lys Thr Thr | |
| | 80 85 90 95 | |
| 25 | CAA GAA CAA CTC AAG AGA AAT GTC CGA TTC CAC GCA TTT ATT TCA TAC | 334 |
| | Gln Glu Gln Leu Lys Arg Asn Val Arg Phe His Ala Phe Ile Ser Tyr | |
| | 100 105 110 | |
| 30 | AGT GAA CAT GAT TCT CTG TGG GTG AAG AAT GAA TTG ATC CCC AAT CTA | 382 |
| | Ser Glu His Asp Ser Leu Trp Val Lys Asn Glu Leu Ile Pro Asn Leu | |
| | 115 120 125 | |
| 35 | GAG AAG GAA GAT GGT TCT ATC TTG ATT TGC CTT TAT GAA AGC TAC TTT | 430 |
| | Glu Lys Glu Asp Gly Ser Ile Leu Ile Cys Leu Tyr Glu Ser Tyr Phe | |
| | 130 135 140 | |
| 40 | GAC CCT GGC AAA AGC ATT AGT GAA AAT ATT GTA AGC TTC ATT GAG AAA | 478 |
| | Asp Pro Gly Lys Ser Ile Ser Glu Asn Ile Val Ser Phe Ile Glu Lys | |
| | 145 150 155 | |
| 45 | AGC TAT AAG TCC ATC TTT GTT TTG TCT CCC AAC TTT GTC CAG AAT GAG | 526 |
| | Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Asn Glu | |
| | 160 165 170 175 | |
| | TGG TGC CAT TAT GAA TTC TAC TTT GCC CAC CAC AAT CTC TTC CAT GAA | 574 |
| | Trp Cys His Tyr Glu Phe Tyr Phe Ala His His Asn Leu Phe His Glu | |
| | 180 185 190 | |
| 50 | AAT TCT GAT CAC ATA ATT CTT ATC TTA CTG GAA CCC ATT CCA TTC TAT | 622 |
| | Asn Ser Asp His Ile Ile Leu Ile Leu Leu Glu Pro Ile Pro Phe Tyr | |
| | 195 200 205 | |
| 55 | TGC ATT CCC ACC AGG TAT CAT AAA CTG GAA GCT CTC CTG GAA AAA AAA | 670 |
| | Cys Ile Pro Thr Arg Tyr His Lys Leu Glu Ala Leu Glu Lys Lys | |
| | 210 215 220 | |
| 60 | GCA TAC TTG GAA TGG CCC AAG GAT AGG CGT AAA TGT GGG CTT TTC TGG | 718 |
| | Ala Tyr Leu Glu Trp Pro Lys Asp Arg Arg Lys Cys Gly Leu Phe Trp | |
| | 225 230 235 | |

GCA AAC CTT CGA GCT GCT GTT AAT GTT AAT GTA TTA GCC ACC AGA GAA 766
 Ala Asn Leu Arg Ala Ala Val Asn Val Asn Val Leu Ala Thr Arg Glu
 240 245 250 255

5 ATG TAT GAA CTG CAG ACA TTC ACA GAG TTA AAT GAA GAG TCT CGA GGT 814
 Met Tyr Glu Leu Gln Thr Phe Thr Glu Leu Asn Glu Glu Ser Arg Gly
 260 265 270

10 TCT ACA ATC TCT CTG ATG AGA ACA GAC TGT CTA TAAAATCCCA CAGTCCTTGG 867
 Ser Thr Ile Ser Leu Met Arg Thr Asp Cys Leu
 275 280

GAAGTTGGGG ACCACATACA CTGTTGGGAT GTACATTGAT ACAACCTTTA TGATGGCAAT 927

15 TTGACAATAT TTATTAAAT AAAAAATGGT TATTCCTTC AAAAAAAAAA AAAAAAAAAA 987
 AAAAAAAAAA AA 999

20 (2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 282 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

30 Ser Asp Ala Lys Ile Arg His Gln Ala Tyr Ser Glu Val Met Met Val
 1 5 10 15

35 Gly Trp Ser Asp Ser Tyr Thr Cys Glu Tyr Pro Leu Asn Leu Arg Gly
 20 25 30

Thr Arg Leu Lys Asp Val His Leu His Glu Leu Ser Cys Asn Thr Ala
 35 40 45

40 Leu Leu Ile Val Thr Ile Val Val Ile Met Leu Val Leu Gly Leu Ala
 50 55 60

Val Ala Phe Cys Cys Leu His Phe Asp Leu Pro Trp Tyr Leu Arg Met
 65 70 75 80

45 Leu Gly Gln Cys Thr Gln Thr Trp His Arg Val Arg Lys Thr Thr Gln
 85 90 95

50 Glu Gln Leu Lys Arg Asn Val Arg Phe His Ala Phe Ile Ser Tyr Ser
 100 105 110

Glu His Asp Ser Leu Trp Val Lys Asn Glu Leu Ile Pro Asn Leu Glu
 115 120 125

55 Lys Glu Asp Gly Ser Ile Leu Ile Cys Leu Tyr Glu Ser Tyr Phe Asp
 130 135 140

Pro Gly Lys Ser Ile Ser Glu Asn Ile Val Ser Phe Ile Glu Lys Ser
 145 150 155 160

60 Tyr Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Asn Glu Trp

165 170 175
 Cys His Tyr Glu Phe Tyr Phe Ala His His Asn Leu Phe His Glu Asn
 180 185 190
 5 Ser Asp His Ile Ile Leu Ile Leu Leu Glu Pro Ile Pro Phe Tyr Cys
 195 200 205
 10 Ile Pro Thr Arg Tyr His Lys Leu Glu Ala Leu Leu Glu Lys Lys Ala
 210 215 220
 Tyr Leu Glu Trp Pro Lys Asp Arg Arg Lys Cys Gly Leu Phe Trp Ala
 225 230 235 240
 15 Asn Leu Arg Ala Ala Val Asn Val Asn Val Leu Ala Thr Arg Glu Met
 245 250 255
 Tyr Glu Leu Gln Thr Phe Thr Glu Leu Asn Glu Glu Ser Arg Gly Ser
 260 265 270
 20 Thr Ile Ser Leu Met Arg Thr Asp Cys Leu
 275 280
 (2) INFORMATION FOR SEQ ID NO:33:
 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1173 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 30 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: cDNA
 35 (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..1008
 (ix) FEATURE:
 40 (A) NAME/KEY: misc_feature
 (B) LOCATION: 854
 (D) OTHER INFORMATION: /note= "nucleotide 854 designated
 A, may be A or T"
 45 (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 1171
 (D) OTHER INFORMATION: /note= "nucleotides 1171 and 1172
 designated C, each may be A, C, G, or T"
 50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
 CTG CCT GCT GGC ACC CGG CTC CGG AGG CTG GAT GTC AGC TGC AAC AGC 48
 55 Leu Pro Ala Gly Thr Arg Leu Arg Arg Leu Asp Val Ser Cys Asn Ser
 1 5 10 15
 ATC AGC TTC GTG GCC CCC GGC TTC TTT TCC AAG GCC AAG GAG CTG CGA 96
 60 Ile Ser Phe Val Ala Pro Gly Phe Phe Ser Lys Ala Lys Glu Leu Arg
 20 25 30

| | | |
|----|---|-----|
| | GAG CTC AAC CTT AGC GCC AAC GCC CTC AAG ACA GTG GAC CAC TCC TGG | 144 |
| | Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys Thr Val Asp His Ser Trp | |
| | 35 40 45 | |
| 5 | TTT GGG CCC CTG GCG AGT GCC CTG CAA ATA CTA GAT GTA AGC GCC AAC | 192 |
| | Phe Gly Pro Leu Ala Ser Ala Leu Gln Ile Leu Asp Val Ser Ala Asn | |
| | 50 55 60 | |
| 10 | CCT CTG CAC TGC GCC TGT GGG GCG GCC TTT ATG GAC TTC CTG CTG GAG | 240 |
| | Pro Leu His Cys Ala Cys Gly Ala Ala Phe Met Asp Phe Leu Leu Glu | |
| | 65 70 75 80 | |
| 15 | GTG CAG GCT GCC GTG CCC GGT CTG CCC AGC CGG GTG AAG TGT GGC AGT | 288 |
| | Val Gln Ala Ala Val Pro Gly Leu Pro Ser Arg Val Lys Cys Gly Ser | |
| | 85 90 95 | |
| 20 | CCG GGC CAG CTC CAG GGC CTC AGC ATC TTT GCA CAG GAC CTG CGC CTC | 336 |
| | Pro Gly Gln Leu Gln Gly Leu Ser Ile Phe Ala Gln Asp Leu Arg Leu | |
| | 100 105 110 | |
| 25 | TGC CTG GAT GAG GCC CTC TCC TGG GAC TGT TTC GCC CTC TCG CTG CTG | 384 |
| | Cys Leu Asp Glu Ala Leu Ser Trp Asp Cys Phe Ala Leu Ser Leu Leu | |
| | 115 120 125 | |
| 30 | GCT GTG GCT CTG GGC CTG GGT GTG CCC ATG CTG CAT CAC CTC TGT GGC | 432 |
| | Ala Val Ala Leu Gly Leu Gly Val Pro Met Leu His His Leu Cys Gly | |
| | 130 135 140 | |
| 35 | TGG GAC CTC TGG TAC TGC TTC CAC CTG TGC CTG GCC TGG CTT CCC TGG | 480 |
| | Trp Asp Leu Trp Tyr Cys Phe His Leu Cys Leu Ala Trp Leu Pro Trp | |
| | 145 150 155 160 | |
| 40 | CGG GGG CGG CAA AGT GGG CGA GAT GAG GAT GCC CTG CCC TAC GAT GCC | 528 |
| | Arg Gly Arg Gln Ser Gly Arg Asp Glu Asp Ala Leu Pro Tyr Asp Ala | |
| | 165 170 175 | |
| 45 | TTC GTG GTC TTC GAC AAA ACG CAG AGC GCA GTG GCA GAC TGG GTG TAC | 576 |
| | Phe Val Val Phe Asp Lys Thr Gln Ser Ala Val Ala Asp Trp Val Tyr | |
| | 180 185 190 | |
| 50 | AAC GAG CTT CGG GGG CAG CTG GAG GAG TGC CGT GGG CGC TGG GCA CTC | 624 |
| | Asn Glu Leu Arg Gly Gln Leu Glu Glu Cys Arg Gly Arg Trp Ala Leu | |
| | 195 200 205 | |
| 55 | CGC CTG TGC CTG GAG GAA CGC GAC TGG CTG CCT GGC AAA ACC CTC TTT | 672 |
| | Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu Pro Gly Lys Thr Leu Phe | |
| | 210 215 220 | |
| 60 | GAG AAC CTG TGG GCC TCG GTC TAT GGC AGC CGC AAG ACG CTG TTT GTG | 720 |
| | Glu Asn Leu Trp Ala Ser Val Tyr Gly Ser Arg Lys Thr Leu Phe Val | |
| | 225 230 235 240 | |
| 65 | CTG GCC CAC ACG GAC CGG GTC AGT GGT CTC TTG CGC GCC AGC TTC CTG | 768 |
| | Leu Ala His Thr Asp Arg Val Ser Gly Leu Leu Arg Ala Ser Phe Leu | |
| | 245 250 255 | |
| 70 | CTG GCC CAG CAG CGC CTG CTG GAG GAC CGC AAG GAC GTC GTG GTG CTG | 816 |
| | Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg Lys Asp Val Val Val Leu | |
| | 260 265 270 | |
| 75 | GTG ATC CTG AGC CCT GAC GGC CGC CGC TCC CGC TAC GAG CGG CTG CGC | 864 |

Val Ile Leu Ser Pro Asp Gly Arg Arg Ser Arg Tyr Glu Arg Leu Arg
 275 280 285

5 CAG CGC CTC TGC CGC CAG AGT GTC CTC CTC TGG CCC CAC CAG CCC AGT 912
 Gln Arg Leu Cys Arg Gln Ser Val Leu Leu Trp Pro His Gln Pro Ser
 290 295 300

10 GGT CAG CGC AGC TTC TGG GCC CAG CTG GGC ATG GCC CTG ACC AGG GAC 960
 Gly Gln Arg Ser Phe Trp Ala Gln Leu Gly Met Ala Leu Thr Arg Asp
 305 310 315 320

15 AAC CAC CAC TTC TAT AAC CGG AAC TTC TGC CAG GGA CCC ACG GCC GAA 1008
 Asn His His Phe Tyr Asn Arg Asn Phe Cys Gln Gly Pro Thr Ala Glu
 325 330 335

20 TAGCCGTGAG CCGGAATCCT GCACGGTGCC ACCTCCACAC TCACCTCACC TCTGCCTGCC 1068
 TGGTCTGACC CTCCCCTGCT CGCCTCCCTC ACCCCACACC TGACACAGAG CAGGCACTCA 1128
 ATAAATGCTA CCGAAGGCTA AAAAAAAAAA AAAAAAAAAA AACCA 1173

(2) INFORMATION FOR SEQ ID NO:34:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 336 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

35 Leu Pro Ala Gly Thr Arg Leu Arg Arg Leu Asp Val Ser Cys Asn Ser
 1 5 10 15

Ile Ser Phe Val Ala Pro Gly Phe Phe Ser Lys Ala Lys Glu Leu Arg
 20 25 30

40 Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys Thr Val Asp His Ser Trp
 35 40 45

45 Phe Gly Pro Leu Ala Ser Ala Leu Gln Ile Leu Asp Val Ser Ala Asn
 50 55 60

Pro Leu His Cys Ala Cys Gly Ala Ala Phe Met Asp Phe Leu Leu Glu
 65 70 75 80

50 Val Gln Ala Ala Val Pro Gly Leu Pro Ser Arg Val Lys Cys Gly Ser
 85 90 95

Pro Gly Gln Leu Gln Gly Leu Ser Ile Phe Ala Gln Asp Leu Arg Leu
 100 105 110

55 Cys Leu Asp Glu Ala Leu Ser Trp Asp Cys Phe Ala Leu Ser Leu Leu
 115 120 125

60 Ala Val Ala Leu Gly Leu Gly Val Pro Met Leu His His Leu Cys Gly
 130 135 140

Trp Asp Leu Trp Tyr Cys Phe His Leu Cys Leu Ala Trp Leu Pro Trp

| | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | 145 | | | | 150 | | | | 155 | | | | 160 | | | |
| 5 | Arg | Gly | Arg | Gln | Ser | Gly | Arg | Asp | Glu | Asp | Ala | Leu | Pro | Tyr | Asp | Ala |
| | | | | | 165 | | | | | 170 | | | | | 175 | |
| | Phe | Val | Val | Phe | Asp | Lys | Thr | Gln | Ser | Ala | Val | Ala | Asp | Trp | Val | Tyr |
| | | | | 180 | | | | | 185 | | | | | 190 | | |
| 10 | Asn | Glu | Leu | Arg | Gly | Gln | Leu | Glu | Glu | Cys | Arg | Gly | Arg | Trp | Ala | Leu |
| | | | 195 | | | | | 200 | | | | | 205 | | | |
| | Arg | Leu | Cys | Leu | Glu | Glu | Arg | Asp | Trp | Leu | Pro | Gly | Lys | Thr | Leu | Phe |
| | | 210 | | | | | 215 | | | | | 220 | | | | |
| 15 | Glu | Asn | Leu | Trp | Ala | Ser | Val | Tyr | Gly | Ser | Arg | Lys | Thr | Leu | Phe | Val |
| | 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| | Leu | Ala | His | Thr | Asp | Arg | Val | Ser | Gly | Leu | Leu | Arg | Ala | Ser | Phe | Leu |
| 20 | | | | | 245 | | | | | 250 | | | | | 255 | |
| | Leu | Ala | Gln | Gln | Arg | Leu | Leu | Glu | Asp | Arg | Lys | Asp | Val | Val | Val | Leu |
| | | | | 260 | | | | | 265 | | | | | 270 | | |
| | Val | Ile | Leu | Ser | Pro | Asp | Gly | Arg | Arg | Ser | Arg | Tyr | Glu | Arg | Leu | Arg |
| 25 | | | 275 | | | | | 280 | | | | | 285 | | | |
| | Gln | Arg | Leu | Cys | Arg | Gln | Ser | Val | Leu | Leu | Trp | Pro | His | Gln | Pro | Ser |
| | | 290 | | | | | 295 | | | | | 300 | | | | |
| 30 | Gly | Gln | Arg | Ser | Phe | Trp | Ala | Gln | Leu | Gly | Met | Ala | Leu | Thr | Arg | Asp |
| | 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| | Asn | His | His | Phe | Tyr | Asn | Arg | Asn | Phe | Cys | Gln | Gly | Pro | Thr | Ala | Glu |
| | | | | | 325 | | | | | 330 | | | | | 335 | |

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

40 (A) LENGTH: 497 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

| | | | | | | | |
|----|------------|------------|------------|------------|------------|------------|-----|
| | TGGCCACAC | GGACCGCGTC | AGTGGCCTCC | TGCGCACCAG | CTTCCTGCTG | GCTCAGCAGC | 60 |
| 55 | GCCTGTTGGA | AGACCGCAAG | GACGTGGTGG | TGTTGGTGAT | CCTGCGTCCG | GATGCCCCAC | 120 |
| | CGTCCCGCTA | TGTGCGACTG | CGCCAGCGTC | TCTGCCGCCA | GAGTGTGCTC | TTCTGGCCCC | 180 |
| | AGCGACCCAA | CGGGCAGGGG | GGCTTCTGGG | CCCAGCTGAG | TACAGCCCTG | ACTAGGGACA | 240 |
| 60 | ACCGCCACTT | CTATAACCAG | AACTTCTGCC | GGGGACCTAC | AGCAGAATAG | CTCAGAGCAA | 300 |

| | | | | | | |
|--------------|------------|------------|------------|------------|------------|-----|
| CAGCTGGAAA | CAGCTGCATC | TTCATGTCTG | GTTCCCGAGT | TGCTCTGCCT | GCCTTGCTCT | 360 |
| GTCTTACTAC | ACCGCTATTT | GGCAAGTGCG | CAATATATGC | TACCAAGCCA | CCAGGCCAC | 420 |
| 5 GGAGCAAAGG | TTGGCTGTAA | AGGGTAGTTT | TCTTCCCATG | CATCTTTCAG | GAGAGTGAAG | 480 |
| ATAGACACCA | AACCCAC | | | | | 497 |

WHAT IS CLAIMED IS:

1. A substantially pure or recombinant DTLR2 protein or peptide which exhibits at least about 85% sequence
5 identity over a length of at least about 12 amino acids to SEQ ID NO: 4.
2. A substantially pure or recombinant DTLR3 protein or peptide which exhibits at least about 85% sequence
10 identity over a length of at least about 12 amino acids to SEQ ID NO: 6.
3. A substantially pure or recombinant DTLR4 protein or peptide which exhibits at least about 85% sequence
15 identity over a length of at least about 12 amino acids to SEQ ID NO: 26.
4. A substantially pure or recombinant DTLR5 protein or peptide which exhibits at least about 85% sequence
20 identity over a length of at least about 12 amino acids to SEQ ID NO: 10.
5. A substantially pure or recombinant DTLR6 protein or peptide which exhibits at least about 85% sequence
25 identity over a length of at least about 12 amino acids to SEQ ID NO: 12.
6. A substantially pure or recombinant DTLR7 protein or peptide which exhibits at least about 85% sequence
30 identity over a length of at least about 12 amino acids to SEQ ID NO: 16 or 18.
7. A substantially pure or recombinant DTLR8 protein or peptide which exhibits at least about 85% sequence
35 identity over a length of at least about 12 amino acids to SEQ ID NO: 32.

8. A substantially pure or recombinant DTLR9 protein or peptide which exhibits at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 22.

5

9. A substantially pure or recombinant DTLR10 protein or peptide which exhibits at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 34.

10

10. A fusion protein comprising the protein or peptide of any of claims 1-9.

11. A binding compound which specifically binds to the protein or peptide of any of claims 1-9.

15

12. The binding compound of claim 11 which is an antibody or antibody fragment.

13. A nucleic acid encoding the protein or peptide of any of claims 1-9.

20

14. An expression vector comprising the nucleic acid of claim 13.

25

15. A host cell comprising the vector of claim 14.

16. A process for recombinantly producing a polypeptide comprising culturing the host cell of claim 15 under conditions in which the polypeptide is expressed.

30

1/5




FIG. 1

FIG. 2A





FIG. 2B



SUBSTITUTE SHEET (RULE 26)








FIG. 3

4/5






FIG. 5C




FIG. 5F




FIG. 5B




FIG. 5E




FIG. 5A




FIG. 5D